PCNA inhibitors and uses thereof

By providing a compound related to PCNA activity, inhibiting PCNA activity, the problem of limited success in the prior art for caPCNA treatment is solved, and effective treatment of cancer and selective inhibition of cancer cell growth is achieved.

CN119013247AInactive Publication Date: 2024-11-22CITY OF HOPE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033235.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-07
Filing Date
2023-03-06
Publication Date
2024-11-22
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing drug development for caPCNA has been limited in success and it is difficult to effectively treat related cancers.

Method used

Provided is a compound or a pharmaceutically acceptable salt thereof that inhibits PCNA activity by targeting disease associated with PCNA activity for the treatment of cancer, including the structure and preparation methods of compounds.

Benefits of technology

Effectively inhibits PCNA activity, showing anti-tumor growth activity in the body and selectively inhibits cancer cell growth without obvious side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013247A_ABST
    Figure CN119013247A_ABST
Patent Text Reader

Abstract

Inhibitors of PCNA and uses thereof are described herein, inter alia.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 317,430, filed on March 7, 2022, which is incorporated herein by reference in its entirety for all purposes.

[0003] Reference to electronic sequence listing

[0004] The contents of the electronic sequence listing (048440-826001WO_Sequence_Listing_ST26.xml; size 15,199 bytes; and creation date: February 13, 2023) are hereby incorporated by reference into this document in its entirety.

[0005] STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

[0006] This invention was made with government support from the Medical Research and Development Command under Award W81XWH-19-1-0326. The government has certain rights in this invention. Background Art

[0007] Proliferating cell nuclear antigen (PCNA) is crucial for DNA replication and repair processes, and it is also a proliferation biomarker in a variety of human tumors. Previously, a unique isoform of a protein associated with cancer, caPCNA, has been identified, which has the potential to become a selective therapeutic target for cancer cells. Currently, a variety of strategies have been used to develop agents targeting caPCNA, including inhibitors based on peptides and small molecules, but the success achieved in developing compounds that can be used for treatment remains limited. Solutions to these and other problems in the art are particularly disclosed herein. Summary of the Invention

[0008] In one aspect, a compound or a pharmaceutically acceptable salt thereof is provided, which has the formula:

[0009]

[0010] L 1 -O-, -NR 7 , -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 7 C(O)-、-C(O)NR 7 、-NR 7 C(O)NR 8 、-NR 7 S(O)2O-、-OS(O)2NR 7 、-NR 7 S(O)2-、-S(O)2NR7 , -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OR 7 )-、-OP(O)(OR 7 )O-、-OP(O)(OR 7 )-、-P(O)(OR 7 )O-, or -CR 8 R 9 .

[0011] R 7 、R 8 and R 9 are independently hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl.

[0012] Ring A is a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- to 6-membered heteroaryl group.

[0013] Ring B is substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted quinolyl, or substituted or unsubstituted isoquinolyl.

[0014] R 1 are independently halogen, -CX 1 3. -CHX 1 2. -CH2X 1 、-OCX 1 3. -OCHX 1 2. -OCH2X 1 、-CN、-SO n1 R 1D 、-SO v1 NR 1A R 1B 、-NR 1C NR 1A R 1B 、-ONR 1A R 1B 、-NHC(O)NR 1C NR 1A R 1B 、-NR 1C C(O)NR 1A R 1B 、-N(O) m1 、-NR 1A R 1B 、-C(O)R 1C 、-C(O)OR 1C 、-OC(O)R 1C 、-OC(O)OR 1C 、-C(O)NR1A R 1B 、-OR 1D 、-SR 1D 、-NR 1A SO2R 1D 、-NR 1A C(O)R 1C 、-NR 1A C(O)OR 1C 、-OC(O)NR 1A R 1B 、-NR 1A OR 1C 、-P(O)R 1A R 1B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 1 Substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl.

[0015] R 2 For hydrogen, halogen, -CX 2 3. -CHX 2 2. -CH2X 2 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0016] R 3 For hydrogen, halogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0017] R 6 For hydrogen, halogen, -CX 6 3. -CHX 6 2. -CH2X 6 、-OCX 6 3. -OCHX 6 2. -OCH2X 6、-CN、-SO n6 R 6D 、-SO v6 NR 6A R 6B 、-NR 6C NR 6A R 6B 、-ONR 6A R 6B 、-NHC(O)NR 6C NR 6A R 6B 、-NR 6C C(O)NR 6A R 6B 、-N(O) m6 、-NR 6A R 6B 、-C(O)R 6C 、-C(O)OR 6C 、-OC(O)R 6C 、-OC(O)OR 6C 、-C(O)NR 6A R 6B 、-OR 6D 、-SR 6D 、-NR 6A SO2R 6D 、-NR 6A C(O)R 6C 、-NR 6A C(O)OR 6C 、-OC(O)NR 6A R 6B 、-NR 6A OR 6C 、-P(O)R 6A R 6B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0018] R 3 and R 6 Can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl.

[0019] R 1A 、R 1B 、R 1C 、R 1D 、R 6A 、R 6B 、R 6C and R 6DR is independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 1A and R 1B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R 6A and R 6B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl.

[0020] The symbol z1 is an integer from 0 to 4. The symbols m1, m6, v1, and v6 are independently 1 or 2. The symbols n1 and n6 are independently integers from 0 to 4.

[0021] X, X 1 、X 2 、X 3 and X 6 is independently -Cl, -Br, -I, or -F.

[0022] The symbol m is an integer from 0 to 5. The symbol n is an integer from 0 to 10.

[0023] In one aspect, a compound or a pharmaceutically acceptable salt thereof is provided, which has the formula:

[0024] L 1 , Ring A, R 1 ,z1,R 2 、R 3 、R 6 and m are as described herein (including in the embodiments).

[0025] In one aspect, a pharmaceutical composition is provided, comprising a compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0026] In one aspect, provided is a method of treating a disease associated with PCNA activity in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof.

[0027] In one aspect, provided is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject in need thereof a therapeutically effective amount of a compound described herein or a pharmaceutically acceptable salt thereof.

[0028] In one aspect, a method of inhibiting PCNA activity is provided, comprising contacting PCNA with an effective amount of a compound described herein or a pharmaceutically acceptable salt thereof.

[0029] In one aspect, a method for preparing Compound (I) or a pharmaceutically acceptable salt thereof is provided, the method comprising mixing Compound (VII) and Compound (X) together in a reaction vessel. Compound (I) has the following formula: Compound (VII) has the following formula: Compound (X) has the following formula: L 1 , Ring A, R 1 ,z1,R 2 、R 3 、R 6 , m and n are as described herein (including in the embodiments). LG is a leaving group. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figures 1A to 1E .Interaction of AOH1160 analogs with PCNA. Figure 1A : Thermal shift assay: Normalized reverse derivative thermal denaturation curve of 9 μM apo-PCNA, wherein the DMSO control is shown in black dashed line, PCNA in the presence of 10 μM AOH1160LE is shown in light grey, and PCNA in the presence of 30 μM AOH1160LE is shown in dark grey. m value. Figure 1B :like Figure 1A As shown in FIG, PCNA in the presence of 10 μM AOH1996 is shown in light grey, and PCNA in the presence of 30 μM AOH1996 is shown in dark grey. Figure 1C : The four monomers of PCNA (chains A to D) are present in the asymmetric unit of the crystal. Chains A, B, and C form a homotrimeric biological unit, while chain D is oriented perpendicular to the plane of the ring, located below the interface between chains B and C, and it belongs to the adjacent ring. Inset: Three AOH1160LE molecules are bound within the PIP box cavity of each PCNA ring subunit and its adjacent region. The outline of the omitted figure (grey grid) is 1.5σ. Two PCNA monomer subunits from adjacent rings stack against each other, with the PIP box and IDCL of each subunit positioned in opposite directions. Figure 1D : Three AOH1160LE molecules are shown as stick figures. The two compounds on the left and center bind to the PIP box cavity at the known PCNA-partner / compound interaction site. Figure 1E: Superposition of PCNA:T2AA and PCNA:AOH1160LE complexes centered in the PIP box cavity, with the carbons of T2AA shown in dark grey. Electrostatic surface maps are presented as Poisson-Boltzmann electrostatic surface potentials, with dark grey and light grey corresponding to -10 kT / e to +10 kT / e, respectively.

[0031] Figures 2A to 2D .Interaction of AOH1996 with PCNA. Figure 2A The PCNA gene was mutated using CRISPR, resulting in a codon replacement for leucine 47 with a valine codon. The figure shows DNA sequencing results for cell lines heterozygous or homozygous for the mutant gene. Original sequence: ACGTCTCTTTGGTGCAGCTCACC (SEQ ID NO: 1); donor sequence: ACGTCTCTGTCGTGCAGCTCACC (SEQ ID NO: 2); homozygous: ACGTCTCTGTCGTGCAGCTCACCC (SEQ ID NO: 3). Figures 2B to 2C : Heterozygous or homozygous cell lines expressing a PCNA mutation were treated with the indicated concentrations of AOH1996 or R9-caPep for 72 hours. Parental SK-N-AS cells were used as controls. Relative cell growth was averaged over three replicates and ±SD plotted. Figure 2D : Expression of γH2A.X was measured by Western blotting in cell lines heterozygous (#25H and #37H) or homozygous (#33 and #35) for mutant PCNA alleles after treatment with 500 nM AOH1996 or 30 μM R9-caPep for the indicated times.

[0032] Figures 3A to 3D .Therapeutic properties of AOH1996. Figure 3A : Normal cells (7SM0032) or cancer cells (SH-SY5Y and SK-N-BE(2)c) were fixed, stained with PI, and analyzed by flow cytometry after treatment with 500 nM AOH1996 for the indicated times. Figure 3B SK-N-DZ neuroblastoma cells and non-malignant 7SM0032 stem cells were incubated with 500 nM AOH1996 for 24 hours. After being fixed on a slide, apoptosis was analyzed by TUNEL assay. Left: TMR fluorophores attached to free ends of DNA indicate that cells are undergoing apoptosis. DAPI-stained nuclei are also shown. Right: The figure shows the mean abundance ± SD of apoptotic 7SM0032 (black histogram) and SK-N-DZ (grey histogram) cells relative to the total number of cells in 5 randomly selected fields. Figure 3C: In the absence or presence of 500nM AOH1996, human SK-N-DZ neuroblastoma cells were treated with or without the indicated concentrations of cisplatin for 18 hours. Cells were washed twice with growth medium and cultured in fresh medium for 18 days to allow colony formation. The colony counts (black) in the culture dishes treated with cisplatin but not treated with AOH1996 were normalized to the colony counts in the culture dishes not treated with any of the agents. The colony counts (grey) in the culture dishes treated with cisplatin and AOH1996 were normalized to the colony counts in the culture dishes treated with 500nM AOH1996 alone. The relative number of colonies measured in triplicate under each treatment condition was averaged and plotted ± SD (*, P < 0.01). Figure 3D SK-N-AS cells were treated with the indicated concentrations of AOH1996, topotecan, or a combination of these two agents. Cells were imaged every 6 hours for a total of 48 hours, and cell growth was measured as a percentage of cell confluence.

[0033] Figures 4A to 4H .Pharmacokinetics and anti-tumor growth activity of AOH1996 in vivo. Figure 4A : After oral administration, three male and three female ES1 e AOH1996 plasma concentrations in SCID / SCID mice at the indicated time points are averaged and plotted ± SD. Insets contain PK parameters determined by standard non-compartmental methods. Figure 4B : A similar PK study of AOH1996 was conducted in dogs. Figures 4C to 4E : Immediately after the first measurement, Figure 4C :SK-N-BE(2)c)、Breast cancer( Figure 4D : MDA-MB-468) and small cell lung cancer ( Figure 4E Mice bearing xenograft tumors of WT H82 (H82) were given vehicle alone (black) or 40 mg / kg AOH1996 (grey) twice daily. Tumor size was measured weekly with a vernier caliper. Tumor volume (0.4 × L × W 2 ) were averaged and plotted as ± SE (*, P < 0.01). Figure 4F : Animal body weight was monitored throughout the study as an indicator of toxicity. Figure 4C Representative results from studies using the SK-N-BE(2)c tumor model described in . Figure 4G : Phospho-Chk1 (pChk1) and γH2A.X levels in SK-N-BE(2)c-derived tumor samples were analyzed by IHC. Shown are representative images of tumors treated with vehicle alone or 40 mg / kg AOH1996. Figure 4H: ES1 cells carrying SK-N-AS-derived xenograft tumors e SCID mice were treated with 80 mg / kg AOH1996 (black, n=7) for 8 days starting 8 days after tumor implantation; 15 mg / kg CPT-11 (n=8) for 3 days starting 12 days after tumor implantation; or both agents (combination, n=8) were treated at the same dose and schedule as when they were administered alone. Untreated mice implanted with the same tumors served as controls (n=8). Shown are survival curves. P values ​​for the combination treatments compared to the respective control groups, as determined by the log-rank test (Mantel-Cox), were p=0.0003 (combination treatment vs. untreated), p=0.005 (combination treatment vs. AOH1996 alone), and p=0.024 (combination treatment vs. CPT-11 alone), respectively.

[0034] Figures 5A to 5E .Regulation of the interaction between PCNA and RNA polymerase II. Figure 5A : After using or not 500nM AOH1996 treatment cells, from the HEK293T cells expressing FLAG-tagged PCNA, fractionated chromatin binding (CB) protein. The protein compounded with FLAG-PCNA was immunoprecipitated and analyzed by mass spectrometry. Shown in the figure is the protein quantity that protein abundance was changed (grey) or did not change (black) more than 2 times by AOH1996 treatment. Figure 5B SK-N-AS cells expressing exogenously FLAG-tagged RPB1 were fractionated before and after overnight treatment with 500 nM AOH1996. PCNA complexed with chromatin-bound (CB) FLAG-RBP1 was analyzed by Western blot. Figure 5C Human SK-N-AS cells were treated with UV in the presence or absence of AOH1996 (AOH) or R9-caPep (caPep). Whole cell extracts were analyzed by Western blot. Figure 5D Cells expressing exogenously FLAG-tagged wild-type RPB1 or FLAG-tagged APIM mutant RPB1 were fractionated and PCNA complexed with chromatin-bound (CB) FLAG-RBP1 was analyzed by Western blotting. Figure 5E HEK293T cells were transiently transfected with FLAG-tagged wild-type RPB1 gene (APIM WT) or mutant RPB1 gene (APIM mutant). After treatment with the indicated agents and / or UV, intracellular MCM7 and RBP1 (both hypophosphorylated RNAPIIa and hyperphosphorylated RNAPIIo) were analyzed by Western blotting.

[0035] Figures 6A to 6C.The effect of AOH1996 is mediated through the interaction between PCNA and RPB1. Figure 6A : Cell lines heterozygous or homozygous for the APIM mutant RPB1 gene were treated with the indicated concentrations of AOH1996 for 72 hours. Parental SK-N-AS cells were used as controls. Relative cell growth was averaged from triplicate replicates and plotted as ±SD. Figure 6B : The whole cell proteome of SK-N-AS cells homozygous for the APIM mutant RPB1 gene was analyzed in quadruplicate by mass spectrometry before and after treating the cells overnight with 500 nM AOH1996. To average out any clonal differences unrelated to the RPB1 mutant, these four samples were derived from two independent RPB1 mutant clones. Quadruplicate parental SK-N-AS cells were used as controls. The enrichment of proteins whose expression was altered at least 2-fold by AOH1996 in cells of either genotype with a p-value less than 0.05 was analyzed by MetaCore's (Clarivate Analysis, Philadelphia, PA) gene ontology program. Shown in the cricos figure are the enriched GO processes associated with these proteins and the average fold change in expression of these proteins induced by AOH1996 treatment. Figure 6C : Calculated relative to the average expression level in untreated corresponding cells Figure 6B The fold change in protein expression for each AOH1996-treated sample identified in the PCR results was visualized in a heat plot. The heat plot also shows the difference between treated and untreated samples of the same genotype as a -log 10 (p-value) indicates statistical significance.

[0036] 7A to 7E .Transcription-dependent effects on DNA replication and damage. Figure 7A : Left: Schematic diagram of cell fractionation procedure. Right: MDA-MB-468 cells were treated with AOH1996 (5nM, 50nM or 500nM) at increasing concentrations for 24 hours. Cells treated with DMSO were used as controls. Whole cell extracts (WCE) and protein fractions associated with actively transcribed chromatin (CB: RNA+) or low or non-transcribed chromatin (CB: RNA-) were analyzed by Western blotting using antibodies against PCNA, CAF-1 and MCM7. Figure 7B: Synchronized cancer cells were sequentially incubated in the presence of CldU (light gray) and IdU (dark gray) before and after AOH1996 treatment. Cells sequentially incubated with the same two nucleotide analogs but not treated with AOH1996 served as controls. Left: Representative images of labeled DNA strands from cells treated with or without AOH1996. Center and Right: The lengths of DNA fragments incorporating CldU (light gray) and IdU (dark gray) were averaged and plotted ± SD, measured for more than 30 independent DNA strands from the indicated cancer cell types. Figure 7C Whole-cell lysates were extracted from SK-N-AS cells homozygous for the wild-type RPB1 allele or the APIM mutant allele and analyzed by Western blotting for histone H2A.X and γH2A.X after overnight treatment with or without AOH1996. Figure 7D : Histone H2A.X and γH2A.X in whole-cell lysates of SK-N-AS cells were analyzed by Western blotting after overnight treatment with 500 nM AOH1996 and / or 50 μM DRB. Figure 7E Working model of AOH1996's mechanism of action: Binding of AOH1996 to PCNA stabilizes its interaction with RNA polymerase II and interferes with TRC resolution, leading to PCNA dissociation from chromatin in a transcription-dependent manner. By exploiting this cancer vulnerability, AOH1996 selectively inhibits tumor growth without causing any identifiable side effects.

[0037] Figure 8 Schematic diagram of the interaction of three AOH1160LE molecules in the PCNA PIP box / APIM binding pocket. Figures 1A to 1E Positions within the indicated PIP box pocket are listed from left to right. Specific protein-ligand interactions are highlighted based on the legend provided.

[0038] Figure 9 Structural superposition of the centrally bound AOH1160LE molecule in complex with the PCNA:APIM peptide. The central AOH1160LE (dark grey) binds to the same hydrophobic pocket as the ZRANB3APIM peptide (PDB code: 5MLW) (light grey). The ZRANB3Phe1075 side chain is also depicted, where it interacts with the second region of the PCNA APIM binding pocket, where a single AOH1160LE molecule ( Figure 8 Inset: A close-up view of the two hydrophobic binding regions of PCNA, with the diphenyl ether of AOH1160LE positioned at the junction of Ile1072 and Val1077 of the APIM peptide.

[0039] Figure 10 Orientation of AOH1160LE bound to the PIP box cavity of PCNA. Chains A through D are depicted with solid boxes, and their corresponding symmetrically paired chains are depicted with dashed lines. Each chain is labeled accordingly. The orientation of the central AOH1160LE diphenyl ether binding is depicted and further indicated by the direction of the black arrow.

[0040] Figure 11 The central AOH1160LE molecule in chain C interacts with PCNA via the naphthyl group. Specific protein-ligand interactions are highlighted based on the provided legend.

[0041] 12A to 12E .AOH1996 Metabolism and in vivo pharmacokinetics. Figure 12A : Schematic representation of AOH1160 degradation by carboxylesterase-mediated cleavage or by hydroxylation. Figure 12B : Chromatograms of liver microsomal reaction mixtures of AOH1160 and AOH1996. Figure 12A The metabolites shown in are shown above their corresponding peaks. Figure 12C Aliquots of the liver microsomal reaction mixture were taken after different incubation times with AOH1996 in the presence or absence of NADPH as an energy source. AOH1996 concentrations determined by LC / MS-MS were plotted as a percentage of the input concentration. Figure 12D : AOH1996 plasma concentrations at the indicated time points were averaged for three male and three female ES1e / SCID mice after oral administration and plotted as ± SD. Insets contain PK parameters determined by standard non-compartmental methods. Figure 12E : A similar PK study of AOH1996 was conducted in dogs.

[0042] 13A to 13E .Selective inhibition of cancer cells. Figure 13A : Cancer cells from the NCI60 panel were incubated for 48 hours in the presence of different concentrations of AOH1996. After fixing the cells with ice-cold 10% trichloroacetic acid (TCA), cell growth was analyzed using the sulforhodamine B (SRB) assay. The GI in moles was calculated for each cell line by NCI 50(For details, see Example 2.) Cell lines: Leukemias: CCRF-CEM, HL-60(TB), K-562, MOLT-4, RPMI-8226, SR; Non-small cell lung cancers: A549 / ATCC, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, NCI-H522; Colon cancers: COLO205, HCC-2998, HCT-116, HCT-15, HT29, KM12, SW-620; CNS cancers: SF-268, SF-295, SF-539, SNB-19, SNB-75, U251; Melanoma: LOX IMVI, MALME-3M, M14, MDA-MB-435, SK-MEL-2, SK-MEL-28, SK-MEL-5, UACC-257, UACC-62; ovarian cancer: IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, NCI / ADR-RES, SK-OV-3; renal cancer: 786-0, A498, ACHN, CAKI-1, RXF 393, SN12C, TK-10, UO-31; prostate cancer: PC-3, DU-145; breast cancer: MCF7, MDA-MC-231 / ATCC, HS 578T, BT-549, T-47D, MDA-MB-468. 13B to 13D :The picture shows LogGI 50 As shown in the figure, small cell lung cancer ( Figure 13B :H-82, H-524, H-526, LX22 and LX33), neuroblastoma ( Figure 13C :SK-N-BE(2)c, SH-SY5Y and SK-N-AS), prostate cancer ( Figure 13D : LN-caP, LN-caP-R, 22RV1, H660, LASCPC, PC3 and DU145) cell lines were treated with different concentrations of AOH1996 for 72 hours. Non-malignant cells ( Figure 13B : hSAEC and PBMC; and Figure 13C :7SM0032) was used as a control. Cell growth was measured by luminescence assay. Relative cell growth of triplicate replicates was averaged and plotted as ± SD. Figure 13E : Histone H2A.X and γH2A.X in whole-cell lysates from the indicated cells were analyzed by Western blotting after treatment with 500 nM AOH1996 for different times.

[0043] Figure 14 .Chemical structures of AOH1996 and AOH1160.

[0044] Figure 15 Features of the binding pocket within the PIP box domain of PCNA. A, B: Primarily a hydrophobic depression extending well below the IDCL. Some polarity "deep inside," but difficult to access. The IDCL is shaded. C: A distinct depression, but with higher polarity than A or B. D: The "wall" is hydrophobic, but has polar properties. E, F, G: Additional hydrophobic pockets important for alternative binding configurations. H: Large hydrophobic region, difficult to use with shorter length compounds.

[0045] Figure 16 .Schematic diagram of the lowest energy conformation of AOH1996 (E=-8.7).

[0046] Figure 17 .Schematic diagram of the lowest energy configuration of fluorinated AOH1996.

[0047] Figure 18 Schematic representation of the lowest energy configuration of AOH1160 containing isopenpiperidinic acid in place of the glycine linker.

[0048] Figure 19 Schematic representation of the conformations of AOH1996 and D-homophenylalanine docked to the PIP-binding domain of caPCNA.

[0049] Figure 20 Schematic representation of the conformation of the AOH1996 analog containing the adamantyl amides of D-aspartate and D-glutamate docked to the PIP domain of caPCNA.

[0050] 21A to 21D .AOH1990-2 in the PCNA active site ( Figure 21A )、AOH1160NH( Figure 21B )、AOH1160RCHF( Figure 21C ) and AOH1160CF2( Figure 21D ) binary complex model.

[0051] FIG. 22A to FIG. 22B .AOH1996 in the PCNA active site ( Figure 22A ) and AOH1160( Figure 22B ) binary complex model.

[0052] FIG. 23A to FIG. 23B .AOH1160eNaph in the PCNA active site ( Figure 23A ) and AOH1996eeNaph( Figure 23B ) binary complex model.

[0053] Figure 24 .TSA data of AOH1160LV. AOH1160LV shows very similar ΔT compared to AOH1996 m .

[0054] Figure 25 .AOH1160LA IC 50 Data.IC 50 = about 3 μM.

[0055] Figure 26 .AOH1996LA IC 50 Data. ICs for AK-N-AS, H1752, and H358 50 1.5μM, 1.6μM and 1.8μM respectively.

[0056] Figure 27 .AOH1996TMB IC 50 Data.IC 50 Values: Hela: 6.5μM, A673: 5.5μM, A549: 4.7μM.

[0057] 28A to 28D IC of AOH analogs in MDA-MB-468 cell line 50 Data. IC of AOH1996 50 Value: 740nM( Figure 28A ), AOH1160S: 316nM( Figure 28B ), AOH1160LA: 4900nM( Figure 28C ), AOH1996LA: 2300nM( Figure 28D ).

[0058] Figure 29 IC of selected compounds 50 Data. The indicated cell lines were cultured at 10 4 Cells were seeded in 96-well plates at 400 cells / well. After allowing cells to attach overnight, they were treated with different concentrations of the indicated compounds in triplicate for 72 hours. Cell growth was measured by SRB assay. The cell abundance relative to the baseline for each treatment condition was averaged and plotted ± SD. The baseline was defined as the median of the cell abundance under the two lowest compound concentrations. IC was calculated using the Prism program. 50 . DETAILED DESCRIPTION

[0059] I. Definition

[0060] Abbreviations used herein have their conventional meanings in the chemical and biological arts.Chemical structures and formulae depicted herein are constructed according to standard rules of chemical valence known in the chemical arts.

[0061] When substituents are described by their conventional chemical formula written from left to right, these substituents equally encompass the chemically identical substituents resulting from writing the structure from right to left, for example, -CH2O- is equivalent to -OCH2-.

[0062] Unless otherwise indicated, the term "alkyl," by itself or as part of another substituent, means a straight (i.e., unbranched) or branched carbon chain (or carbons), or combinations thereof, which may be fully saturated, monounsaturated, or polyunsaturated, and may include monovalent, divalent, and polyvalent groups. An alkyl group may contain the specified number of carbon atoms (e.g., C1-C 10 Meaning one carbon to ten carbons). In embodiments, the alkyl group is fully saturated. In embodiments, the alkyl group is monounsaturated. In embodiments, the alkyl group is polyunsaturated. The alkyl group is an uncyclized chain. Examples of saturated hydrocarbon groups include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl, methyl, homologues and isomers of, for example, n-pentyl, n-hexyl, n-heptyl, n-octyl, etc. Unsaturated alkyl groups are alkyl groups having one or more double or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl, 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3-(1,4-pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and higher homologues and isomers. Alkoxy groups are alkyl groups connected to the rest of the molecule via an oxygen linker (-O-). The alkyl moiety can be an alkenyl moiety. The alkyl moiety can be an alkynyl moiety. Alkenyl groups contain one or more double bonds. Alkynyl groups contain one or more triple bonds.

[0063] Unless otherwise stated, the term "alkylene" by itself or as part of another substituent means a divalent group derived from an alkyl group, such as, but not limited to, -CH2CH2CH2CH2-. Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred herein. "Lower alkyl" or "lower alkylene" is a short-chain alkyl or alkylene group typically having eight or fewer carbon atoms. Unless otherwise stated, the term "alkenylene" by itself or as part of another substituent means a divalent group derived from an alkene group. Unless otherwise stated, the term "alkynylene" by itself or as part of another substituent means a divalent group derived from an alkyne group. In an embodiment, an alkylene group is fully saturated. In an embodiment, an alkylene group is monounsaturated. In an embodiment, an alkylene group is polyunsaturated. An alkenylene group includes one or more double bonds. An alkynylene group includes one or more triple bonds.

[0064] Unless otherwise stated, the term "heteroalkyl," alone or in combination with another term, means a stable straight or branched chain, or combination thereof, comprising at least one carbon atom and at least one heteroatom (e.g., O, N, P, Si, and S), and wherein the nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. One or more heteroatoms (e.g., N, S, Si, or P) may be placed at any interior position of the heteroalkyl group or at the position where the alkyl group is attached to the rest of the molecule. A heteroalkyl group is an uncyclized chain. Examples include, but are not limited to: -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -CH2-S-CH2-CH3, -S-CH2-CH2, -S(O)-CH3, -CH2-CH2-S(O)2-CH3, -CH=CH-O-CH3, -Si(CH3)3, -CH2-CH=N-OCH3, -CH=CH-N(CH3)-CH3, -O-CH3, -O-CH2-CH3, and -CN. Up to two or three heteroatoms can be consecutive, such as, for example, -CH2-NH-OCH3 and -CH2-O-Si(CH3)3. The heteroalkyl moiety can contain one heteroatom (e.g., O, N, S, Si, or P). The heteroalkyl moiety can contain two optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include three optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include four optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include five optionally different heteroatoms (e.g., O, N, S, Si, or P). The heteroalkyl moiety may include up to 8 optionally different heteroatoms (e.g., O, N, S, Si, or P). Unless otherwise stated, the term "heteroalkenyl" by itself or in combination with another term means a heteroalkyl group comprising at least one double bond. The heteroalkyl group may optionally include more than one double bond and / or one or more triple bonds in addition to one or more double bonds. Unless otherwise stated, the term "heteroalkynyl" by itself or in combination with another term means a heteroalkyl group comprising at least one triple bond. The heteroalkynyl group may optionally include more than one triple bond and / or one or more double bonds in addition to one or more triple bonds. In an embodiment, the heteroalkyl group is fully saturated. In an embodiment, the heteroalkyl group is monounsaturated. In an embodiment, the heteroalkyl group is polyunsaturated.

[0065] Similarly, unless otherwise stated, the term "heteroalkylene," by itself or as part of another substituent, means a divalent radical derived from a heteroalkyl group, such as, but not limited to, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene, heteroatoms may also occupy either or both of the chain termini (e.g., alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediamino, etc.). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)2R'- represents both -C(O)2R'- and -R'C(O)2-. As described above, heteroalkyl groups as used herein include those groups that are attached to the rest of the molecule through a heteroatom, such as -C(O)R', -C(O)NR', ​​-NR'R", -OR', -SR' and / or -S02R'. Where the recitation of "heteroalkyl" is followed by a recitation of a specific heteroalkyl group, such as -NR'R", it should be understood that the terms heteroalkyl and -NR'R" are not redundant or mutually exclusive. Rather, the recitation of the specific heteroalkyl group is for added clarity. Thus, the term "heteroalkyl" should not be construed herein to exclude specific heteroalkyl groups, such as -NR'R", etc. The term "heteroalkenylene" by itself or as part of another substituent means, unless otherwise stated, a divalent radical derived from a heteroalkene. The term "heteroalkynyl" by itself or as part of another substituent means, unless otherwise stated, a divalent radical derived from a heteroalkyne. In an embodiment, a heteroalkylene is fully saturated. In an embodiment, a heteroalkylene is monounsaturated. In an embodiment, a heteroalkylene is polyunsaturated. A heteroalkenylene includes one or more double bonds. Heteroalkynylene groups include one or more triple bonds.

[0066] Unless otherwise stated, the terms "cycloalkyl" and "heterocycloalkyl," alone or in combination with other terms, mean cyclic versions of "alkyl" and "heteroalkyl," respectively. Cycloalkyl and heterocycloalkyl are not aromatic. Additionally, for heterocycloalkyl, a heteroatom may occupy the position at which the heterocycle is attached to the rest of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, 3-cyclohexenyl, cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1-(1,2,5,6-tetrahydropyridinyl), 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-morpholinyl, 3-morpholinyl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothiophen-2-yl, tetrahydrothiophen-3-yl, 1-piperazinyl, 2-piperazinyl, and the like. "Cycloalkylene" and "heterocycloalkylene," by themselves or as part of another substituent, mean a divalent radical derived from cycloalkyl and heterocycloalkyl, respectively. In embodiments, cycloalkyl is fully saturated. In embodiments, cycloalkyl is monounsaturated. In embodiments, cycloalkyl is polyunsaturated. In embodiments, heterocycloalkyl is fully saturated. In embodiments, heterocycloalkyl is monounsaturated. In embodiments, heterocycloalkyl is polyunsaturated.

[0067] In embodiments, the term "cycloalkyl" refers to a monocyclic, bicyclic, or polycyclic cycloalkyl ring system. In embodiments, a monocyclic ring system is a cycloalkyl group containing from 3 to 8 carbon atoms, wherein such groups may be saturated or unsaturated, but not aromatic. In embodiments, a cycloalkyl group is fully saturated. A bicyclic or polycyclic cycloalkyl ring system refers to multiple rings fused together, wherein at least one of the fused rings is a cycloalkyl ring, and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within the cycloalkyl rings of the multiple rings.

[0068] In an embodiment, a cycloalkyl is a cycloalkenyl. The term "cycloalkenyl" is used according to its ordinary general meaning. In an embodiment, a cycloalkenyl is a monocyclic, bicyclic, or polycyclic cycloalkenyl ring system. A bicyclic or polycyclic cycloalkenyl ring system refers to a plurality of rings fused together, wherein at least one of the fused rings is a cycloalkenyl ring, and wherein the plurality of rings is attached to the parent molecular moiety through any carbon atom contained within the cycloalkenyl rings of the plurality of rings.

[0069] In embodiments, the term "heterocycloalkyl" means a monocyclic, bicyclic, or polycyclic heterocycloalkyl ring system. In embodiments, the heterocycloalkyl is fully saturated. A bicyclic or polycyclic heterocycloalkyl ring system refers to multiple rings fused together, wherein at least one of the fused rings is a heterocycloalkyl ring, and wherein the multiple rings are attached to the parent molecular moiety through any carbon atom contained within the heterocycloalkyl rings of the multiple rings.

[0070] Unless otherwise stated, the term "halo" or "halogen," alone or as part of another substituent, means a fluorine, chlorine, bromine, or iodine atom. Additionally, terms like "haloalkyl" are meant to include monohaloalkyl and polyhaloalkyl. For example, the term "halo(C1-C4)alkyl" includes, but is not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.

[0071] Unless otherwise indicated, the term "acyl" means -C(O)R, where R is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

[0072] Unless otherwise indicated, the term "aryl" means a polyunsaturated aromatic hydrocarbon substituent, which can be a monocyclic or polycyclic ring (preferably 1 to 3 rings) that are fused together (i.e., fused ring aryl) or covalently linked. A fused ring aryl refers to multiple rings fused together, wherein at least one fused ring is an aromatic ring, and wherein the multiple rings are attached to the parent molecular moiety via any carbon atom contained within the aromatic rings of the multiple rings. The term "heteroaryl" refers to an aryl group (or ring) containing at least one heteroatom (such as N, O, or S), wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atoms are optionally quaternized. Thus, the term "heteroaryl" includes fused ring heteroaryls (i.e., multiple rings fused together, wherein at least one fused ring is a heteroaromatic ring, and wherein the multiple rings are attached to the parent molecular moiety via any atom contained within the heteroaromatic rings of the multiple rings). A 5,6-fused ring heteroarylene refers to two rings fused together, wherein one ring has 5 members and the other ring has 6 members, and wherein at least one ring is a heteroaryl ring. Likewise, a 6,6-fused ring heteroarylene refers to two rings fused together, one ring having 6 members and the other having 6 members, and wherein at least one ring is a heteroaryl ring. And a 6,5-fused ring heteroarylene refers to two rings fused together, one ring having 6 members and the other having 5 members, and wherein at least one ring is a heteroaryl ring. A heteroaryl group can be attached to the rest of the molecule through a carbon or heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, naphthyl, pyrrolyl, pyrazolyl, pyridazinyl, triazinyl, pyrimidinyl, imidazolyl, pyrazinyl, purinyl, oxazolyl, isoxazolyl, thiazolyl, furanyl, thienyl, pyridyl, pyrimidinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzofuran, isobenzofuranyl, indolyl, isoindolyl, benzothienyl, isoquinolyl, quinoxalinyl, quinolyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below. "Arylene" and "heteroarylene," by themselves or as part of another substituent, mean a divalent radical derived from aryl and heteroaryl, respectively. A heteroaryl substituent can be -O- bonded to a ring heteroatom nitrogen.

[0073] Spirocycle is two or more rings in which adjacent rings are connected by a single atom. The single rings in the spirocycle can be the same or different. The single ring in the spirocycle can be substituted or unsubstituted and can have substituents different from other single rings in the spirocycle set. The possible substituents of each ring in the spirocycle are possible substituents of the same ring (when not part of the spirocycle) (for example, substituents of a cycloalkyl ring or a heterocycloalkyl ring). The spirocycle can be substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heterocycloalkylene, and each ring in the spirocyclic group can be any ring in the previous list, including all rings with one type (for example, all rings are substituted heterocycloalkylene, wherein each ring can be the same or different substituted heterocycloalkylene). When referring to a spirocycle system, heterocyclic spirocycle means a spirocycle in which at least one ring is a heterocycle and wherein each ring can be a different ring. When referring to a spiro ring system, substituted spiro means that at least one ring is substituted and each substituent may optionally be different.

[0074] symbol Indicates the point of attachment of a chemical moiety to the rest of a molecule or chemical formula.

[0075] As used herein, the term "oxo" refers to an oxygen double-bonded to a carbon atom.

[0076] The term "alkylarylene" is an arylene moiety covalently bonded to an alkylene moiety (also referred to herein as an alkylene linker). In an embodiment, the alkylarylene group has the formula:

[0077]

[0078] The alkylenaryl moiety can be substituted (e.g., with a substituent) at the alkylenyl moiety or arylene linker, e.g., at carbon 2, 3, 4, or 6, with halogen, oxo, -N3, -CF3, -CCl3, -CBr3, -CI3, -CN, -CHO, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO2CH3, -SO3H, -OSO3H, -SONH2, -NHNH2, -ONH2, -NHC(O)NHNH2, substituted or unsubstituted C1-C5 alkyl, or substituted or unsubstituted 2-5 membered heteroalkyl. In an embodiment, the alkylenaryl group is unsubstituted.

[0079] Each of the above terms (e.g., "alkyl," "heteroalkyl," "cycloalkyl," "heterocycloalkyl," "aryl," and "heteroaryl") includes substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.

[0080] Substituents for alkyl and heteroalkyl groups (including those groups commonly referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyl, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) can be one or more of a variety of groups selected from, but not limited to, -OR', =O, =NR', =N-OR', -NR'R', -SR', halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -C02R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'C(O)NR"R"', -NR" C(O)2R′, -NRC(NR′R″R″′)=NR″″, -NRC(NR′R″)=NR″′, -S(O)R′, -S(O)2R′, -S(O)2NR′R″, -NRSO2R′, -NR′NR″R″′, -ONR′R″, -NR′C(O)NR″NR″′R″″, -CN, -NO2, -NR′SO2R″, -NR′C(O)R″, -NR′C(O)OR″, -NR′OR″, in a number ranging from zero to (2m′+1), where m′ is the total number of carbon atoms in such a group. R, R', R", R'' and R"" each preferably independently represent hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl (e.g., aryl substituted with 1-3 halogens), substituted or unsubstituted heteroaryl, substituted or unsubstituted alkyl, alkoxy or thioalkoxy, or aralkyl. When a compound described herein contains more than one R group, each of the R groups is independently selected, for example, as are each R' group, R" group, R"' group, and R"" group when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can combine with the nitrogen atom to form a 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" includes, but is not limited to, 1-pyrrolidinyl and 4-morpholinyl. Based on the above discussion of substituents, one skilled in the art will understand that the term "alkyl" is intended to include groups containing carbon atoms bonded to groups other than hydrogen groups, such as haloalkyl groups (e.g., -CF3 and -CH2CF3) and acyl groups (e.g., -C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, etc.).

[0081] Similar to the substituents described for alkyl groups, the substituents for aryl and heteroaryl groups are varied and are selected from, for example, -OR', -NR'R", -SR', halogen, -SiR'R"R"', -OC(O)R', -C(O)R', -C02R', -CONR'R", -OC(O)NR'R", -NR"C(O)R', -NR'C(O)NR"R"', -NR"C(O)2R', -NR-C(NR'R"R"')=NR"", -NR-C(NR'R")=NR"', -S(O)R', -S(O)2R', -S(O)2NR'R", -NRSO2R', -NR'NR"R"', -ONR'R", -NR'C(O)NR"NR"'R"', -CN, NO2, -R', -N 3, -CH(Ph)2, fluoro(C1-C4)alkoxy and fluoro(C1-C4)alkyl, -NR'S02R", -NR'C(O)R", -NR'C(O)OR", -NR'OR", in a number ranging from zero to the total number of open valences on the aromatic ring system; and wherein R', R", R'' and R"' are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. When a compound described herein contains more than one R group, for example, each of the R groups is independently selected as each R' group, R" group, R"' group and R"" group is independently selected when more than one of these groups is present.

[0082] The substituents of a ring (e.g., cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylidene, heterocycloalkylidene, arylidene or heteroarylidene) can be depicted as substituents on the ring rather than on the specific atom of the ring (commonly referred to as floating substituents). In this case, the substituent can be connected to any of the ring atoms (following chemical valence rules), and in the case of a fused ring or spirocycle, the substituent depicted as being associated with a member of the fused ring or spirocycle (floating substituent on a monocycle) can be a substituent on any of the fused rings or spirocycles (floating substituents on multiple rings). When the substituent is connected to the ring rather than a specific atom (floating substituent) and the subscript of the substituent is an integer greater than one, multiple substituents can be located on the same atom, the same ring, different atoms, different fused rings, different spirocycles, and each substituent can optionally be different. In the case where the point of attachment of the ring to the rest of the molecule is not limited to a single atom (floating substituent), the point of attachment can be any atom of the ring, and in the case of a fused ring or spirocycle, it can be any atom of any of the fused rings or spirocycles (following chemical valence rules). Where a ring, fused ring or spiro ring contains one or more ring heteroatoms and the ring, fused ring or spiro ring is shown as having a further floating substituent (including but not limited to a point of attachment to the rest of the molecule), the floating substituent may be bonded to the heteroatom. When a ring heteroatom is shown bonded to one or more hydrogens in a structure or formula having a floating substituent (e.g., a ring nitrogen with two bonds to a ring atom and a third bond to a hydrogen), the substituent will be understood to replace the hydrogen when the heteroatom is bonded to the floating substituent, while respecting chemical valence rules.

[0083] In another embodiment, the ring-forming substituent is connected to the adjacent members of the basic structure. For example, two ring-forming substituents connected with the adjacent members of the cyclic basic structure produce condensed ring structure. In another embodiment, the ring-forming substituent is connected to the single member of the basic structure. For example, two ring-forming substituents connected with the single member of the cyclic basic structure produce spirocyclic structure. In another embodiment, the ring-forming substituent is connected to the non-adjacent members of the basic structure.

[0084] Two substituents on adjacent atoms of an aryl or heteroaryl ring may optionally form a group of the formula -TC(O)-(CRR') q -U-, wherein T and U are independently -NR-, -O-, -CRR'- or a single bond, and q is an integer from 0 to 3. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally replaced by a substituent of the formula -A-(CH2) rwherein A and B are independently -CRR'-, -O-, -NR-, -S-, -S(O)-, -S(O)2-, -S(O)2NR'-, or a single bond, and r is an integer from 1 to 4. One of the single bonds of the new ring thus formed may optionally be replaced by a double bond. Alternatively, two substituents on adjacent atoms of the aryl or heteroaryl ring may be optionally replaced by substituents of the formula: -(CRR') s -X′-(C″R″R″′) d- , wherein s and d are independently integers from 0 to 3, and X′ is —O—, —NR 7 -, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 7 C(O)-、-C(O)NR 7 -、-NR 7 C(O)NR 8 -、-NR 7 S(O)2O-、-OS(O)2NR 7 -、-NR 7 S(O)2-、-S(O)2NR 7 -, -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OR 7 )-、-OP(O)(OR 7 )O-、-OP(O)(OR 7 )-、-P(O)(OR 7 )O-, -S(O)2- or -S(O)2NR'-. The substituents R, R', R" and R'" are preferably independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.

[0085] As used herein, the term "heteroatom" or "ring heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), selenium (Se), and silicon (Si). In an embodiment, the term "heteroatom" or "ring heteroatom" is meant to include oxygen (O), nitrogen (N), sulfur (S), phosphorus (P), and silicon (Si).

[0086] As used herein, "substituent group" means a group selected from the following moieties:

[0087] (A) Oxo, halogen, -CCl3, -CBr3, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCl2, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I, -OCH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC (O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C8 10 Aryl, c 10 aryl or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0088] (B) an alkyl group (e.g., a C1-C8 alkyl group, a C1-C6 alkyl group, or a C1-C4 alkyl group), a heteroalkyl group (e.g., a 2- to 8-membered heteroalkyl group, a 2- to 6-membered heteroalkyl group, or a 2- to 4-membered heteroalkyl group), a cycloalkyl group (e.g., a C3-C8 cycloalkyl group, a C3-C6 cycloalkyl group, or a C5-C6 cycloalkyl group), a heterocycloalkyl group (e.g., a 3- to 8-membered heterocycloalkyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heterocycloalkyl group), an aryl group (e.g., a C6 ... 10 Aryl, C 10 aryl or phenyl), heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl):

[0089] (i) oxo, halogen, -CCl3, -CBr3, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCl2, -OCHBr2, -OCHl2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I, -OCH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC (O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C8 10 Aryl, C 10 aryl or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0090] (ii) an alkyl group (e.g., a C1-C8 alkyl group, a C1-C6 alkyl group, or a C1-C4 alkyl group), a heteroalkyl group (e.g., a 2- to 8-membered heteroalkyl group, a 2- to 6-membered heteroalkyl group, or a 2- to 4-membered heteroalkyl group), a cycloalkyl group (e.g., a C3-C8 cycloalkyl group, a C3-C6 cycloalkyl group, or a C5-C6 cycloalkyl group), a heterocycloalkyl group (e.g., a 3- to 8-membered heterocycloalkyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heterocycloalkyl group), an aryl group (e.g., a C6 ... 10 Aryl, C 10 aryl or phenyl), heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl):

[0091] (a) oxo, halogen, -CCl3, -CBr3, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCl2, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCH2I, -OCH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC (O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C8 10 Aryl, C 10 aryl or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), and

[0092] (b) alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), heteroalkyl (e.g., 2- to 8-membered heteroalkyl, 2- to 6-membered heteroalkyl, or 2- to 4-membered heteroalkyl), cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), heterocycloalkyl (e.g., 3- to 8-membered heterocycloalkyl, 3- to 6-membered heterocycloalkyl, or 5- to 6-membered heterocycloalkyl), aryl (e.g., C6-C 10 Aryl, C 10-aryl or phenyl), heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl), which is substituted by at least one substituent selected from the group consisting of oxo, halogen, -CCl3, -CBr3, -CF3, -CI3, -CHCl2, -CHBr2, -CHF2, -CHI2, -CH2Cl, -CH2Br, -CH2F, -CH2I, -OCCl3, -OCF3, -OCBr3, -OCI3, -OCHCl2, -OCHBr2, -OCHI2, -OCHF2, -OCH2Cl, -OCH2Br, -OCHI, -OCH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OS O3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, -SF5, unsubstituted alkyl (e.g., C1-C8 alkyl, C1-C6 alkyl, or C1-C4 alkyl), unsubstituted heteroalkyl (e.g., 2-8 membered heteroalkyl, 2-6 membered heteroalkyl, or 2-4 membered heteroalkyl), unsubstituted cycloalkyl (e.g., C3-C8 cycloalkyl, C3-C6 cycloalkyl, or C5-C6 cycloalkyl), unsubstituted heterocycloalkyl (e.g., 3-8 membered heterocycloalkyl, 3-6 membered heterocycloalkyl, or 5-6 membered heterocycloalkyl), unsubstituted aryl (e.g., C6-C 10 Aryl, C 10 aryl, or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered heteroaryl, 5- to 9-membered heteroaryl, or 5- to 6-membered heteroaryl).

[0093] As used herein, "a substituent of limited size" or "a substituent of limited size" means a group selected from all substituents described above for "a substituent", wherein each substituted or unsubstituted alkyl group is a substituted or unsubstituted C1-C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2-20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3-8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 10-membered heteroaryl.

[0094] As used herein, a “lower substituent” or “lower substituent group” means a group selected from all substituents described above for “substituent”, wherein each substituted or unsubstituted alkyl is a substituted or unsubstituted C1-C8 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2- to 8-membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C7 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3- to 7-membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted phenyl, and each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 6-membered heteroaryl.

[0095] In some embodiments, each substituted group described in the compounds herein is substituted with at least one substituent. More specifically, in some embodiments, each substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene described in the compounds herein is substituted with at least one substituent. In other embodiments, at least one or all of these groups are substituted with at least one substituent of limited size. In other embodiments, at least one or all of these groups are substituted with at least one low substituent.

[0096] In other embodiments of the compounds herein, each substituted or unsubstituted alkyl group may be a substituted or unsubstituted C1-C 20 alkyl, each substituted or unsubstituted heteroalkyl is a substituted or unsubstituted 2-20 membered heteroalkyl, each substituted or unsubstituted cycloalkyl is a substituted or unsubstituted C3-C8 cycloalkyl, each substituted or unsubstituted heterocycloalkyl is a substituted or unsubstituted 3-8 membered heterocycloalkyl, each substituted or unsubstituted aryl is a substituted or unsubstituted C6-C 10 aryl, and / or each substituted or unsubstituted heteroaryl is a substituted or unsubstituted 5- to 10-membered heteroaryl. In some embodiments of the compounds herein, each substituted or unsubstituted alkylene is a substituted or unsubstituted C1-C 20alkylene, each substituted or unsubstituted heteroalkylene is a substituted or unsubstituted 2-20 membered heteroalkylene, each substituted or unsubstituted cycloalkylene is a substituted or unsubstituted C3-C8 cycloalkylene, each substituted or unsubstituted heterocycloalkylene is a substituted or unsubstituted 3-8 membered heterocycloalkylene, each substituted or unsubstituted arylene is a substituted or unsubstituted C6-C8 10 The arylene group, and / or each substituted or unsubstituted heteroarylene group is a substituted or unsubstituted 5- to 10-membered heteroarylene group.

[0097] In some embodiments, each substituted or unsubstituted alkyl group is a substituted or unsubstituted C1-C8 alkyl group, each substituted or unsubstituted heteroalkyl group is a substituted or unsubstituted 2-8 membered heteroalkyl group, each substituted or unsubstituted cycloalkyl group is a substituted or unsubstituted C3-C7 cycloalkyl group, each substituted or unsubstituted heterocycloalkyl group is a substituted or unsubstituted 3-7 membered heterocycloalkyl group, each substituted or unsubstituted aryl group is a substituted or unsubstituted C6-C 10 In some embodiments, each substituted or unsubstituted alkylene group is a substituted or unsubstituted C1-C8 alkylene group, each substituted or unsubstituted heteroalkylene group is a substituted or unsubstituted 2-8 membered heteroalkylene group, each substituted or unsubstituted cycloalkylene group is a substituted or unsubstituted C3-C7 cycloalkylene group, each substituted or unsubstituted heterocycloalkylene group is a substituted or unsubstituted 3-7 membered heterocycloalkylene group, each substituted or unsubstituted arylene group is a substituted or unsubstituted C6-C8 alkylene group. 10 The arylene group, and / or each substituted or unsubstituted heteroarylene group is a substituted or unsubstituted 5- to 9-membered heteroarylene group. In some embodiments, the compound is a chemical species described in the Examples section, Figures, or Tables below.

[0098] In embodiments, a substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is unsubstituted (e.g., unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, unsubstituted heteroaryl, unsubstituted alkylene, unsubstituted heteroalkylene, unsubstituted cycloalkylene, unsubstituted heterocycloalkylene, unsubstituted arylene, and / or unsubstituted heteroalkylene, respectively). In embodiments, the substituted or unsubstituted moiety (e.g., substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, and / or substituted or unsubstituted heteroarylene) is substituted (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene, respectively).

[0099] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent, wherein if the substituted moiety is substituted with multiple substituents, each substituent may optionally be different. In an embodiment, if the substituted moiety is substituted with multiple substituents, each substituent is different.

[0100] In embodiments, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one size-restricted substituent, wherein if the substituted moiety is substituted with multiple size-restricted substituents, each size-restricted substituent can optionally be different. In embodiments, if the substituted moiety is substituted with multiple size-restricted substituents, each size-restricted substituent is different.

[0101] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one lower substituent, wherein if the substituted moiety is substituted with multiple lower substituents, each lower substituent may optionally be different. In an embodiment, if the substituted moiety is substituted with multiple lower substituents, each lower substituent is different.

[0102] In an embodiment, a substituted moiety (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, substituted heteroaryl, substituted alkylene, substituted heteroalkylene, substituted cycloalkylene, substituted heterocycloalkylene, substituted arylene, and / or substituted heteroarylene) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted moiety is substituted with multiple groups selected from substituents, size-restricted substituents, or lower substituents; each substituent, size-restricted substituent, and / or lower substituent may optionally be different. In an embodiment, if the substituted moiety is substituted with multiple groups selected from substituents, size-restricted substituents, or lower substituents; each substituent, size-restricted substituent, and / or lower substituent is different.

[0103] In the claims or formula descriptions described herein, each R substituent or L linker described as "substituted," without reference to the identity of any chemical moiety comprising the "substituted" group (also referred to herein as "open substitution" on the R substituent or L linker or an "openly substituted" R substituent or L linker), in embodiments, may be substituted with one or more first substituents as defined below.

[0104] The first substituent is represented by the corresponding first decimal point numbering system, so that, for example, R 1You can use one or more R 1.1 The first substituent represented by R 2 You can use one or more R 2.1 The first substituent represented by R 3 You can use one or more R 3.1 The first substituent represented by R 4 You can use one or more R 4.1 The first substituent represented by R 5 You can use one or more R 5.1 The first substituent represented by R may be substituted, and so on up to or beyond the first substituent represented by R 100.1 The first substituent substituted R 100 As another example, R 1A One or more R 1A.1 The first substituent represented by R 2A One or more R 2A.1 The first substituent represented by R 3A One or more R 3A.1 The first substituent represented by R 4A One or more R 4A.1 The first substituent represented by R 5A One or more R 5A.1 The first substituent represented by R is substituted, and so on until or beyond R 100A One or more R 100A.1 As another example, L 1 One or more R L1.1 The first substituent represented by L 2 One or more R L2.1 The first substituent represented by L 3 One or more R L3.1 The first substituent represented by L 4 One or more R L4.1 The first substituent represented by L 5 One or more R L5.1 The first substituent represented by L is substituted, and so on until or beyond L 100 One or more R L100.1 Thus, each numbered R group or L group (or R herein) described herein is substituted with the first substituent represented by WW or L WW , wherein "WW" represents the superscript number of the subject R group or L group) can be respectively replaced by one or more groups generally referred to herein as R WW.1 or RLWW.1 Then, each first substituent (e.g., R 1.1 、R 2.1 、R 3.1 、R 4.1 、R 5.1 ...R 100.1 ; R 1A.1 、R 2A.1 、R 3A.1 、R 4A.1 、R 5A.1 ...R 100A.1 ; R L1.1 、R L2.1 、R L3.1 、R L4.1 、R L5.1 ...R L100.1 ) may be replaced by one or more second substituents (e.g., R 1.2 、R 2.2 、R 3.2 、R 4.2 、R 5.2 ...R 100.2 ; R 1A.2 、R 2A.2 、R 3A.2 、R 4A.2 、R 5A.2 ...R 100A.2 ; R L1.2 、R L2.2 、R L3.2 、R L4.2 、R L5.2 ...R L100.2 ) is further substituted. Thus, each first substituent, which may alternatively be represented herein as R as described above WW.1 , which may be further substituted by one or more second substituents, which may alternatively be represented herein as R WW.2 .

[0105] Finally, each second substituent (e.g., R 1.2 、R 2.2 、R 3.2 、R 4.2 、R 5.2 ...R 100.2 ; R 1A.2 、R 2A.2 、R 3A.2 、R 4A.2 、R SA.2 ...R 100A.2 ; R L1.2 、R L2.2 、R L3.2 、R L4.2 、R L5.2...R L100.2 ) may be replaced by one or more third substituents (e.g., R 1.3 、R 2.3 、R 3.3 、R 4.3 、R 5.3 ...R 100.3 ; R 1A.3 、R 2A.3 、R 3A.3 、R 4A.3 、R 5A.3 ...R 100A.3 ; R L1.3 、R L2.3 、R L3.3 、R L4.3 、R L5.3 ...R L100.3 ;) further substituted. Thus, each second substituent, which may alternatively be represented herein as R as described above WW.2 , may be further substituted by one or more third substituents, which may alternatively be represented herein as R WW.3 Each of the first substituents may optionally be different. Each of the second substituents may optionally be different. Each of the third substituents may optionally be different.

[0106] Therefore, as used herein, R WW "WW" represents the substituents described in the claims or chemical formula description herein. "WW" represents the superscript number of the subject R group (1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). Similarly, L WW is an open substituted linker as described in the claims or in the chemical formula description herein. Likewise, "WW" represents the superscript number of the subject L group (1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). As described above, in embodiments, each R WW may be unsubstituted or independently substituted with one or more substituted radicals referred to herein as R WW.1 The first substituent of each substituent R WW.1 may be unsubstituted or independently substituted with one or more substituted radicals referred to herein as R WW.2 and each second substituent may be unsubstituted or independently substituted with one or more substituents referred to herein as R WW.3 Similarly, each L WW The linker may be unsubstituted or independently substituted with one or more residues referred to herein as R LWW.1 The first substituent of each substituent R LWW.1 may be unsubstituted or independently substituted with one or more substituted radicals referred to herein as RLWW.2 and each second substituent may be unsubstituted or independently substituted with one or more substituents referred to herein as R LWW.3 Each first substituent is optionally different. Each second substituent is optionally different. Each third substituent is optionally different. For example, if R WW is phenyl, then the phenyl group is optionally replaced by one or more R WW.1 Group substitution, for example, when R WW.1 R WW.2 - substituted or unsubstituted alkyl, examples of such groups include but are not limited to itself optionally substituted with one or more R WW.2 Substituted, the R WW.2 Optionally, one or more R WW.3 For example, when R WW The group is R WW.1 When phenyl is substituted, the methyl group may be further substituted to form groups including but not limited to the following:

[0107]

[0108] R WW.1 are independently oxo, halogen, -CX WW.1 3. -CHX WW.1 2. -CH2X WW.1 、-OCX WW.1 3. -OCH2X WW.1 、-OCHX WW.1 2. -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(0)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(0)H, -NHC(O)OH, -NHOH, -N3, R WW.2 - substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2), R WW.2 - substituted or unsubstituted heteroalkyl (eg, 2-8 membered, 2-6 membered, 4-6 membered, 2-3 membered, or 4-5 membered), R WW.2 - substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), R WW.2 - substituted or unsubstituted heterocycloalkyl (e.g., 3-8 membered, 3-6 membered, 4-6 membered, 4-5 membered, or 5-6 membered), R WW.2 - substituted or unsubstituted aryl (e.g., C6-C12 、C6-C 10 or phenyl), or R WW.2 - substituted or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). In one embodiment, R WW.1 are independently oxo, halogen, -CX WW.1 3. -CHX WW.1 2. CH2X WW.1 、-OCX WW.1 3. -OCH2X WW.1 、-OCHX WW.1 2, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, unsubstituted alkyl (e.g. , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5 or 5-6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). X WW.1 are independently -F, -Cl, -Br or -I.

[0109] R WW.2 are independently oxo, halogen, -CX WW.2 3. -CHX WW.2 2. -CH2X WW.2 、-OCX WW.2 3. -OCH2X WW.2 、-OCHX WW.2 2. -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, R WW.3- substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2), R WW.3 - substituted or unsubstituted heteroalkyl (eg, 2-8 membered, 2-6 membered, 4-6 membered, 2-3 membered, or 4-5 membered), R WW.3 - substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6 or C s -C6), R WW.3 - substituted or unsubstituted heterocycloalkyl (e.g., 3-8 membered, 3-6 membered, 4-6 membered, 4-5 membered, or 5-6 membered), R WW.3 - substituted or unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or R WW.3 - substituted or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). In one embodiment, R WW.2 are independently oxo, halogen, -CX WW.2 3. -CHX WW.2 2. -CH2X WW.2 、-OCX WW.2 3. -OCH2X WW.2 、-OCHX WW.2 2, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, unsubstituted alkyl (e.g. , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5 or 5-6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). X WW.2 are independently -F, -Cl, -Br or -I.

[0110] R WW.3 are independently oxo, halogen, -CX WW.3 3. -CHX WW.3 2. -CH2XWW.3 、-OCX WW.3 3. -OCH2X WW.3 、-OCHX WW.3 2, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, unsubstituted alkyl (e.g. , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5 or 5-6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). X WW.3 are independently -F, -Cl, -Br or -I.

[0111] In two different R WW Where substituents are joined together to form an open substituted ring (e.g., a substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl), in embodiments, the open substituted ring may be independently replaced by one or more substituents referred to herein as R WW.1 The first substituent of each substituent R WW.1 may be unsubstituted or independently substituted with one or more substituted radicals referred to herein as R WW.2 and each second substituent R WW.2 may be unsubstituted or independently substituted with one or more substituted radicals referred to herein as R WW.3 and each third substituent R WW.3 is unsubstituted. Each first substituent is optionally different. Each second substituent is optionally different. Each third substituent is optionally different. WW When the substituents are joined together to form an open substituted ring, R WW.1 、R WW.2 and R WW.3 The "WW" symbol in the code refers to two different R WW The specified number of one of the substituents. For example, in R 100A and R100B In embodiments where R is optionally joined to form an open substituted ring, WW.1 R 100A.1 、R WW.2 R 100A.2 , and R WW.3 R 100A.3 Alternatively, in R 100A and R 100B In embodiments where R is optionally joined to form an open substituted ring, WW.1 R 100B.1 、R WW.2 R 100B.2 , and R WW.3 R 100B.3 . R in this paragraph WW.1 、R WW.2 and R WW.3 As defined in the preceding paragraph.

[0112] R LWW.1 are independently oxo, halogen, -CX LWW.1 3. -CHX LWW.1 2. -CH2X LWW.1 、-OCX LWW.1 3. -OCH2X LWW.1 、-OCHX LWW.1 2. -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, R LWW.2 - substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2), R LWW.2 - substituted or unsubstituted heteroalkyl (eg, 2-8 membered, 2-6 membered, 4-6 membered, 2-3 membered, or 4-5 membered), R LWW.2 - substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), R LWW.2 - substituted or unsubstituted heterocycloalkyl (e.g., 3-8 membered, 3-6 membered, 4-6 membered, 4-5 membered, or 5-6 membered), R LWW.2 - substituted or unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or R LWW.2 - substituted or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). In one embodiment, RLWW.1 are independently oxo, halogen, -CX LWW.1 3. -CHX LWW.1 2. -CH2X LWW.1 、-OCX LWW.1 3. -OCH2X LWW.1 、-OCHX LWW.1 2, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, unsubstituted alkyl (e.g. , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5 or 5-6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). X LWW.1 are independently -F, -Cl, -Br or -I.

[0113] R LWW.2 are independently oxo, halogen, -CX LWW.2 3. -CHX LWW.2 2. -CH2X LWW.2 、-OCX LWW.2 3. -OCH2X LWW.2 、-OCHX LWW.2 2. -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, R LWW.3 - substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2), R LWW.3 - substituted or unsubstituted heteroalkyl (eg, 2-8 membered, 2-6 membered, 4-6 membered, 2-3 membered, or 4-5 membered), R WW.3- substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), R LWW.3 - substituted or unsubstituted heterocycloalkyl (e.g., 3-8 membered, 3-6 membered, 4-6 membered, 4-5 membered, or 5-6 membered), R LWW.3 - substituted or unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or R LWW.3 - substituted or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). In one embodiment, R LWW.2 are independently oxo, halogen, -CX LWW.2 3. -CHX LWW.2 2. -CH2X LWW.2 、-OCX LWW.2 3. -OCH2X LWW.2 、-OOCHX LWW.2 2, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, unsubstituted alkyl (e.g. , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5 or 5-6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). X LWW.2 are independently -F, -Cl, -Br or -I.

[0114] R LWW.3 are independently oxo, halogen, -CX LWW.3 3. -CHX LWW.3 2. -CH2X LWW.3 、-OCX LWW.3 3. -OCH2X LWW.3 、-OCHX LWW.32, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(O)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, unsubstituted alkyl (e.g. , C1-C8, C1-C6, C1-C4 or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3 or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6 or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5 or 5-6 members), unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). X LWW.3 are independently -F, -Cl, -Br or -I.

[0115] Any R group (R WW In the case where a substituent) is not specifically defined in the present disclosure, the R group (R WW Groups) are thus defined as being independently oxo, halogen, -CX WW 3. -CHX WW 2. -CH2X WW 、-OCX WW 3. -OCH2X WW 、-OCHX WW 2. -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -SO3H, -OSO3H, -SO2NH2, -NHNH2, -ONH2, -NHC(O)NHNH2, -NHC(0)NH2, -NHC(NH)NH2, -NHSO2H, -NHC(O)H, -NHC(O)OH, -NHOH, -N3, R WW.1 - substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2), R WW.1 - substituted or unsubstituted heteroalkyl (eg, 2-8 membered, 2-6 membered, 4-6 membered, 2-3 membered, or 4-5 membered), R WW.1 - substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), R WW.1- substituted or unsubstituted heterocycloalkyl (e.g., 3-8 membered, 3-6 membered, 4-6 membered, 4-5 membered, or 5-6 membered), R WW.1 - substituted or unsubstituted aryl (e.g., C6-C 12 、C6-C 10 or phenyl), or R WW.1 - substituted or unsubstituted heteroaryl (eg, 5- to 12-membered, 5- to 10-membered, 5- to 9-membered, or 5- to 6-membered). X WW R is independently -F, -Cl, -Br or -I. Likewise, "WW" represents the superscript number of the subject R group (e.g., 1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). WW.1 、R WW.2 and R WW.3 As defined above.

[0116] Any L linker group (i.e., L WW If the substituent) is not clearly defined, the L group (L WW Groups) are defined herein as independently a bond, -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -NHS(O)2O-, -OS(O)2NH-, -NHS(O)2-, -S(O)2NH-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -OP(O)(OH)-, -P(O)(OH)O-, R LWW.1 - substituted or unsubstituted alkylene (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), R LWW.1 - substituted or unsubstituted heteroalkylene (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 membered), R LWW.1 - substituted or unsubstituted cycloalkylene (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), R LWW.1 - substituted or unsubstituted heterocycloalkylene (e.g., 3-8 membered, 3-6 membered, 4-6 membered, 4-5 membered, or 5-6 membered), R LWW.1 - substituted or unsubstituted arylene (e.g., C6-C 12 、C6-C 10 or phenyl), or R LWW.1- substituted or unsubstituted heteroarylene (e.g., 5-12 membered, 5-10 membered, 5-9 membered, or 5-6 membered). Likewise, "WW" represents the superscript number of the subject L group (1, 2, 3, 1A, 2A, 3A, 1B, 2B, 3B, etc.). R LWW.1 and R LWW.2 and R LWW.3 As defined above.

[0117] Certain compounds of the present disclosure have asymmetric carbon atoms (optical or chiral centers) or double bonds; in terms of absolute stereochemistry, they can be defined as (R)- or (S)- of amino acids or as (D)- or (L)- enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms, and each isomer is included within the scope of the present disclosure. The compounds of the present disclosure do not include compounds that are too unstable to be synthesized and / or separated as known in the art. The present disclosure is intended to include compounds in racemic and optically pure forms. Optically active (R)- and (S)- or (D)- and (L)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless otherwise indicated, it is intended that these compounds contain both E and Z geometric isomers.

[0118] As used herein, the term "isomers" refers to compounds that have the same number and kind of atoms, and therefore the same molecular weight, but differ in the structural arrangement or configuration of the atoms.

[0119] As used herein, the term "tautomer" refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.

[0120] It will be apparent to those skilled in the art that certain compounds of the present disclosure may exist in tautomeric forms and all such tautomeric forms of the compounds are within the scope of the present disclosure.

[0121] Unless otherwise stated, structures depicted herein are also intended to include all stereochemical forms of the structure; that is, the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the present disclosure.

[0122] Unless otherwise stated, structures depicted herein are also intended to include compounds that differ only in the presence or absence of one or more isotopically enriched atoms. For example, structures having a structure other than the replacement of a hydrogen by a deuterium or tritium or by a 13 C-enriched or 14Compounds of the present structures in which a C-enriched carbon replaces a carbon other than carbon are within the scope of the present disclosure.

[0123] The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be treated with, for example, tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) and other radioactive isotopes. All isotopic variations of the compounds of the present disclosure, whether radioactive or non-radioactive, are encompassed within the scope of the present disclosure.

[0124] It should be noted that throughout the application, alternatives are written in Markush groups, for example, in each amino acid position that contains more than one possible amino acid. It is specifically contemplated that each member of the Markush group should be considered individually, thereby comprising another embodiment, and that the Markush group should not be construed as a single unit.

[0125] As used herein, the terms "bioconjugate" and "bioconjugate linker" refer to the association between bioconjugate reactive groups or atoms or molecules of a bioconjugate reactive moiety. The association can be direct or indirect. For example, the conjugation between a first bioconjugate reactive group (e.g., -NH2, -COOH, -N-hydroxysuccinimide, or -maleimide) and a second bioconjugate reactive group (e.g., a sulfhydryl, a sulfur-containing amino acid, an amine, an amine side chain containing an amino acid, or a carboxylate) provided herein can be direct, for example, via a covalent bond or a linker (e.g., a first linker of a second linker), or indirect, for example, via non-covalent bonds (e.g., electrostatic interactions (e.g., ionic bonds, hydrogen bonds, halogen bonds), van der Waals interactions (e.g., dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (π effect), hydrophobic interactions, etc.). In an embodiment, the bioconjugate or bioconjugate linker is formed using bioconjugate chemistry (i.e., the association of two bioconjugate reactive groups), including but not limited to nucleophilic substitution (e.g., reaction of amines and alcohols with acyl halides, active esters), electrophilic substitution (e.g., enamine reaction), and addition of carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael reaction, Diels-Alder addition). These and other useful reactions are discussed, for example, in March, ADVANCED ORGANIC CHEMISTRY, 3rd ed., John Wiley & Sons, New York, 1985; Hermanson, BIOCONJUGATE TECHNIQUES, Academic Press, San Diego, 1996; and Feeney et al., MODIFICATION OF PROTEINS; Advances in Chemistry Series, Vol. 198, American Chemical Society, Washington, DC, 1982. In embodiments, a first bioconjugate reactive group (e.g., a maleimide moiety) is covalently linked to a second bioconjugate reactive group (e.g., a sulfhydryl group). In embodiments, a first bioconjugate reactive group (e.g., a haloacetyl moiety) is covalently linked to a second bioconjugate reactive group (e.g., a sulfhydryl group). In embodiments, a first bioconjugate reactive group (e.g., a pyridyl moiety) is covalently linked to a second bioconjugate reactive group (e.g., a sulfhydryl group). In embodiments, a first bioconjugate reactive group (e.g., an N-hydroxysuccinimide moiety) is covalently linked to a second bioconjugate reactive group (e.g., a sulfhydryl group). In embodiments, a first bioconjugate reactive group (e.g., a maleimide moiety) is covalently linked to a second bioconjugate reactive group (e.g., a sulfhydryl group).In embodiments, a first bioconjugate reactive group (eg, a -sulfo-N-hydroxysuccinimide moiety) is covalently linked to a second bioconjugate reactive group (eg, an amino group).

[0126] Useful bioconjugate reactive moieties for use in the bioconjugate chemistry herein include, for example: (a) carboxyl groups and their various derivatives, including but not limited to N-hydroxysuccinimide esters, N-hydroxybenzotriazole esters, acid halides, acylimidazoles, thioesters, p-nitrophenyl esters, alkyl esters, alkenyl esters, alkynyl esters, and aromatic esters; (b) hydroxyl groups that can be converted into esters, ethers, aldehydes, etc.; (c) haloalkyl groups, where the halide can subsequently be displaced by a nucleophilic group such as an amine, carboxylate anion, thiol anion, carbonanion, or alkoxide ion, resulting in a new group covalently attached at the position of the halogen atom; (d) dienophilic groups capable of participating in a Diels-Alder reaction, such as a maleimido or maleimide group; (e) aldehyde or ketone groups, which can allow for the formation of carbonyl derivatives such as imines, hydrazones, semicarbazones, or oximes or via (f) sulfonyl halide groups that subsequently react with amines, for example, to form sulfonamides; (g) thiol groups that can be converted to disulfides, reacted with acyl halides, or bonded to metals such as gold, or reacted with maleimides; (h) amines or sulfhydryl groups (e.g., as found in cysteine), which can be, for example, acylated, alkylated, or oxidized; (i) alkenes, which can undergo, for example, cycloadditions, acylations, Michael additions, etc.; (j) epoxides, which can react with, for example, amines and hydroxyl compounds; (k) phosphoramidites and other standard functional groups useful in nucleic acid synthesis; (i) metal-silica bonding; (m) metal bonding to reactive phosphorus groups (e.g., phosphines) to form, for example, phosphodiester bonds; (n) azides coupled to alkynes using copper-catalyzed cycloaddition click chemistry; and ( o ) The biotin conjugate can react with avidin or streptavidin to form an avidin-biotin complex or a streptavidin-biotin complex.

[0127] Bioconjugate reactive groups can be selected so that they do not participate in or interfere with the chemical stability of the conjugates described herein. Alternatively, reactive functional groups can be protected from participating in cross-linking reactions by the presence of protecting groups. In embodiments, the bioconjugate includes a molecular entity derived from the reaction of an unsaturated bond (such as maleimide) with a sulfhydryl group.

[0128] "Analog," "analogue," or "derivative" are used according to their ordinary general meaning in chemistry and biology and refer to compounds that are structurally similar but compositionally different from another compound (i.e., the so-called "reference" compound), for example, in the replacement of an atom by an atom of a different element, or in the presence or absence of a particular functional group, or in the replacement of one functional group by another functional group, or in the absolute stereochemistry of one or more chiral centers of the reference compound. Thus, an analog is a compound that is similar or equivalent to a reference compound in function and appearance, but not in structure or origin.

[0129] As used herein, the term "a" or "an" means one or more. In addition, as used herein, the phrase "substituted with [n]..." means that the specified group may be substituted with one or more of any or all of the named substituents. For example, in the case of a group such as an alkyl or heteroaryl group, "substituted with an unsubstituted C1-C 20 In the case of "substituted with alkyl or unsubstituted 2 to 20 membered heteroalkyl", the group may contain one or more unsubstituted C1-C 20 alkyl, and / or one or more unsubstituted 2- to 20-membered heteroalkyl groups.

[0130] Additionally, when a moiety is substituted with an R substituent, the group may be referred to as "R-substituted." When a moiety is R-substituted, the moiety is substituted with at least one R substituent, and each R substituent is optionally different. When a specific R group is present in a description of a chemical species, such as Formula (I), the Roman letter symbol may be used to distinguish each appearance of that specific R group. For example, when multiple R 13 In the case of a substituent, each R 13 Substituents can be divided into R 13.A 、R 13.B 、R 13.C 、R 13.D etc., where R 13.A 、R 13.B 、R 13.C 、R 13.D Each of the above is in R 13 Where an R moiety, group or substituent as disclosed herein is indicated to be attached by a single bond and the R moiety, group or substituent is an oxo group, one of ordinary skill in the art will immediately recognize that according to normal rules of chemical valence, the oxo group is attached by a double bond.

[0131] The description of the disclosed compounds is limited by the principles of chemical bonding known to those skilled in the art. Thus, where a group may be substituted by one or more of a plurality of substituents, such substitutions are selected so as to conform to the principles of chemical bonding and to yield compounds that are not inherently unstable and / or, as known to those skilled in the art, would likely be unstable under environmental conditions (such as aqueous, neutral, and several known physiological conditions). For example, heterocycloalkyl or heteroaryl groups, in accordance with the principles of chemical bonding known to those skilled in the art, are connected to the rest of the molecule via a ring heteroatom, thereby avoiding inherently unstable compounds.

[0132] The term " leaving group " is used according to its common meaning in chemistry, and refers to a part (for example, atom, functional group, molecule) that separates from a molecule after a chemical reaction (for example, bond formation, reduction elimination, condensation, cross-coupling reaction) that involves an atom or chemical moiety (also referred to herein as " leaving group reactive moiety ") to which the leaving group is connected and a complementary reactive moiety (that is, a chemical moiety that reacts with the leaving group reactive moiety) to form a new key between the residual portion of the leaving group reactive moiety and the complementary reactive moiety. Therefore, the leaving group reactive moiety and the complementary reactive moiety form a complementary reactive group pair. The non-limiting example of a leaving group includes hydrogen, hydroxide, organotin moiety (for example, organotin heteroalkyl), halogen (for example, Br), perfluoroalkyl sulfonate (for example trifluoromethanesulfonate), toluenesulfonate, mesylate, water, alcohol, nitrate, phosphate, thioether, amine, ammonia, fluoride, carboxylate, phenolate, boric acid, borate ester and alkoxide. In an embodiment, the leaving group is designed to promote reaction.

[0133] The term "blocking group" is used according to its ordinary meaning in organic chemistry and refers to a portion of a heteroatom, heterocycloalkyl or heteroaryl group that is covalently bound to prevent the reactivity of a heteroatom, heterocycloalkyl or heteroaryl group during one or more chemical reactions carried out before removing the blocking group. Typically, in a part of a multi-part synthesis in which a heteroatom is not desired to react with a reagent (e.g., chemical reduction), a blocking group is combined with a heteroatom (e.g., O). After protection, the blocking group can be removed (e.g., by adjusting the pH). In embodiments, the blocking group is an alcohol blocking group. The non-limiting example of an alcohol blocking group includes acetyl, benzoyl, benzyl, methoxymethyl ether (MOM), tetrahydropyranyl (THP) and silyl ether (e.g., trimethylsilyl (TMS)). In embodiments, the blocking group is an amine blocking group. Non-limiting examples of amine protecting groups include carbonylbenzyloxy (Cbz), tert-butoxycarbonyl (BOC), 9-fluorenylmethoxycarbonyl (FMOC), acetyl, benzoyl, benzyl, carbamate, p-methoxybenzyl ether (PMB), and tosyl (Ts).

[0134] The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When the compounds of the present disclosure contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine, or magnesium salts, or the like. When the compounds of the present disclosure contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, and salts derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, oxalic acid, methanesulfonic acid, etc. Also included are salts of amino acids such as arginine salts, and salts of organic acids such as glucuronic acid or galacturonic acid, and the like (see, for example, Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow these compounds to be converted into either base or acid addition salts.

[0135] Therefore, the compounds of the present disclosure can exist in the form of salts (such as having a pharmaceutically acceptable acid). The present disclosure includes such salts. Non-limiting examples of such salts include hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, propionates, tartrates (e.g., (+)-tartrates, (-)-tartrates or their mixtures comprising a racemic mixture), succinates, benzoates and salts with amino acids (such as glutamic acid) and quaternary ammonium salts (e.g., methyl iodide, ethyl iodide, etc.). These salts can be prepared by methods known to those skilled in the art.

[0136] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner.The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents.

[0137] In addition to salt forms, the present disclosure also provides compounds in prodrug form. Prodrugs of the compounds described herein are those compounds that are susceptible to undergoing chemical changes under physiological conditions to provide compounds of the present disclosure. Prodrugs of the compounds described herein can be converted in vivo after administration. Additionally, prodrugs can be converted into compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment (such as, for example, when contacted with a suitable enzyme or chemical reagent).

[0138] Some compounds of the present disclosure can exist in unsolvated form and solvated form (including hydrated form). Generally, solvated form is equivalent to unsolvated form and is encompassed within the scope of the present disclosure. Some compounds of the present disclosure can exist in multiple crystallized or amorphous forms. Generally, all physical forms are equivalent for the purposes contemplated by the present disclosure and are intended to be within the scope of the present disclosure.

[0139] A polypeptide or cell is "recombinant" when it is artificial or engineered, or is derived from or contains an artificial or engineered protein or nucleic acid (e.g., non-natural or non-wild type). For example, a polynucleotide that is inserted into a vector or any other heterologous location, such as the genome of a recombinant organism, so that it is not associated with nucleotide sequences that normally flank the polynucleotide as it is found in nature is a recombinant polynucleotide. Proteins expressed in vitro or in vivo from a recombinant polynucleotide are examples of recombinant polypeptides. Similarly, polynucleotide sequences that do not occur in nature (e.g., variants of naturally occurring genes) are recombinant.

[0140] "Co-administration" means administering a composition described herein simultaneously with, just before, or just after administration of one or more additional therapies. The compounds of the present invention may be administered alone or co-administered to a patient. Co-administration is meant to encompass simultaneous or sequential administration of the compounds (more than one compound), alone or in combination. Thus, the formulations may also be combined with other active substances, if desired (e.g., to reduce metabolic degradation).

[0141] As used herein, "cell" refers to a cell that performs metabolic or other functions sufficient to maintain or replicate its genomic DNA. Cells can be identified by methods well known in the art, including, for example, the presence of an intact membrane, staining with a specific dye, the ability to reproduce offspring, or, if gametes are present, the ability to combine with a second gamete to produce viable offspring. Cells can include prokaryotic cells and eukaryotic cells. Prokaryotic cells include, but are not limited to, bacteria. Eukaryotic cells include, but are not limited to, yeast cells and cells derived from plants and animals, such as mammalian cells, insect (e.g., moth) cells, and human cells. Cells may be useful when they are naturally non-adherent or when they are treated to be non-adherent to a surface, such as by trypsinization.

[0142] The term "treating" or "treatment" refers to any mark of success in the treatment or improvement of an injury, disease, pathology, or condition, including any objective or subjective parameter, such as alleviation; remission; alleviation of symptoms or making the patient more tolerant to the injury, pathology, or condition; slowing the rate of degeneration or decline; making the end point of degeneration less debilitating; improving the patient's physical or mental health. The treatment or improvement of symptoms can be based on objective or subjective parameters; including the results of a physical examination, a neuropsychiatric examination, and / or a psychiatric evaluation. For example, certain methods presented herein successfully treat cancer by reducing the incidence of cancer and / or causing remission of cancer. In some embodiments of the compositions or methods described herein, treating cancer includes slowing the growth or spread rate of cancer cells, reducing metastasis, or reducing the growth of metastatic tumors. For example, certain methods herein treat diseases associated with PCNA activity. Certain methods described herein can treat diseases associated with PCNA activity (e.g., cancer or neuroblastoma) by inhibiting PCNA activity. The term "treating" and its conjugates include preventing injuries, pathologies, conditions, or diseases. In embodiments, treatment is prevention. In embodiments, treatment does not include prevention. In various aspects, treating or treatment is not prophylactic treatment.

[0143] An "effective amount" is an amount sufficient to allow a compound to achieve the stated purpose (e.g., achieve the effect of its administration, treat a disease, reduce enzyme activity, increase enzyme activity, reduce a signaling pathway, alleviate one or more symptoms of a disease or condition) relative to the absence of the compound. When referred to in this context, an example of an "effective amount" is an amount sufficient to facilitate the treatment, prevention, or reduction of one or more symptoms of a disease, which amount may also be referred to as a "therapeutically effective amount." "Reduction" of one or more symptoms (and grammatical equivalents of this phrase) means reducing the severity or frequency of one or more symptoms, or eliminating one or more symptoms. A "prophylactically effective amount" of a drug is an amount of the drug that, when administered to a subject, will have the intended prophylactic effect, such as preventing or delaying the onset (or recurrence) of an injury, disease, pathology, or condition or reducing the likelihood of the onset (or recurrence) of an injury, disease, pathology, or condition or its symptoms. A complete prophylactic effect does not necessarily occur by administering a single dose, and may occur after administering only a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. As used herein, an "activity-reducing amount" refers to the amount of an antagonist required to reduce the activity of an enzyme relative to the absence of the antagonist. As used herein, a "function-disrupting amount" refers to the amount of an antagonist required to disrupt the function of an enzyme or protein relative to the absence of the antagonist. As used herein, an "activity-increasing amount" refers to the amount of an agonist required to increase the activity of an enzyme relative to the absence of the agonist. As used herein, a "function-increasing amount" refers to the amount of an agonist required to increase the function of an enzyme or protein relative to the absence of the agonist. The exact amount will depend on the purpose of the treatment, and will be determined by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (Vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th ed., 2003, Gennaro, ed., Lippincott, Williams & Wilkins).

[0144] "Control" or "controlled experiment" is used according to its ordinary general meaning to refer to an experiment in which the experimental subjects or reagents are treated as in a parallel experiment, except that the experimental procedures, reagents, or variables are omitted. In some cases, a control is used as a standard of comparison when evaluating the effects of an experiment. In some embodiments, a control is a measure of the activity of a protein (e.g., a signaling pathway) in the absence of a compound as described herein, including the embodiments, examples, figures, or tables.

[0145] "Contacting" is used according to its ordinary general meaning and refers to the process of allowing at least two different substances (e.g., compounds including biomolecules or cells) to become close enough to react, interact, or come into physical contact. However, it is understood that the resulting reaction product can be produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents that can be produced in the reaction mixture.

[0146] The term "contacting" can include allowing two species to react, interact, or physically contact, where the two species can be a compound as described herein and a cellular component (e.g., a protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, virus, lipid droplet, vesicle, small molecule, protein complex, protein aggregate, or macromolecule). In some embodiments, contacting includes allowing a compound as described herein to interact with a cellular component (e.g., a protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, virus, lipid droplet, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule) involved in a signaling pathway.

[0147] As defined herein, the term "activation" (activate, activate, activating, etc.) with respect to a protein refers to the conversion of a protein from an initially inactive or inactive state to a biologically active derivative. These terms refer to activation, or the activation, sensitization, or upregulation of signal transduction or enzymatic activity, or the amount of a protein that is reduced in a disease.

[0148] The terms "agonist," "activator," "up-regulator," and the like refer to substances that can detectably increase the expression or activity of a given gene or protein. An agonist can increase expression or activity by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% compared to a control in the absence of the agonist. In some cases, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more compared to the expression or activity in the absence of the agonist.

[0149] As defined herein, the terms "inhibition", "inhibit", "inhibiting", and the like with respect to cellular component-inhibitor interactions mean negatively affecting (e.g., reducing) the activity or function of a cellular component relative to the activity or function of the cellular component in the absence of the inhibitor (e.g., reducing a signaling pathway stimulated by a cellular component (e.g., a protein, ion, lipid, virus, lipid droplet, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule)). In embodiments, inhibition means negatively affecting (e.g., reducing) the concentration or level of a cellular component relative to the concentration or level of the cellular component in the absence of the inhibitor. In some embodiments, inhibition refers to a reduction in a disease or a symptom of a disease. In some embodiments, inhibition refers to a reduction in the activity of a signal transduction pathway or a signaling pathway (e.g., a reduction in a pathway involving a cellular component). Thus, inhibition includes, at least in part, partial or complete blocking of stimulation, reduction, prevention, or delay of activation, desensitization, or downregulation of a signaling pathway or enzyme activity or the amount of a cellular component.

[0150] Interchangeably, the terms "inhibitor," "repressor," or "antagonist," or "downregulator" refer to a substance that detectably reduces the expression or activity of a given gene or protein. Antagonists can reduce expression or activity by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, or 99% compared to a control in the absence of the antagonist. In some cases, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more compared to the expression or activity in the absence of the antagonist.

[0151] The term "modulator" refers to a compound that increases or decreases the level of a target molecule or the function of a target molecule or the physical state of a molecule relative to the absence of the composition (e.g., a target can be a cellular component (e.g., a protein, an ion, a lipid, a virus, a lipid droplet, a nucleic acid, a nucleotide, an amino acid, a protein, a particle, an organelle, a cellular compartment, a microorganism, a vesicle, a small molecule, a protein complex, a protein aggregate, or a macromolecule)).

[0152] "Anticancer" or "anticancer drug" is used according to its ordinary, general meaning and refers to a composition (e.g., compound, drug, antagonist, inhibitor, modulator) that has anti-tumor properties or the ability to inhibit cell growth or proliferation. In some embodiments, the anticancer agent is a chemotherapeutic agent. In some embodiments, the anticancer agent is an agent approved by the FDA or similar regulatory agency in a country other than the United States for the treatment of cancer. Examples of anticancer agents include, but are not limited to, antiandrogens (e.g., Casodex, flutamide, MDV3100, or ARN-509), MEK (e.g., MEK1, MEK2, or MEK1 and MEK2) inhibitors (e.g., XL518, CI-1040, PD035901, selumetinib / AZD6244, GSK1120212 / trametinib, GDC-0973, ARRY-162, ARRY-300, AZD8330, PD0325901, U0126, PD98059, TAK-733, PD318088, AS7 03026, BAY869766), alkylating agents (e.g., cyclophosphamide, ifosfamide, chlorambucil, busulfan, melphalan, mechlorethamine, uracil, thiotepa, nitrosoureas, nitrogen mustards (e.g., mechlorethamine, cyclophosphamide, chlorambucil, melphalan), ethyleneimine and methylmelamines (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozotocin), triazenes (dacarbazine), antimetabolites (e.g., 5-thioprine, leucovorin, capecitabine, fludarabine, gemcitabine, Pemetrexed, raltitrexed, folic acid analogs (e.g., methotrexate), pyrimidine analogs (e.g., fluorouracil, floxuridine, cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin, etc.), plant alkaloids (e.g., vincristine, vinblastine, vinorelbine, vindesine, podophyllotoxin, paclitaxel, docetaxel, etc.), topoisomerase inhibitors (e.g., irinotecan, topotecan, amsacrine, etoposide (VP16), etoposide phosphate, teniposide, etc.), antitumor antibiotics (e.g., doxorubicin, adriamycin, daunorubicin, epirubicin, actinomycin, bleomycin, mitomycin, etc.), , mitoxantrone, plicamycin, etc.), platinum-based compounds (e.g., cisplatin, oxaliplatin, carboplatin), anthracenediones (e.g., mitoxantrone), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), adrenocortical suppressants (e.g., mitotane, aminoglutethimide), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), mitogen-activated protein kinase signaling inhibitors (e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886,SB239063, SP600125, BAY 43-9006, wortmannin or LY294002), mTOR inhibitors, antibodies (e.g., rituxan), 5-aza-2′-deoxycytidine, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec.RTM.), geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), bortezomib, trastuzumab, anastrozole; angiogenesis inhibitors; antiandrogens,Antiestrogens; antisense oligonucleotides; apoptosis gene modulators; apoptosis regulators; arginine deaminase; BCR / ABL antagonists; beta-lactam derivatives; bFGF inhibitors; bicalutamide; camptothecin derivatives; casein kinase inhibitors (ICOS); clomifene analogues; cytarabine; dexamethasone; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; finasteride; difludarabine; fluorodaunorunicin hydrochloride; gadolinium depot texaphyrin; gallium nitrate; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; immunostimulatory peptides; insulin-like growth factor-1 receptor inhibitors; interferon agonists; interferons; interleukins; letrozole; leukemia inhibitory factor; leukocyte interferon-alpha; leuprolide, estrogen, and progesterone; leuprorelin; matrix dissolving factor inhibitors; matrix metalloproteinase inhibitors; MIF inhibitors; mifepristone; mismatched double-stranded RNA; monoclonal antibodies; mycobacterial cell wall extracts; nitric oxide modulators; oxaliplatin; panomifene; pentrozole; phosphatase inhibitors; plasminogen activator inhibitors; platinum complexes; platinum compounds ; prednisone; proteasome inhibitors; protein A-based immunomodulators; protein kinase C inhibitors; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitors; ribozymes; signal transduction inhibitors; signal transduction regulators; single-chain antigen binding proteins; stem cell inhibitors; stem cell division inhibitors; stromelysin inhibitors; synthetic glycosaminoglycans; tamoxifen methiodide; telomerase inhibitors; thyroid stimulating hormone; translation inhibitors; tyrosine kinase inhibitors; urokinase receptor antagonists; steroids (e.g., dexamethasone), finasteride, aromatase inhibitors, gonadotropin-releasing hormone agonists (GnRH) such as goserelin or leuprorelin, adrenocortical steroids (e.g., prednisone), progestins (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogens (e.g., diethylstilbestrol, ethinyl estradiol), antiestrogens (e.g., tamoxifen),androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogens (e.g., flutamide), immunostimulants (e.g., bacillus Calmette-Guérin (BCG)), levamisole, interleukin-2, α-interferon, etc.), monoclonal antibodies (e.g., anti-CD20, anti-HER2, anti-CD52, anti-HLA-DR, and anti-VEGF monoclonal antibodies), immunotoxins (e.g., anti-CD33 monoclonal antibody-calicheamicin conjugate, anti-CD22 monoclonal antibody-Pseudomonas exotoxin conjugate, etc.), radioimmunotherapy (e.g., conjugated to, 111 In, 90 Y or 131 I, etc.), triptolide, homoharringtonine, dactinomycin D, doxorubicin, epirubicin, topotecan, itraconazole, vindesine, cerivastatin, vincristine, deoxyadenosine, sertraline, pitavastatin, irinotecan, clofazimine, 5-nonyloxytryptamine, vemurafenib, dabrafenib, erlotinib, gefitinib, EGFR inhibitors, epidermal growth factor receptor (EGFR) targeted therapies or therapeutic agents (e.g., gefitinib (Iressa TM ), erlotinib (Tarceva TM ), Cetuximab (Erbitux TM ), Lapatinib (Tykerb TM ), panitumumab (Vectibix TM ), Vandetanib (Caprelsa TM), afatinib / BIBW2992, CI-1033 / canertinib, neratinib / HKI-272, CP-724714, TAK-285, AST-1306, ARRY334543, ARRY-380, AG-1478, dacomitinib / PF299804, OSI-420 / norerlotinib, AZD8931, AEE788, pelitinib / EKB-569, CUDC-101, WZ8040, WZ4002, WZ3146, AG-490, XL647, PD153035, BMS-599626), sorafenib, imatinib, sunitinib, dasatinib, pyrrolobenzodiazepine class (such as tomamycin), carboplatin, CC-1065 and CC-1065 analogs, including amino-CBI, nitrogen mustards (such as chlorambucil and melphalan), dolastatin and dolastatin analogs (including auristatins: for example, monomethyl auristatin E), anthracycline antibiotics (such as doxorubicin, daunorubicin, etc.), duocarmycins and duocarmycin analogs, enediynes (such as neocarzinostatin and calicheamicin), leptomycin derivatives, maytansinoids and maytansinoid analogs (such as maytansine), methotrexate, mitomycin C, taxanes, vinca alkaloids (such as vinblastine and vincristine), epothilones (such as epothilone B), camptothecin and its clinical analogs topotecan and irinotecan, etc.

[0153] The term "expression" includes any step involved in producing the polypeptide, including but not limited to transcription, post-transcriptional modification, translation, post-translational modification and secretion. Expression can be detected using conventional techniques for detecting protein (e.g., ELISA, Western blotting, flow cytometry, immunofluorescence, immunohistochemistry, etc.).

[0154] The term "modulate" is used according to its ordinary general meaning and refers to the act of changing or altering one or more properties. "Modulation" refers to the process of changing or varying one or more properties. For example, when applied to the effect of a modulator on a target protein, modulating means changing by increasing or decreasing a property or function of the target molecule or the amount of the target molecule.

[0155] "Patient," "in need thereof," "subject," or "subject in need thereof" refers to a living organism having or susceptible to a disease or condition that can be treated by administering a pharmaceutical composition provided herein. Non-limiting examples include humans, other mammals, cattle, rats, mice, dogs, monkeys, goats, sheep, cows, deer, and other non-mammals. In some embodiments, the patient is a human. In embodiments, the patient in need thereof is a human. In embodiments, the subject is a human. In embodiments, the subject in need thereof is a human.

[0156] "Disease" or "condition" refers to a state or health condition in a patient or subject that can be treated with the compounds or methods provided herein. In some embodiments, the disease is a disease associated with (caused by) a cellular component (e.g., a protein, ion, lipid, nucleic acid, nucleotide, amino acid, protein, particle, organelle, cellular compartment, microorganism, vesicle, small molecule, protein complex, protein aggregate, or macromolecule). In embodiments, the disease is cancer (e.g., sarcoma, adenocarcinoma, leukemia, or lymphoma).

[0157] As used herein, the term "cancer" refers to all types of cancers, tumors, or malignancies found in mammals (e.g., humans), including leukemias, lymphomas, carcinomas, and sarcomas. Exemplary cancers that can be treated with the compounds or methods provided herein include thyroid cancer, endocrine system cancer, brain cancer, breast cancer, cervical cancer, colon cancer, head and neck cancer, liver cancer, kidney cancer, lung cancer, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, stomach cancer, uterine cancer, medulloblastoma, colorectal cancer, or pancreatic cancer. Additional examples include: Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, ovarian cancer, rhabdomyosarcoma, essential thrombocythemia, essential macroglobulinemia, primary brain tumor, carcinoma, malignant pancreatic cancer, malignant carcinoid, bladder cancer, precancerous skin lesions, testicular cancer, lymphoma, thyroid cancer, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, endometrial cancer, adrenal cortical cancer, endocrine or exocrine pancreatic neoplasm, medullary thyroid cancer, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, or prostate cancer.

[0158] The term "leukemia" refers to a progressive, malignant disease of the blood-forming organs and is generally characterized by the dysregulated proliferation and development of white blood cells and their precursors in the blood and bone marrow. Clinical classification of leukemias is generally based on (1) the duration and character of the disease - acute or chronic; (2) the cell type involved - myeloid (myelocytic), lymphoid (lymphoblastic), or monocytic; and (3) the presence or absence of an increase in the number of abnormal cells in the leukemic or non-leukemic lineages (subleukemic). Exemplary leukemias that can be treated with the compounds or methods provided herein include, for example, acute non-lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute promyelocytic leukemia, adult T-cell leukemia, non-leukemic leukemia, leukocytic leukemia, basophilic leukemia, blast cell leukemia, bovine leukemia, chronic myelogenous leukemia, leukemia cutis, embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy cell leukemia, hemoblastic leukemia, leukemia), hemoblastic leukemia, histiocytic leukemia, stem cell leukemia, acute monocytic leukemia, leukopenic leukemia, lymphocytic leukemia, lymphoblastic leukemia, lymphocytic leukemia, lymphoid leukemia, lymphosarcoma cell leukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, myeloblastic leukemia, myelocytic leukemia, myelogranulocytic leukemia, myelomonocytic leukemia, Naegeli leukemia, plasma cell leukemia, multiple myeloma, plasma cell leukemia, promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia leukemia), stem cell leukemia, subleukemic leukemia, or undifferentiated cell leukemia.

[0159] As used herein, the term "lymphoma" refers to a group of cancers that affect the hematopoietic and lymphoid tissues. It begins in lymphocytes, which are blood cells found primarily in the lymph nodes, spleen, thymus, and bone marrow. The two main types of lymphoma are non-Hodgkin's lymphoma and Hodgkin's disease. Hodgkin's disease accounts for approximately 15% of all diagnosed lymphomas. It is a cancer related to Reed-Sternberg malignant B lymphocytes. Non-Hodgkin's lymphoma (NHL) can be classified based on the growth rate of the cancer and the type of cells involved. There are aggressive (high-grade) and indolent (low-grade) types of NHL. Based on the type of cells involved, there are B-cell and T-cell NHL. Exemplary B cell lymphomas that can be treated with the compounds or methods provided herein include, but are not limited to, small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, extranodal (MALT) lymphoma, nodular (monocytoid B cell) lymphoma, splenic lymphoma, diffuse large cell B lymphoma, Burkitt's lymphoma, lymphoblastic lymphoma, immunoblastic large cell lymphoma, or precursor B lymphoblastic lymphoma. Exemplary T cell lymphomas that can be treated with the compounds or methods provided herein include, but are not limited to, cutaneous T cell lymphoma, peripheral T cell lymphoma, pleomorphic large cell lymphoma, mycosis fungoides, and precursor T lymphoblastic lymphoma.

[0160] The term "sarcoma" generally refers to a tumor composed of material resembling embryonic connective tissue and usually consisting of tightly packed cells embedded in a fibrous or homogeneous mass. Sarcomas that can be treated with the compounds or methods provided herein include chondrosarcoma, fibrosarcoma, lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy's sarcoma, liposarcoma, liposarcoma, alveolar soft part sarcoma, ameloblastic sarcoma, botryoid sarcoma, green carcinosarcoma, choriocarcinoma, embryonal sarcoma, Wilms' tumor sarcoma, endometrial sarcoma, stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma, giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathic multiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of B cells, lymphoma, immunoblastic sarcoma of T cells, Jensen's sarcoma, Kaposi's sarcoma, sarcoma), Kupffer cell sarcoma, angiosarcoma, leukemic sarcoma, malignant mesenchymal sarcoma, extraperiosteal sarcoma, reticulum cell sarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, or telangiectatic sarcoma.

[0161] The term "melanoma" is understood to refer to tumors of the melanocytic system of the skin and other organs. Melanomas that can be treated using the compounds or methods provided herein include, for example, acral lentiginous melanoma, amelanotic melanoma, benign juvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passey melanoma, juvenile melanoma, lentigo maligna melanoma, malignant melanoma, nodular melanoma, subungal melanoma, or superficial spreading melanoma.

[0162] The term "carcinoma" refers to a malignant new growth composed of epithelial cells that tends to infiltrate surrounding tissues and give rise to metastases. Exemplary cancers that can be treated with the compounds or methods provided herein include, for example, medullary thyroid carcinoma, familial medullary thyroid carcinoma, acinar carcinoma, acinar carcinoma, glandular cystic carcinoma, adenoid cystic carcinoma, adenocarcinoma, adrenocortical carcinoma, alveolar carcinoma, alveolar cell carcinoma, basal cell carcinoma, basaloid cell tumor, basaloid carcinoma, basosquamous cell carcinoma, bronchioloalveolar carcinoma, bronchiolar carcinoma, bronchial carcinoma, cerebriform carcinoma, cholangiocellular carcinoma, choriocarcinoma, colloid carcinoma, comedo carcinoma, uterine corpus carcinoma, cribriform carcinoma, armored carcinoma, carcinoma cutaneum, columnar carcinoma, columnar cell carcinoma, ductal carcinoma, scirrhous carcinoma, embryonal carcinoma, medullary carcinoma, epidermoid carcinoma, adenoid epithelial cell carcinoma, carcinoma ex ulcere, fibrocarcinoma, gelatinifomi carcinoma, gelatinous carcinoma, carcinoma), giant cell carcinoma, glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma, hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma, hyaline carcinoma, adrenal carcinoma, embryonal carcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelial carcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large cell carcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatous carcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullary carcinoma, melanoma, soft tissue carcinoma, mucinous carcinoma, mucinous carcinoma, mucinous cell carcinoma mucocellulare), mucoepidermoid carcinoma, carcinoma mucosum, myxoid carcinoma, myxomatous carcinoma, nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans, osteoid carcinoma, papillary carcinoma, periportal carcinoma, preinvasive carcinoma, acanthocyte carcinoma, pultaceous carcinoma, renal cell carcinoma of the kidney, reserve cell carcinoma, sarcomatoid carcinoma, schneiderian carcinoma, scirrhous carcinoma, carcinoma scrotumscroti), signet ring cell carcinoma, simple carcinoma, small cell carcinoma, potato carcinoma, spheroid cell carcinoma, spindle cell carcinoma, medullary carcinoma (carcinomaspongiosum), squamous cell carcinoma, squamous cell carcinoma, rope-shaped carcinoma, carcinoma with vasculature (carcinoma langiectaticum), carcinoma with telangiectodes (carcinoma telangiectodes), transitional cell carcinoma, carcinoma tuberosum, tuberous carcinoma, verrucous carcinoma, or villous carcinoma.

[0163] As used herein, the terms "metastasis," "metastatic," and "metastatic cancer" are used interchangeably and refer to the spread of a proliferative disease or condition (e.g., cancer) from one organ to another non-adjacent organ or part of the body. "Metastatic cancer" is also referred to as "stage IV cancer." Cancer arises at the site of origin (e.g., the breast), which is called the primary tumor, such as primary breast cancer. Some cancer cells in the primary tumor or site of origin acquire the ability to penetrate and infiltrate normal tissue surrounding the local area, and / or penetrate the walls of the lymphatic system or vascular system through systemic circulation to other parts of the body and tissues. A second clinically detectable tumor formed by cancer cells from the primary tumor is called a metastatic or secondary tumor. When cancer cells metastasize, it is presumed that the metastatic tumor and its cells are similar to the primary tumor. Thus, if lung cancer metastasizes to the breast, the secondary tumor at the breast site is composed of abnormal lung cells rather than abnormal breast cells. A secondary tumor in the breast is referred to as metastatic lung cancer. Thus, the phrase metastatic cancer refers to a disease in which a subject has or has had a primary tumor and has one or more secondary tumors. The phrases non-metastatic cancer or a subject having non-metastatic cancer refer to a disease in which a subject has a primary tumor but does not have one or more secondary tumors. For example, metastatic lung cancer refers to a disease in a subject who has a primary lung tumor or a history of a primary lung tumor and has one or more secondary tumors in a second location or locations (e.g., in the breast).

[0164] The term "cutaneous metastasis" or "skin metastasis" refers to secondary malignant cell growth in the skin, where the malignant cells originate from the primary cancer site (e.g., breast). In cutaneous metastasis, cancer cells from the primary cancer site can migrate to the skin, where they divide and cause lesions. Skin metastasis can be caused by cancer cells migrating from a breast cancer tumor to the skin.

[0165] The term "visceral metastasis" refers to the growth of secondary malignant cells in an internal organ (e.g., heart, lung, liver, pancreas, intestine) or body cavity (e.g., pleura, peritoneum), where the malignant cells originate from the primary cancer site (e.g., head and neck, liver, breast). In visceral metastasis, cancer cells from the primary cancer site can migrate to an internal organ where they divide and cause lesions. Visceral metastasis can be caused by cancer cells migrating from a liver cancer tumor or a head and neck tumor to an internal organ.

[0166] The term "drug" is used according to its ordinary meaning and refers to a substance that has a physiological effect (e.g., a beneficial effect, useful for treating a subject) when introduced into or on a subject (e.g., into or on a subject or patient). A drug moiety is a group of a drug.

[0167] A "detectable agent," "detectable compound," "detectable label," or "detectable moiety" is a substance (e.g., an element), molecule, or composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, magnetic resonance imaging, or other physical means. For example, detectable agents include 18 F. 32 P. 33 P. 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 77 As、 86 Y. 90 Y. 89 Sr. 89 Zr, 94 Tc, 94 Tc, 99m Tc, 99 Mo, 105 Pd, 105 Rh, 111 Ag, 111 In, 123 I. 124 I. 125 I. 131 I. 142 Pr, 143 pr, 149 Pm, 153 Sm, 154-158 Gd, 161 Tb, 166 Dy, 166 Ho, 169 Second,175 Lu, 177 Lu, 186 Re、 188 Re、 189 Re、 194 Ir, 198 Au, 199 Au, 211 At 211 Pb, 212 Bi, 212 Pb, 213 Bi, 223 Ra, 225 Ac, Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, 32 P, fluorophores (e.g., fluorescent dyes), modified oligonucleotides (e.g., portions described in PCT / US2015 / 022063, which is incorporated herein by reference), electron dense reagents, enzymes (e.g., enzymes commonly used in ELISA), biotin, digoxigenin, paramagnetic molecules, paramagnetic nanoparticles, ultrasmall superparamagnetic iron oxide ("USPIO") nanoparticles, USPIO nanoparticle aggregates, superparamagnetic iron oxide ("SPIO") nanoparticles, SPIO nanoparticle aggregates, single crystalline iron oxide nanoparticles, single crystalline iron oxide, nanoparticle contrast agents, liposomes or other delivery vehicles containing gadolinium chelate ("Gd-chelate") molecules, gadolinium, radioisotopes, radionuclides (e.g., carbon-11, nitrogen-13, oxygen-15, fluorine-18, rubidium-82), fluorodeoxyglucose (e.g., fluorine-18 labeled), any emitting γ gamma-ray emitting radionuclides, positron emitting radionuclides, radiolabeled glucose, radiolabeled water, radiolabeled ammonia, biocolloids, microbubbles (e.g., comprising a microbubble shell comprising albumin, galactose, lipids and / or polymers; a microbubble gas core comprising air, heavy gas, perfluorocarbon, nitrogen, octafluoropropane, perfluoropropane lipid microspheres, perfluoroethers, etc.), iodinated contrast agents (e.g., iohexol, iodixanol, ioversol, iopamidol, iopromide, diatrizoate, metrizoate, iocolic acid), barium sulfate, thorium dioxide, gold, gold nanoparticles, gold nanoparticle aggregates, fluorophores, two-photon fluorophores or haptens and proteins or other entities that can be detected, for example, by incorporating a radiolabel into a peptide or antibody that specifically reacts with a target peptide.

[0168] Radioactive substances (eg, radioisotopes) that can be used as imaging agents and / or labeling agents according to embodiments of the present disclosure include, but are not limited to 18 F. 32 P.33 P. 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 77 As、 86 Y. 90 Y. 89 Sr. 89 Zr, 94 Tc, 94 Tc, 99m Tc, 99 Mo, 105 pd, 105 Rh, 111 Ag, 111 In, 123 I. 124 I. 125 I. 131 I. 142 Pr, 143 Pr, 149 pm, 153 Sm, 154-158 Gd, 161 Tb, 166 Dy, 166 Ho, 169 Second, 175 Lu, 177 Lu, 186 Re、 188 Re、 189 Re、 194 Ir, 198 Au, 199 Au, 211 At 211 Pb, 212 Bi, 212 pb, 213 Bi, 223 Ra and 225 Ac. Paramagnetic ions that can be used as additional imaging agents according to embodiments of the present disclosure include, but are not limited to, ions of transition metals and lanthanide metals (e.g., metals with atomic numbers 21-29, 42, 43, 44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, and Lu.

[0169] "Pharmaceutically acceptable excipients" and "pharmaceutically acceptable carriers" refer to substances that facilitate administration of the active agent to a subject and facilitate absorption by the subject, and can be included in the compositions of the present invention without causing significant adverse toxicological effects to the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, physiological saline solution, lactated Ringer's solution, ordinary sucrose, ordinary glucose, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavorings, salt solutions (such as Ringer's solution), alcohols, oils, gelatin, carbohydrates (such as lactose, amylose or starch), fatty acid esters, carboxymethyl cellulose, polyvinyl pyrrolidone and pigments, etc. Such preparations can be sterilized and, if necessary, can be mixed with auxiliary agents that do not react deleteriously with the compounds of the present invention, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for affecting osmotic pressure, buffers, coloring substances and / or aromatic substances, etc. Those skilled in the art will recognize that other pharmaceutical excipients can be used in the present invention.

[0170] The term "preparation" is intended to encompass the formulation of an active compound with encapsulating material as a carrier, providing a capsule in which the active ingredient, with or without other carriers, is surrounded by the carrier, which in turn is in association with the active ingredient. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.

[0171] As used herein, the term "about" means a range of values ​​that encompasses the specified value and that one of ordinary skill in the art would consider to be reasonably similar to the specified value. In embodiments, approximately means within a standard deviation using measurements generally accepted in the art. In embodiments, approximately means a range extends to + / - 10% of the specified value. In embodiments, approximately includes the specified value.

[0172] As used herein, the term "administer" is used according to its common and general meaning and includes oral administration to a subject, administration in the form of a suppository, topical contact, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal or subcutaneous administration, or implantation of a sustained-release device (e.g., a mini-osmotic pump). Administration is performed by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular and intracranial. Other modes of delivery include, but are not limited to, the use of liposome formulations, intravenous infusion, transdermal patches, and the like. "Co-administered" means that the compositions described herein are administered simultaneously with, just before, or just after the administration of one or more additional therapies (e.g., cancer therapies such as chemotherapy, hormone therapy, radiotherapy, or immunotherapy). The compounds of the present invention may be administered alone or co-administered to a patient. Co-administered means administering compounds (more than one compound) simultaneously or sequentially, either individually or in combination. Thus, the formulations may also be combined with other active substances if desired (e.g., to reduce metabolic degradation). The compositions of the invention may be delivered transdermally, topically, and may be formulated as applicators, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.

[0173] The compounds described herein can be used in combination with each other, with other active agents known to be useful in treating diseases associated with cells expressing disease-associated cellular components, or with adjunct agents that alone may not be effective but may aid in the efficacy of the active agents.

[0174] In some embodiments, co-administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, or 24 hours of a second active agent. Co-administration includes administering the two active agents simultaneously, approximately simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, co-administration can be accomplished by co-formulating, i.e., preparing a single pharmaceutical composition comprising the two active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active agent and / or adjuvant can be linked or conjugated to each other.

[0175] In therapeutic applications for treating diseases, the compound used in the pharmaceutical composition of the present invention can be administered at an initial dose of about 0.001 mg / kg to about 1000 mg / kg per day. The daily dose range can be about 0.01 mg / kg to about 500 mg / kg, or about 0.1 mg / kg to about 200 mg / kg, or about 1 mg / kg to about 100 mg / kg, or about 10 mg / kg to about 50 mg / kg. However, the dosage can vary according to the patient's needs, the severity of the condition being treated, and the compound or drug being used. For example, the dosage can be determined empirically based on the type and stage of the disease (e.g., cancer) diagnosed in a particular patient. In the context of the present invention, the dosage administered to the patient should be sufficient to produce a beneficial therapeutic response in the patient over time. The size of the dosage will also depend on the presence, nature, and extent of any adverse side effects associated with the administration of the compound in a particular patient. It is within the practitioner's skill to determine the appropriate dosage for a specific situation. Typically, treatment is initiated with a smaller dose than the optimal dose of the compound. Thereafter, the dosage is increased in small increments until the best effect is achieved in multiple cases. For convenience, the total daily dosage may be divided and administered in portions during the day as needed.

[0176] In the context of the material or material activity or function relevant to a disease (e.g., protein-related disease, the disease relevant to a cellular component), the term "related" or "related to ... related to " means that a disease (e.g., cancer) is (wholly or in part) caused by a material or material activity or function, or that the symptom of a disease is (wholly or in part) caused by a material or material activity or function, or that a disease or the symptom of a disease can be treated by regulating (e.g., suppressing or activating) a material (e.g., a cellular component). As used herein, if a pathogen can be a target for treating a disease, it is described as being relevant to a disease. For example, a disease relevant to PCNA activity can be treated using an agent (e.g., compound as described herein) that effectively reduces PCNA activity levels.

[0177] As used herein, the term "abnormal" means different from normal. When used to describe enzymatic activity, abnormal refers to activity that is greater or less than the average of a normal control or normal non-diseased control sample. Abnormal activity can refer to an amount of activity that causes disease, wherein returning the abnormal activity to a normal or non-disease associated amount (e.g., by administering a compound or using a method as described herein) results in a reduction in the disease or one or more disease symptoms.

[0178] As used herein, the term "electrophile" refers to a chemical group that is capable of accepting electron density. An "electrophilic substituent," "electrophilic chemical moiety," or "electrophilic moiety" refers to an electron-deficient chemical group, substituent, or moiety (a monovalent chemical group) that can react with an electron-donating group, such as a nucleophile, to form a bond by accepting an electron pair or electron density.

[0179] As used herein, "nucleophile" refers to a chemical group that is capable of donating electron density.

[0180] The term "isolated" when applied to a nucleic acid or protein means that the nucleic acid or protein is substantially free of other cellular components with which it is naturally associated. It can, for example, be in a homogeneous state and can be in a dry state or in aqueous solution. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The major protein present in a preparation is substantially purified.

[0181] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are subsequently modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., an alpha carbon bound to a hydrogen, carboxyl, amino, and R groups), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to compounds that have a structure that differs from the general chemical structure of an amino acid but function in a manner similar to naturally occurring amino acids. The terms "non-natural amino acids" and "unnatural amino acids" refer to amino acid analogs, synthetic amino acids, and amino acid mimetics that are not found in nature.

[0182] The term "amino acid side chain" refers to the side chain on an amino acid. For example, if an amino acid has the formula Then -LR is an amino acid side chain. For example, leucine has the following formula And the L-leucine side chain is

[0183] Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Likewise, nucleotides may be referred to by their commonly accepted single-letter codes.

[0184] The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to a polymer of amino acid residues, which polymer may, in embodiments, be conjugated to a moiety that does not consist of amino acids. The terms apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.

[0185] The "position" of an amino acid or nucleotide base is represented by a number that sequentially identifies each amino acid (or nucleotide base) in the reference sequence according to its position relative to the N-terminus (or 5' end). Because deletions, insertions, truncations, fusions, etc. must be considered when determining optimal alignment, the numbering of amino acid residues in a test sequence, as determined by counting only from the N-terminus, is not necessarily the same as the numbering of their corresponding positions in the reference sequence. For example, where a variant has a deletion relative to the aligned reference sequence, there will be no amino acid in the variant that corresponds to the position at the site of the deletion in the reference sequence. Where there is an insertion in the aligned reference sequence, the insertion will not correspond to a numbered amino acid position in the reference sequence. In the case of truncations or fusions, there may be stretches of amino acids in the reference sequence or aligned sequence that do not correspond to any amino acid in the corresponding sequence.

[0186] When used in the context of the numbering of a given amino acid or polynucleotide sequence, the term "reference number" or "corresponding to" refers to the numbering of the residues of a given reference sequence when comparing the given amino acid or polynucleotide sequence to the reference sequence.

[0187] In some embodiments, the amino acid residue in the protein occupies the same basic structure position as a given residue in the protein, and the amino acid residue " corresponds to " a given residue. For example, when selected residue occupies the same basic space or other structural relationships as the His44 in the PCNA, the selected residue in the selected protein corresponds to the His44 of PCNA. In some embodiments in which selected protein and PCNA are compared with maximum homology, the position compared with His44 in the compared selected protein is called as corresponding to His44. Instead of the primary sequence comparison, the three-dimensional structure comparison can also be used, for example, wherein the structure of the selected protein and PCNA are compared with maximum correspondence, and overall structure is relatively large. In this case, the amino acid that occupies the same basic position as His44 in the structural model is considered to correspond to the His44 residue.

[0188] The term "proliferating cell nuclear antigen" or "PCNA" refers to a protein of approximately 29 kDa that self-assembles into a protein complex consisting of three subunits of a single PCNA protein. These connected PCNA molecules together form a DNA clamp that acts as a processivity factor for DNA polymerase δ in eukaryotic cells. The term "PCNA" may refer to the nucleotide sequence or protein sequence of human PCNA (e.g., Entrez 5111, Uniprot P12004, RefSeq NM_002592, or RefSeq NP_002583). The term "PCNA" includes both the wild-type form of the nucleotide sequence or the protein and any mutants thereof. In some embodiments, "PCNA" is wild-type PCNA. In some embodiments, "PCNA" is one or more mutant forms. The term "PCNA" XYZ refers to the nucleotide sequence or protein of a mutant PCNA, wherein the Y-numbered amino acid of PCNA typically has an X amino acid in the wild type and a Z amino acid in the mutant. In an embodiment, PCNA is human PCNA. In an embodiment, PCNA has a nucleotide sequence corresponding to reference number GI:33239449. In an embodiment, PCNA has a nucleotide sequence corresponding to RefSeq NM_002592.2. In an embodiment, PCNA has a protein sequence corresponding to reference number GI:4505641. In an embodiment, PCNA has a nucleotide sequence corresponding to RefSeq NP_002583.1. In an embodiment, PCNA has the following amino acid sequence:

[0189] MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQE YSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS(SEQ ID NO: 4).

[0190] In embodiments, PCNA is mutant PCNA. In embodiments, mutant PCNA is relevant to the disease that is not relevant to wild-type PCNA. In embodiments, compared with above-mentioned sequence, PCNA comprises at least one amino acid mutation (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 mutations). PCNA can be post-translationally modified. Modification can comprise phosphorylation, methylation, methyl ester of acidic amino acid, ribosylation, acetylation, glycosylation with multiple sugars, lipidation with multiple different lipids, poly (ADP) ribosylation or other post-translational modifications known in the art. The degree of modification and the difference of type affect the level (for example, protein level) of caPCNA and nmPCNA isotype. In embodiments, the post-translational modification or modifications alter the inhibition of PCNA by a compound described herein or the binding of a compound described herein to PCNA relative to PCNA without the post-translational modification.

[0191] As used herein, the term "cancer-associated proliferating cell nuclear antigen" or "caPCNA" refers to a PCNA isoform with an acidic isoelectric point (e.g., a peptide comprising protonated amines and / or carboxyl groups, an acidic isoelectric point compared to non-cancer-associated PCNA, PCNA in non-cancerous cells, non-malignant PCNA, the prevalent PCNA isoform in non-cancerous cells, or the less acidic PCNA isoform in non-cancerous cells). In embodiments, the caPCNA protein comprises methylated amino acids (e.g., glutamic acid, aspartic acid). In embodiments, the caPCNA protein is post-translationally modified with methyl esters of acidic amino acids. In embodiments, the methyl esterification of acidic amino acid residues on PCNA exhibits a T of about 20 minutes at pH 8.5. 1 / 2 In embodiments, caPCNA is post-translationally modified as described in F. Shen et al., J Cell Biochem. 2011 Mar; 112(3):756-760, which is incorporated herein by reference in its entirety for all purposes.

[0192] As used herein, the term "non-malignant proliferating cell nuclear antigen" or "nmPCNA" refers to a PCNA isoform with a basic isoelectric point (e.g., a peptide comprising deprotonated amine and / or carboxyl groups, a basic isoelectric point compared to caPCNA, caPCNA in cancer cells). In embodiments, nmPCNA is a PCNA isoform prevalent in non-cancerous cells.

[0193] II.Compounds

[0194] In one aspect, a compound or a pharmaceutically acceptable salt thereof is provided, which has the formula:

[0195]

[0196] L 1 -O-, -NR 7 -, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 7 C(O)-、-C(O)NR 7 -、-NR 7 C(O)NR 8 、-NR 7 S(O)2O-、-OS(O)2NR 7 -、-NR 7 S(O)2-、-S(O)2NR 7 , -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OR 7 )-、-OP(O)(OR 7 )O-、-OP(O)(OR 7 )-、-P(O)(OR 7 )O-, or -CR 8 R 9 .

[0197] R 7 、R 8 and R 9 are independently hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2).

[0198] Ring A is a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- to 6-membered heteroaryl group.

[0199] Ring B is substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted quinolyl, or substituted or unsubstituted isoquinolyl.

[0200] R 1 are independently halogen, -CX 1 3. -CHX 1 2. -CH2X 1 、-OCX 1 3. -OCHX 1 2. -OCH2X 1 、-CN、-SO n1 R 1D 、-SO v1 NR 1AR 1B 、-NR 1C NR 1A R 1B 、-ONR 1A R 1B 、-NHC(O)NR 1C NR 1A R 1B 、-NR 1C C(O)NR 1A R 1B 、-N(O) m1 、-NR 1A R 1B 、-C(O)R 1C 、-C(O)OR 1C 、-OC(O)R 1C 、-OC(O)OR 1C 、-C(O)NR 1A R 1B 、-OR 1D 、-SR 1D 、-NR 1A SO2R 1D 、-NR 1A C(O)R 1C 、-NR 1A C(O)OR 1C 、-OC(O)NR 1A R 1B 、-NR 1A OR 1C 、-P(O)R 1A R 1B , -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (eg, 5-10 membered, 5-9 membered, or 5-6 membered); two adjacent R 1 Substituents can be optionally joined to form substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0201] R 2 For hydrogen, halogen, -CX 2 3. -CHX 2 2. -CH2X 2 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0202] R 3 For hydrogen, halogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0203] R 6 For hydrogen, halogen, -CX 6 3. -CHX 6 2. -CH2X 6 、-OCX 6 3. -OCHX 6 2. -OCH2X 6 、-CN、-SO n6 R 6D 、-SO v6 NR 6A R 6B、-NR 6C NR 6A R 6B 、-ONR 6A R 6B 、-NHC(O)NR 6C NR 6A R 6B 、-NR 6C C(O)NR 6A R 6B 、-N(O) m6 、-NR 6A R 6B 、-C(O)R 6C 、-C(O)OR 6C 、-OC(O)R 6C 、-OC(O)OR 6C 、-C(O)NR 6A R 6B 、-OR 6D 、-SR 6D 、-NR 6A SO2R 6D 、-NR 6A C(O)R 6C 、-NR 6A C(O)OR 6C 、-OC(O)NR 6A R 6B 、-NR 6A OR 6C 、-P(O)R 6A R 6B , -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0204] R 3 and R 6 can be optionally joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered) or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered).

[0205] R1A 、R 1B 、R 1C 、R 1D 、R 6A 、R 6B 、R 6C and R 6D and -C3-C8, C3-C6, C4-C6, or C5-C6, substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted cycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted cycloalkyl (e.g., 3-8, 3-6, 4-6, 4- 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); R bonded to the same nitrogen atom 1A and R 1B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered); R 6A and R 6B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered).

[0206] Symbol z1 is an integer from 0 to 4.

[0207] The symbols m1, m6, v1 and v6 are independently 1 or 2.

[0208] The symbols n1 and n6 are independently integers from 0 to 4.

[0209] X, X 1 、X 2 、X 3 and X 6 is independently -Cl, -Br, -I, or -F.

[0210] The symbol m is an integer from 0 to 5.

[0211] The symbol n is an integer from 0 to 10.

[0212] In an embodiment, the compound, or a pharmaceutically acceptable salt thereof, has the formula:

[0213] L 1 -O-, -NR 7 -, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 7 C(O)-、-C(O)NR 7 -、-NR 7 C(O)NR 8 -、-NR 7 S(O)2O-、-OS(O)2NR 7 -、-NR 7 S(O)2-、-S(O)2NR 7 -, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OR 7 )-、-OP(O)(OR 7 )O-、-OP(O)(OR 7 )-、-P(O)(OR 7 )O-, or -CR 8 R 9 -;R 7 、R 8 and R 9 are independently hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2); Ring A is substituted or unsubstituted phenyl, or substituted or unsubstituted 5- to 6-membered heteroaryl; Ring B is substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted quinolyl, or substituted or unsubstituted isoquinolyl; R 1 are independently halogen, -CX 1 3. -CHX 1 2. -CH2X 1 、-OCX 1 3. -OCHX 1 2. -OCH2X 1 、-CN、-SO n1 R 1D 、-SO v1 NR 1A R 1B 、-NR 1C NR 1A R 1B 、-ONR 1A R 1B 、-NHC(O)NR 1C NR 1A R1B 、-NR 1C C(O)NR 1A R 1B 、-N(O) m1 、-NR 1A R 1B 、-C(O)R 1C 、-C(O)OR 1C 、-OC(O)R 1C 、-OC(O)OR 1C 、-C(O)NR 1A R 1B 、-OR 1D 、-SR 1D 、-NR 1A SO2R 1D 、-NR 1A C(O)R 1C 、-NR 1A C(O)OR 1C 、-OC(O)NR 1A R 1B 、-NR 1A OR 1C 、-P(O)R 1A R 1B , -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (eg, 5-10 membered, 5-9 membered, or 5-6 membered); two adjacent R 1 Substituents can be optionally joined to form substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); R 2 For hydrogen, halogen, -CX 2 3. -CHX 2 2. -CH2X 2, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); R 3 For hydrogen, halogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); R 6 For hydrogen, halogen, -CX 6 3. -CHX 6 2. -CH2X 6 、-OCX 6 3. -OCHX 6 2. -OCH2X 6 、-CN、-SO n6 R 6D 、-SO v6 NR 6A R 6B 、-NR 6C NR 6A R 6B 、-ONR 6A R 6B 、-NHC(O)NR 6C NR 6A R 6B 、-NR 6C C(O)NR 6A R 6B 、-N(O)m6 、-NR 6A R 6B 、-C(O)R 6C 、-C(O)OR 6C 、-OC(O)R 6C 、-OC(O)OR 6C 、-C(O)NR 6A R 6B 、-OR 6D 、-SR 6D 、-NR 6A SO2R 6D 、-NR 6A C(O)R 6C 、-NR 6A C(O)OR 6C 、-OC(O)NR 6A R 6B 、-NR 6A OR 6C 、-P(O)R 6A R 6B , -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); R 3 and R 6 can optionally be joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered); R 1A 、R 1B 、R 1C 、R 1D 、R 6A 、R 6B 、R 6C and R 6Dand -C3-C8, C3-C6, C4-C6, or C5-C6, substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted cycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted cycloalkyl (e.g., 3-8, 3-6, 4-6, 4- 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); R bonded to the same nitrogen atom 1A and R 1B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered); R 6A and R 6B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered); the symbol z1 is an integer from 0 to 4; the symbols m1, m6, v1, and v6 are independently 1 or 2; the symbols n1 and n6 are independently integers from 0 to 4; X, X 1 、X 2 、X 3 and X 6 independently -Cl, -Br, -I, or -F; the symbol m is an integer from 0 to 5; and the symbol n is an integer from 0 to 10.

[0214] In the embodiment, when L 1 When R is -O-, m is 0, n is 0, and Ring B is a substituted or unsubstituted naphthyl, a substituted or unsubstituted quinolyl, or a substituted or unsubstituted isoquinolyl, then R 6 Not hydrogen.

[0215] In an embodiment, the compound has the formula:

[0216] L 1 、R 1 ,z1,R 2 、R 3 、R 6 , m and n are as described herein (including in the embodiments).

[0217] Ring A is phenyl or a 5- to 6-membered heteroaryl group.

[0218] Ring B is phenyl, naphthyl, quinolyl, or isoquinolyl.

[0219] R 4 are independently halogen, -CX 4 3. -CHX 4 2. -CH2X 4 、-OCX 4 3. -OCHX 4 2. -OCH2X 4 、-CN、-SO n4 R 4D 、-SO v4 NR 4A R 4B 、-NR 4C NR 4A R 4B 、-ONR 4A R 4B 、-NHC(O)NR 4C NR 4A R 4B 、-NR 4C C(O)NR 4A R 4B 、-N(O) m4 、-NR 4A R 4B 、-C(O)R 4C 、-C(O)OR 4C 、-OC(O)R 4C 、-OC(O)OR 4C 、-C(O)NR 4A R 4B 、-OR 4D 、-SR 4D 、-NR 4A SO2R 4D 、-NR 4A C(O)R 4C 、-NR 4A C(O)OR 4C 、-OC(O)NR 4A R 4B 、-NR 4A OR 4C 、-P(O)R 4A R 4B, -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (eg, 5-10 membered, 5-9 membered, or 5-6 membered); two adjacent R 4 Substituents can be optionally joined to form substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0220] R 5 are independently halogen, -CX 5 3. -CHX 5 2. -CH2X 5 、-OCX 5 3. -OCHX 5 2. -OCH2X 5 、-CN、-SO n5 R 5D 、-SO v5 NR 5A R 5B 、-NR 5C NR 5A R 5B 、-ONR 5A R 5B 、-NHC(O)NR 5C NR 5A R 5B 、-NR 5C C(O)NR 5A R 5B 、-N(O) m5 、-NR 5A R 5B 、-C(O)R 5C 、-C(O)OR 5C 、-OC(O)R 5C 、-OC(O)OR 5C 、-C(O)NR5A R 5B 、-OR 5D 、-SR 5D 、-NR 5A SO2R 5D 、-NR 5A C(O)R 5C 、-NR 5A C(O)OR 5C 、-OC(O)NR 5A R 5B 、-NR 5A OR 5C 、-P(O)R 5A R 5B , -N3, substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (eg, 5-10 membered, 5-9 membered, or 5-6 membered); two adjacent R 5 Substituents can be optionally joined to form substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0221] R 4A 、R 4B 、R 4C 、R 4D 、R SA 、R 5B 、R 5C and R 5Dand -C3-C8, C3-C6, C4-C6, or C5-C6, substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), substituted or unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), substituted or unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted cycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), substituted or unsubstituted aryl (e.g., C6-C6, C4-C6, or C5-C6), substituted or unsubstituted cycloalkyl (e.g., 3-8, 3-6, 4-6, 4- 10 or phenyl), or substituted or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); R bonded to the same nitrogen atom 4A and R 4B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered); R SA and R 5B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or a substituted or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered).

[0222] Symbol z4 is an integer from 0 to 5.

[0223] Symbol z5 is an integer from 0 to 7.

[0224] The symbols m4, m5, v4 and v5 are independently 1 or 2.

[0225] The symbols n4 and n5 are independently integers from 0 to 4.

[0226] X, X 4 and X 5 is independently -Cl, -Br, -I or -F.

[0227] In an embodiment, the compound has the formula:

[0228] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0229] In an embodiment, the compound has the formula:

[0230] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0231] In an embodiment, the compound has the formula:

[0232] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0233] In an embodiment, the compound has the formula:

[0234] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0235] In an embodiment, the compound has the formula:

[0236] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0237] In an embodiment, the compound has the formula:

[0238] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0239] In an embodiment, the compound has the formula:

[0240] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0241] In an embodiment, the compound has the formula:

[0242] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0243] In an embodiment, the compound has the formula:

[0244] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0245] In an embodiment, the compound has the formula:

[0246] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0247] In an embodiment, the compound has the formula:

[0248] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0249] In an embodiment, the compound has the formula:

[0250] L 1 , Ring A, Ring B, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0251] In an embodiment, L 1 is -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -NHS(O)2O-, -OS(O)2NH-, -NHS(O)2-, -S(O)2NH-, -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -OP(O)(OH)-, -P(O)(OH)O-, -CHR 9 , or -CR 8 R 9 -; where R 8 and R 9 As described herein (including in the embodiments). In the embodiments, L 1 is -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -S(O)-, -S(O )2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -OP(O)(OH)-, -P(O)(OH)O-, -CHR 9 , or -CR 8 R 9 -; and R 8 and R 9is independently halogen or unsubstituted methyl.

[0252] In an embodiment, L 1 is -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -NHS(O)2O-, -OS(O)2NH-, -NHS(O )2-, -S(O)2NH-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -OP(O)(OH)-, -P(O)(OH)O-, -CHR 9 , or -CR 8 R 9 -; where R 8 and R 9 As described herein (including in the embodiments). In the embodiments, L 1 is -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -S(O)2- , -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -OP(O)(OH)-, -P(O)(OH)O-, -CHR 9 -, or -CR 8 R 9 -; and R 8 and R 9 is independently halogen or unsubstituted methyl.

[0253] In an embodiment, L 1 In the embodiment, L 1 -NR 7 -, where R 7 As described herein (including in the embodiments). In the embodiments, L 1 In the embodiment, L 1 is -NCH3-. In an embodiment, L 1 In the embodiment, L 1 is -C(O)-. In an embodiment, L 1 is -C(O)O-. In an embodiment, L 1 is -OC(O)-. In an embodiment, L 1 -NR 7 C(O)-, where R 7As described herein (including in the embodiments). In the embodiments, L 1 is -NHC(O)-. In an embodiment, L 1 -C(O)NR 7 -, where R 7 As described herein (including in the embodiments). In the embodiments, L 1 is -C(O)NH-. In an embodiment, L 1 -NR 7 C(O)NR 8 -. In an embodiment, L 1 is -NHC(O)NH-. In an embodiment, L 1 -NR 7 S(O)2O-. In the embodiment, L 1 is -NHS(O)2O-. In the embodiment, L 1 -OS(O)2NR 7 -. In an embodiment, L 1 is -OS(O)2NH-. In the embodiment, L 1 -NR 7 S(O)2-. In an embodiment, L 1 is -NHS(O)2-. In an embodiment, L 1 -S(O)2NR 7 -. In an embodiment, L 1 is -S(O)2NH-. In the embodiment, L 1 In the embodiment, L 1 is -S(O)2-. In the embodiment, L 1 is -OS(O)2O-. In the embodiment, L 1 is -S(O)2O-. In the embodiment, L 1 is -OS(O)2-. In the embodiment, L 1 -P(O)(OR 7 )-, wherein R7 is as described herein (including in the embodiments). In the embodiments, L 1 is -P(O)(OH)-. In an embodiment, L 1 -OP(O)(OR 7 )O-, where R 7 As described herein (including in the embodiments). In the embodiments, L 1 is -OP(O)(OH)O-. In an embodiment, L 1 -OP(O)(OR 7 )-, where R 7As described herein (including in the embodiments). In the embodiments, L 1 is -OP(O)(OH)-. In an embodiment, L 1 -P(O)(OR 7 )O-, where R 7 As described herein (including in the embodiments). In the embodiments, L 1 is -P(O)(OH)O-. In an embodiment, L 1 -CHR 9 -, where R 9 As described herein (including in the embodiments). In the embodiments, L 1 -CR 8 R 9 -, where R 8 and R 9 As described herein (including in the embodiments). In the embodiments, L 1 is -CHF-. In an embodiment, L 1 It is -CF2-.

[0254] In an embodiment, substituted R 1 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 1 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 1 When R is substituted, it is substituted with at least one substituent. 1 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 1 When substituted, it is substituted with at least one lower substituent.

[0255] In the embodiment, when two R 1 The substituted ring formed when the substituents are joined (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if two R 1 The substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when two R 1When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. 1 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. 1 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0256] In an embodiment, substituted R 1A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 1A is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 1A When R is substituted, it is substituted with at least one substituent. 1A When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 1A When substituted, it is substituted with at least one lower substituent.

[0257] In an embodiment, substituted R 1B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 1B is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 1B When R is substituted, it is substituted with at least one substituent. 1B When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 1B When substituted, it is substituted with at least one lower substituent.

[0258] In an embodiment, when R bonded to the same nitrogen atom 1A and R 1B The substituted ring formed when the substituents are joined (e.g., substituted heterocycloalkyl and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if R 1Aand R 1B The substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, substituents of limited size, and lower substituents; each substituent, substituent of limited size, and / or lower substituent may optionally be different. In an embodiment, when R 1A and R 1B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. In an embodiment, when R 1A and R 1B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 1A and R 1B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0259] In an embodiment, substituted R 1C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 1C is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 1C When R is substituted, it is substituted with at least one substituent. 1C When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 1C When substituted, it is substituted with at least one lower substituent.

[0260] In an embodiment, substituted R 1D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 1D is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 1D When R is substituted, it is substituted with at least one substituent. 1D When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 1DWhen substituted, it is substituted with at least one lower substituent.

[0261] In an embodiment, R 1 are independently halogen, -CX 1 3. -CHX 1 2. -CH2X 1 、-OCX 1 3. -OCHX 1 2. -OCH2X 1 、-CN、-SO n1 R 1D 、-SO v1 NR 1A R 1B 、-NR 1C NR 1A R 1B 、-ONR 1A R 1B 、-NHC(O)NR 1C NR 1A R 1B 、-NR 1C C(O)NR 1A R 1B 、-N(O) m1 、-NR 1A R 1B 、-C(O)R 1C 、-C(O)OR 1C 、-OC(O)R 1C 、-OC(O)OR 1C 、-C(O)NR 1A R 1B 、-OR 1D 、-SR 1D 、-NR 1A SO2R 1D 、-NR 1A C(O)R 1C 、-NR 1A C(O)OR 1C 、-OC(O)NR 1A R 1B 、-NR 1A OR 1C 、-P(O)R 1A R 1B, -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); two adjacent R 1 Substituents can be optionally joined to form unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0262] In an embodiment, R 1 independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 In one embodiment, R 1 R is independently halogen, -CF3, -OH, -NH2, -SH, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2-4 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl. In an embodiment, R 1 is independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, -NH2, -SH, unsubstituted C1-C4 alkyl, or unsubstituted 2 to 4 membered heteroalkyl. In an embodiment, R 1 are independently halogen, -OH, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, unsubstituted methyl, or unsubstituted methoxy.

[0263] In an embodiment, R 1 are independently halogen. In an embodiment, R 1 is independently -F. In an embodiment, R 1 is independently -Cl. In an embodiment, R 1 is independently -Br. In an embodiment, R 1 is independently -I. In an embodiment, R 1 is independently -CCl3. In an embodiment, R 1 is independently -CBr3. In an embodiment, R 1 is independently -CF3. In an embodiment, R 1 is independently -CI3. In an embodiment, R 1 is independently -CH2Cl. In an embodiment, R 1 is independently -CH2Br. In an embodiment, R 1 is independently -CH2F. In an embodiment, R 1 is independently -CH2I. In an embodiment, R 1 is independently -CHCl2. In an embodiment, R 1 is independently -CHBr2. In an embodiment, R 1 is independently -CHF2. In an embodiment, R 1 is independently -CHI2. In an embodiment, R 1 is independently -CN. In an embodiment, R 1 is independently -OH. In an embodiment, R 1 is independently -NH2. In an embodiment, R 1 is independently -COOH. In an embodiment, R 1 is independently -CONH2. In an embodiment, R 1 is independently -NO2. In an embodiment, R 1 are independently -SH. In an embodiment, R 1 is independently -SO3H. In an embodiment, R 1 is independently -OSO3H. In an embodiment, R 1 is independently -SO2NH2. In an embodiment, R 1 is independently -NHNH2. In an embodiment, R 1 is independently -ONH2. In an embodiment, R 1 is independently -NHC(O)NHNH2. In an embodiment, R 1 is independently -NHC(O)NH2. In an embodiment, R 1 is independently -NHSO2H. In an embodiment, R1 is independently -NHC(O)H. In an embodiment, R 1 is independently -NHC(O)OH. In an embodiment, R 1 is independently -NHOH. In an embodiment, R 1 is independently -OCCl3. In an embodiment, R 1 is independently -OCBr3. In an embodiment, R 1 is independently -OCF3. In an embodiment, R 1 is independently -OCI3. In an embodiment, R 1 is independently -OCH2Cl. In an embodiment, R 1 is independently -OCH2Br. In an embodiment, R 1 is independently -OCH2F. In an embodiment, R 1 is independently -OCH2I. In an embodiment, R 1 is independently -OCHCl2. In an embodiment, R 1 is independently -OCHBr2. In an embodiment, R 1 is independently -OCHF2. In an embodiment, R 1 is independently -OCHI2. In an embodiment, R 1 is independently unsubstituted C1-C4 alkyl. 1 is independently unsubstituted methyl. In an embodiment, R 1 is independently unsubstituted ethyl. In an embodiment, R 1 is independently unsubstituted propyl. In an embodiment, R 1 is independently unsubstituted n-propyl. In an embodiment, R 1 is independently unsubstituted isopropyl. In an embodiment, R 1 is independently unsubstituted butyl. In an embodiment, R 1 is independently unsubstituted n-butyl. In an embodiment, R 1 is independently unsubstituted isobutyl. 1 is independently unsubstituted tert-butyl. 1 is independently unsubstituted 2 to 4 membered heteroalkyl. 1 is independently unsubstituted methoxy. In an embodiment, R 1 is independently unsubstituted ethoxy. In an embodiment, R 1 is independently unsubstituted propoxy. In an embodiment, R 1 is independently unsubstituted n-propoxy. In an embodiment, R1 is independently unsubstituted isopropoxy. 1 is independently unsubstituted butoxy. 1 is independently unsubstituted n-butoxy. In an embodiment, R 1 is independently unsubstituted isobutyloxy. 1 is independently unsubstituted tert-butoxy.

[0264] In an embodiment, z1 is 0. In an embodiment, z1 is 1. In an embodiment, z1 is 2. In an embodiment, z1 is 3. In an embodiment, z1 is 4.

[0265] In an embodiment, substituted R 2 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 2 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 2 When R is substituted, it is substituted with at least one substituent. 2 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 2 When substituted, it is substituted with at least one lower substituent.

[0266] In an embodiment, R 2 For hydrogen, halogen, -CX 2 3. -CHX 2 2. -CH2X 2 , -CN, -COOH, -CONH2, -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0267] In an embodiment, R 2 Hydrogen, -CX 23. -CHX 2 2. -CH2X 2 , -CN, -C(O)H, -C(O)OH, -C(O)NH2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2-6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl. In an embodiment, R 2 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl. In an embodiment, R 2 For hydrogen.

[0268] In an embodiment, R 2 is hydrogen or unsubstituted C1-C4 alkyl. 2 is hydrogen. In an embodiment, R 2 is an unsubstituted C1-C4 alkyl. 2 is an unsubstituted methyl group. In an embodiment, R 2 is an unsubstituted ethyl group. In an embodiment, R 2 is unsubstituted propyl. In an embodiment, R 2 is unsubstituted n-propyl. In an embodiment, R 2 is unsubstituted isopropyl. In an embodiment, R 2 is an unsubstituted butyl group. In an embodiment, R 2 is unsubstituted n-butyl. In an embodiment, R 2 is an unsubstituted isobutyl group. In an embodiment, R 2 is an unsubstituted tert-butyl group.

[0269] In an embodiment, substituted R 3 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 3 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 3 When R is substituted, it is substituted with at least one substituent. 3 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 3 When substituted, it is substituted with at least one lower substituent.

[0270] In an embodiment, R 3 For hydrogen, halogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -COOH, -CONH2, -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0271] In an embodiment, R 3 For hydrogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -C(O)H, -C(O)OH, -C(O)NH2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2-6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl. In an embodiment, R 3 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl. In an embodiment, R 3 For hydrogen.

[0272] In an embodiment, R 3 is hydrogen or unsubstituted C1-C4 alkyl. 3 is hydrogen. In an embodiment, R 3 is an unsubstituted C1-C4 alkyl. 3 is an unsubstituted methyl group. In an embodiment, R 3 is an unsubstituted ethyl group. In an embodiment, R 3 is unsubstituted propyl. In an embodiment, R 3 is unsubstituted n-propyl. In an embodiment, R 3 is unsubstituted isopropyl. In an embodiment, R 3 is an unsubstituted butyl group. In an embodiment, R 3 is unsubstituted n-butyl. In an embodiment, R 3is an unsubstituted isobutyl group. In an embodiment, R 3 is an unsubstituted tert-butyl group.

[0273] In an embodiment, substituted R 4 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 4 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 4 When R is substituted, it is substituted with at least one substituent. 4 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 4 When substituted, it is substituted with at least one lower substituent.

[0274] In the embodiment, when two R 4 The substituted ring formed when the substituents are joined (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if two R 4 The substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when two R 4 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. In an embodiment, when two R 4 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. 4 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0275] In an embodiment, substituted R 4A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 4Ais substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 4A When R is substituted, it is substituted with at least one substituent. 4A When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 4A When substituted, it is substituted with at least one lower substituent.

[0276] In an embodiment, substituted R 4B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 4B is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 4B When R is substituted, it is substituted with at least one substituent. 4B When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 4B When substituted, it is substituted with at least one lower substituent.

[0277] In an embodiment, when R bonded to the same nitrogen atom 4A and R 4B The substituted ring formed when the substituents are joined (e.g., substituted heterocycloalkyl and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if R 4A and R 4B The substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, substituents of limited size, and lower substituents; each substituent, substituent of limited size, and / or lower substituent may optionally be different. In an embodiment, when R 4A and R 4B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. In an embodiment, when R 4A and R 4B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 4A and R 4BWhen the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0278] In an embodiment, substituted R 4C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 4C is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 4C When R is substituted, it is substituted with at least one substituent. 4C When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 4C When substituted, it is substituted with at least one lower substituent.

[0279] In an embodiment, substituted R 4D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 4D is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 4D When R is substituted, it is substituted with at least one substituent. 4D When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 4D When substituted, it is substituted with at least one lower substituent.

[0280] In an embodiment, R 4 are independently halogen, -CX 4 3. -CHX 4 2. -CH2X 4 、-OCX 4 3. -OCHX 4 2. -OCH2X 4 、-CN、-SO n4 R 4D 、-SO v4 NR 4A R 4B 、-NR 4C NR 4AR 4B 、-ONR 4A R 4B 、-NHC(O)NR 4C NR 4A R 4B 、-NR 4C C(O)NR 4A R 4B 、-N(O) m4 、-NR 4A R 4B 、-C(O)R 4C 、-C(O)OR 4C 、-OC(O)R 4C 、-OC(O)OR 4C 、-C(O)NR 4A R 4B 、-OR 4D 、-SR 4D 、-NR 4A SO2R 4D 、-NR 4A C(O)R 4C 、-NR 4A C(O)OR 4C 、-OC(O)NR 4A R 4B 、-NR 4A OR 4C 、-P(O)R 4A R 4B , -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); two adjacent R 4 Substituents can be optionally joined to form unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0281] In an embodiment, R 4independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 In one embodiment, R 4 R is independently halogen, -CF3, -OH, -NH2, -SH, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2-4 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl. In an embodiment, R 4 is independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, -NH2, -SH, unsubstituted C1-C4 alkyl, or unsubstituted 2 to 4 membered heteroalkyl. In an embodiment, R 4 are independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, or unsubstituted methoxy.

[0282] In an embodiment, R 4 are independently halogen. In an embodiment, R 4 is independently -F. In an embodiment, R 4 is independently -Cl. In an embodiment, R 4 is independently -Br. In an embodiment, R 4 is independently -I. In an embodiment, R 4 is independently -CCl3. In an embodiment, R 4 is independently -CBr3. In an embodiment, R 4 is independently -CF3. In an embodiment, R 4 is independently -CI3. In an embodiment, R 4 is independently -CH2Cl. In an embodiment, R 4 is independently -CH2Br. In an embodiment, R 4 is independently -CH2F. In an embodiment, R 4 is independently -CH2I. In an embodiment, R 4 is independently -CHCl2. In an embodiment, R4 is independently -CHBr2. In an embodiment, R 4 is independently -CHF2. In an embodiment, R 4 is independently -CHI2. In an embodiment, R 4 is independently -CN. In an embodiment, R 4 is independently -OH. In an embodiment, R 4 is independently -NH2. In an embodiment, R 4 is independently -COOH. In an embodiment, R 4 is independently -CONH2. In an embodiment, R 4 is independently -NO2. In an embodiment, R 4 are independently -SH. In an embodiment, R 4 is independently -SO3H. In an embodiment, R 4 is independently -OSO3H. In an embodiment, R 4 is independently -SO2NH2. In an embodiment, R 4 is independently -NHNH2. In an embodiment, R 4 is independently -ONH2. In an embodiment, R 4 is independently -NHC(O)NHNH2. In an embodiment, R 4 is independently -NHC(O)NH2. In an embodiment, R 4 is independently -NHSO2H. In an embodiment, R 4 is independently -NHC(O)H. In an embodiment, R 4 is independently -NHC(O)OH. In an embodiment, R 4 is independently -NHOH. In an embodiment, R 4 is independently -OCCl3. In an embodiment, R 4 is independently -OCBr3. In an embodiment, R 4 is independently -OCF3. In an embodiment, R 4 is independently -OCI3. In an embodiment, R 4 is independently -OCH2Cl. In an embodiment, R 4 is independently -OCH2Br. In an embodiment, R 4 is independently -OCH2F. In an embodiment, R 4 is independently -OCH2I. In an embodiment, R 4 is independently -OCHCl2. In an embodiment, R 4 is independently -OCHBr2. In an embodiment, R 4is independently -OCHF2. In an embodiment, R 4 is independently -OCHI2. In an embodiment, R 4 is independently unsubstituted C1-C4 alkyl. 4 is independently unsubstituted methyl. In an embodiment, R 4 is independently unsubstituted ethyl. In an embodiment, R 4 is independently unsubstituted propyl. In an embodiment, R 4 is independently unsubstituted n-propyl. In an embodiment, R 4 is independently unsubstituted isopropyl. In an embodiment, R 4 is independently unsubstituted butyl. In an embodiment, R 4 is independently unsubstituted n-butyl. In an embodiment, R 4 is independently unsubstituted isobutyl. 4 is independently unsubstituted tert-butyl. 4 is independently unsubstituted 2 to 4 membered heteroalkyl. 4 is independently unsubstituted methoxy. In an embodiment, R 4 is independently unsubstituted ethoxy. In an embodiment, R 4 is independently unsubstituted propoxy. In an embodiment, R 4 is independently unsubstituted n-propoxy. In an embodiment, R 4 is independently unsubstituted isopropoxy. 4 is independently unsubstituted butoxy. 4 is independently unsubstituted n-butoxy. In an embodiment, R 4 is independently unsubstituted isobutyloxy. 4 is independently unsubstituted tert-butoxy.

[0283] In an embodiment, R 4 Independently -OR 4D , where R 4D As described herein (including in the embodiments). In the embodiments, R 4D is hydrogen or substituted or unsubstituted alkyl. In an embodiment, R 4D is independently hydrogen or unsubstituted alkyl. 4D is independently hydrogen or unsubstituted C1-C5 alkyl. 4D is independently hydrogen or unsubstituted methyl. 4Dare independently hydrogen. In an embodiment, R 4D is independently unsubstituted C1-C5 alkyl. 4D is independently unsubstituted methyl. In an embodiment, R 4D is independently unsubstituted ethyl. In an embodiment, R 4D is independently unsubstituted propyl. In an embodiment, R 4D is independently unsubstituted n-propyl. In an embodiment, R 4D is independently unsubstituted isopropyl. In an embodiment, R 4D is independently unsubstituted butyl. In an embodiment, R 4D is independently unsubstituted n-butyl. In an embodiment, R 4D is independently unsubstituted isobutyl. 4D is independently unsubstituted tert-butyl.

[0284] In an embodiment, z4 is 0. In an embodiment, z4 is 1. In an embodiment, z4 is 2. In an embodiment, z4 is 3. In an embodiment, z4 is 4.

[0285] In an embodiment, substituted R 5 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 5 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 5 When R is substituted, it is substituted with at least one substituent. 5 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 5 When substituted, it is substituted with at least one lower substituent.

[0286] In the embodiment, when two R 5 The substituted ring formed when the substituents are joined (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if two R 5The substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when two R 5 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. In an embodiment, when two R 5 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. 5 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0287] In an embodiment, substituted R 5A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 5A is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 5A When R is substituted, it is substituted with at least one substituent. 5A When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 5A When substituted, it is substituted with at least one lower substituent.

[0288] In an embodiment, substituted R 5B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 5B is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 5B When R is substituted, it is substituted with at least one substituent. 5B When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 5B When substituted, it is substituted with at least one lower substituent.

[0289] In an embodiment, when R bonded to the same nitrogen atom 5A and R5B The substituted ring formed when the substituents are joined (e.g., substituted heterocycloalkyl and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if R 5A and R 5B The substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, substituents of limited size, and lower substituents; each substituent, substituent of limited size, and / or lower substituent may optionally be different. In an embodiment, when R 5A and R 5B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. In an embodiment, when R 5A and R 5B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 5A and R 5B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0290] In an embodiment, substituted R 5C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 5C is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 5C When R is substituted, it is substituted with at least one substituent. 5C When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 5C When substituted, it is substituted with at least one lower substituent.

[0291] In an embodiment, substituted R5 D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 5Dis substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 5D When R is substituted, it is substituted with at least one substituent. 5D When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 5D When substituted, it is substituted with at least one lower substituent.

[0292] In an embodiment, R 5 are independently halogen, -CX 5 3. -CHX 5 2. -CH2X 5 、-OCX 5 3. -OCHX 5 2. -OCH2X 5 、-CN、-SO n5 R 5D 、-SO v5 NR 5A R 5B 、-NR 5C NR 5A R 5B 、-ONR 5A R 5B 、-NHC(O)NR 5C NR 5A R 5B 、-NR 5C C(O)NR 5A R 5B 、-N(O) m5 、-NR 5A R 5B 、-C(O)R 5C 、-C(O)OR 5C 、-OC(O)R 5C 、-OC(O)OR 5C 、-C(O)NR 5A R 5B 、-OR 5D 、-SR 5D 、-NR 5A SO2R 5D 、-NR 5A C(O)R 5C 、-NR 5A C(O)OR 5C 、-OC(O)NR 5A R 5B 、-NR 5A OR 5C、-P(O)R 5A R 5B , -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered); two adjacent R 5 Substituents can be optionally joined to form unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0293] In an embodiment, R 5 independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 In one embodiment, R 5 R is independently halogen, -CF3, -OH, -NH2, -SH, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2-4 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl. In an embodiment, R 5 is independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, -NH2, -SH, unsubstituted C1-C4 alkyl, unsubstituted 2 to 4 membered heteroalkyl, or unsubstituted phenyl. In an embodiment, R 5independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, unsubstituted methoxy, or unsubstituted phenyl.

[0294] In an embodiment, R 5 are independently halogen. In an embodiment, R 5 is independently -F. In an embodiment, R 5 is independently -Cl. In an embodiment, R 5 is independently -Br. In an embodiment, R 5 is independently -I. In an embodiment, R 5 is independently -CCl3. In an embodiment, R 5 is independently -CBr3. In an embodiment, R 5 is independently -CF3. In an embodiment, R 5 is independently -CI3. In an embodiment, R 5 is independently -CH2Cl. In an embodiment, R 5 is independently -CH2Br. In an embodiment, R 5 is independently -CH2F. In an embodiment, R 5 is independently -CH2I. In an embodiment, R 5 is independently -CHCl2. In an embodiment, R 5 is independently -CHBr2. In an embodiment, R 5 is independently -CHF2. In an embodiment, R 5 is independently -CHI2. In an embodiment, R 5 is independently -CN. In an embodiment, R 5 is independently -OH. In an embodiment, R 5 is independently -NH2. In an embodiment, R 5 is independently -COOH. In an embodiment, R 5 is independently -CONH2. In an embodiment, R 5 is independently -NO2. In an embodiment, R 5 are independently -SH. In an embodiment, R 5 is independently -SO3H. In an embodiment, R 5 is independently -OSO3H. In an embodiment, R 5 is independently -SO2NH2. In an embodiment, R 5 is independently -NHNH2. In an embodiment, R 5 is independently -ONH2. In an embodiment, R5 is independently -NHC(O)NHNH2. In an embodiment, R 5 is independently -NHC(O)NH2. In an embodiment, R 5 is independently -NHSO2H. In an embodiment, R 5 is independently -NHC(O)H. In an embodiment, R 5 is independently -NHC(O)OH. In an embodiment, R 5 is independently -NHOH. In an embodiment, R 5 is independently -OCCl3. In an embodiment, R 5 is independently -OCBr3. In an embodiment, R 5 is independently -OCF3. In an embodiment, R 5 is independently -OCI3. In an embodiment, R 5 is independently -OCH2Cl. In an embodiment, R 5 is independently -OCH2Br. In an embodiment, R 5 is independently -OCH2F. In an embodiment, R 5 is independently -OCH2I. In an embodiment, R 5 is independently -OCHCl2. In an embodiment, R 5 is independently -OCHBr2. In an embodiment, R 5 is independently -OCHF2. In an embodiment, R 5 is independently -OCHI2. In an embodiment, R 5 is independently unsubstituted C1-C4 alkyl. 5 is independently unsubstituted methyl. In an embodiment, R 5 is independently unsubstituted ethyl. In an embodiment, R 5 is independently unsubstituted propyl. In an embodiment, R 5 is independently unsubstituted n-propyl. In an embodiment, R 5 is independently unsubstituted isopropyl. In an embodiment, R 5 is independently unsubstituted butyl. In an embodiment, R 5 is independently unsubstituted n-butyl. In an embodiment, R 5 is independently unsubstituted isobutyl. 5 is independently unsubstituted tert-butyl. 5 is independently unsubstituted 2 to 4 membered heteroalkyl. 5is independently unsubstituted methoxy. In an embodiment, R 5 is independently unsubstituted ethoxy. In an embodiment, R 5 is independently unsubstituted propoxy. In an embodiment, R 5 is independently unsubstituted n-propoxy. In an embodiment, R 5 is independently unsubstituted isopropoxy. 5 is independently unsubstituted butoxy. 5 is independently unsubstituted n-butoxy. In an embodiment, R 5 is independently unsubstituted isobutyloxy. 5 is independently unsubstituted tert-butyloxy. 5 is independently substituted or unsubstituted phenyl. 5 is independently substituted phenyl. In an embodiment, R 5 is independently unsubstituted phenyl.

[0295] In an embodiment, z5 is 0. In an embodiment, z5 is 1. In an embodiment, z5 is 2. In an embodiment, z5 is 3. In an embodiment, z5 is 4. In an embodiment, z5 is 5. In an embodiment, z5 is 6. In an embodiment, z5 is 7.

[0296] In an embodiment, for In an embodiment, for In an embodiment, for In an embodiment, for In an embodiment, for In an embodiment, for

[0297] In an embodiment, substituted R 6 (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 6 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 6When R is substituted, it is substituted with at least one substituent. 6 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 6 When substituted, it is substituted with at least one lower substituent.

[0298] In an embodiment, substituted R 6A (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 6A is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 6A When R is substituted, it is substituted with at least one substituent. 6A When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 6A When substituted, it is substituted with at least one lower substituent.

[0299] In an embodiment, substituted R 6B (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 6B is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 6B When R is substituted, it is substituted with at least one substituent. 6B When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 6B When substituted, it is substituted with at least one lower substituent.

[0300] In an embodiment, when R bonded to the same nitrogen atom 6A and R 6B The substituted ring formed when the substituents are joined (e.g., substituted heterocycloalkyl and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if R 6A and R 6BThe substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, substituents of limited size, and lower substituents; each substituent, substituent of limited size, and / or lower substituent may optionally be different. In an embodiment, when R 6A and R 6B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. In an embodiment, when R 6A and R 6B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 6A and R 6B When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0301] In an embodiment, substituted R 6C (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 6C is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 6C When R is substituted, it is substituted with at least one substituent. 6C When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 6C When substituted, it is substituted with at least one lower substituent.

[0302] In an embodiment, substituted R 6D (e.g., substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and / or substituted heteroaryl) is substituted with at least one substituent, size-restricted substituent, or lower substituent; wherein if the substituted R 6D is substituted with a plurality of groups selected from substituents, size-restricted substituents or lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 6D When R is substituted, it is substituted with at least one substituent. 6D When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 6DWhen substituted, it is substituted with at least one lower substituent.

[0303] In an embodiment, R 6 For hydrogen, halogen, -CX 6 3. -CHX 6 2. -CH2X 6 、-OCX 6 3. -OCHX 6 2. -OCH2X 6 、-CN、-SO n6 R 6D 、-SO v6 NR 6A R 6B 、-NR 6C NR 6A R 6B 、-ONR 6A R 6B 、-NHC(O)NR 6C NR 6A R 6B 、-NR 6C C(O)NR 6A R 6B 、-N(O) m6 、-NR 6A R 6B 、-C(O)R 6C 、-C(O)OR 6C 、-OC(O)R 6C 、-OC(O)OR 6C 、-C(O)NR 6A R 6B 、-OR 6D 、-SR 6D 、-NR 6A SO2R 6D 、-NR 6A C(O)R 6C 、-NR 6A C(O)OR 6C 、-OC(O)NR 6A R 6B 、-NR 6A OR 6C 、-P(O)R 6A R 6B, -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2-8, 2-6, 4-6, 2-3, or 4-5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5-10 membered, 5-9 membered, or 5-6 membered).

[0304] In an embodiment, R 6 is hydrogen, halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 In one embodiment, R 6 is a substituted or unsubstituted C1-C6 alkyl group, or a substituted or unsubstituted 2- to 6-membered heteroalkyl group.

[0305] In an embodiment, R 6 is hydrogen. In an embodiment, R 6 In an embodiment, R 6 In an embodiment, R 6 In the embodiment, R 6 is -Br. In an embodiment, R 6 In an embodiment, R 6 In the embodiment, R 6 is -CBr3. In an embodiment, R 6 In the embodiment, R 6 In the embodiment, R 6 is -CH2Cl. In an embodiment, R 6 is -CH2Br. In an embodiment, R 6 is -CH2F. In an embodiment, R 6 is -CH2I. In an embodiment, R 6 is -CHCl2. In an embodiment, R 6 is -CHBr2. In an embodiment, R 6is -CHF2. In an embodiment, R 6 In an embodiment, R 6 In an embodiment, R 6 In the embodiment, R 6 is -NH2. In an embodiment, R 6 In an embodiment, R 6 is -CONH2. In an embodiment, R 6 In the embodiment, R 6 In the embodiment, R 6 In the embodiment, R 6 is -OSO3H. In an embodiment, R 6 In the embodiment, R 6 is -NHNH2. In an embodiment, R 6 In the embodiment, R 6 is -NHC(O)NHNH2. In an embodiment, R 6 is -NHC(O)NH2. In an embodiment, R 6 is -NHSO2H. In an embodiment, R 6 is -NHC(O)H. In an embodiment, R 6 is -NHC(O)OH. In an embodiment, R 6 In the embodiment, R 6 In the embodiment, R 6 In an embodiment, R 6 In the embodiment, R 6 In the embodiment, R 6 In an embodiment, R 6 is -OCH2Br. In an embodiment, R 6 is -OCH2F. In an embodiment, R 6 In an embodiment, R 6 In an embodiment, R 6 is -OCHBr2. In an embodiment, R 6 In an embodiment, R 6 In the embodiment, R 6 is a substituted or unsubstituted C1-C4 alkyl group. 6 is a substituted C1-C4 alkyl. 6is a substituted methyl group. In an embodiment, R 6 is a substituted ethyl group. In an embodiment, R 6 is a substituted propyl group. In an embodiment, R 6 is a substituted n-propyl group. In an embodiment, R 6 is substituted isopropyl. In an embodiment, R 6 is a substituted butyl group. In an embodiment, R 6 is a substituted n-butyl group. In an embodiment, R 6 is a substituted isobutyl group. In an embodiment, R 6 is a substituted tert-butyl group. 6 is an unsubstituted C1-C4 alkyl. 6 is an unsubstituted methyl group. In an embodiment, R 6 is an unsubstituted ethyl group. In an embodiment, R 6 is unsubstituted propyl. In an embodiment, R 6 is unsubstituted n-propyl. In an embodiment, R 6 is unsubstituted isopropyl. In an embodiment, R 6 is an unsubstituted butyl group. In an embodiment, R 6 is unsubstituted n-butyl. In an embodiment, R 6 is an unsubstituted isobutyl group. In an embodiment, R 6 is an unsubstituted tert-butyl group. In an embodiment, R 6 is a substituted or unsubstituted 2- to 4-membered heteroalkyl group. 6 is a substituted 2- to 4-membered heteroalkyl. 6 is an unsubstituted 2 to 4 membered heteroalkyl group. 6 is unsubstituted methoxy. In an embodiment, R 6 is an unsubstituted ethoxy group. In an embodiment, R 6 is unsubstituted propoxy. In an embodiment, R 6 is unsubstituted n-propoxy. In an embodiment, R 6 is unsubstituted isopropyloxy. In an embodiment, R 6 is an unsubstituted butoxy group. In an embodiment, R 6 is unsubstituted n-butoxy. In an embodiment, R 6 is unsubstituted isobutyloxy. In an embodiment, R 6 is an unsubstituted tert-butoxy group.

[0306] In an embodiment, R 6is an amino acid side chain. In an embodiment, R 6 is a glycine side chain. In an embodiment, R 6 is an alanine side chain. In an embodiment, R 6 is a valine side chain. In an embodiment, R 6 is a leucine side chain. In an embodiment, R 6 isoleucine side chain. 6 is a methionine side chain. In an embodiment, R 6 is a serine side chain. In an embodiment, R 6 is a threonine side chain. In an embodiment, R 6 is a cysteine ​​side chain. In an embodiment, R 6 is an aspartic acid side chain. In an embodiment, R 6 is a glutamic acid side chain. In an embodiment, R 6 is an asparagine side chain. In an embodiment, R 6 is a glutamine side chain. In an embodiment, R 6 is a histidine side chain. In an embodiment, R 6 is a phenylalanine side chain. In an embodiment, R 6 is a tyrosine side chain. In an embodiment, R 6 is a tryptophan side chain. In an embodiment, R 6 is an arginine side chain. In an embodiment, R 6 Lysine side chain.

[0307] In an embodiment, R 6 is an amino acid side chain. In an embodiment, R 6 is the side chain of L-glycine. 6 is an L-alanine side chain. In an embodiment, R 6 is the L-valine side chain. In an embodiment, R 6 is the side chain of L-leucine. 6 is the side chain of L-isoleucine. 6 is the L-methionine side chain. 6 is the L-serine side chain. 6 is an L-threonine side chain. In an embodiment, R 6 is an L-cysteine ​​side chain. In an embodiment, R 6 is an L-aspartic acid side chain. In an embodiment, R 6 is an L-glutamic acid side chain. In an embodiment, R 6 is an L-asparagine side chain. In an embodiment, R 6is an L-glutamine side chain. In an embodiment, R 6 is an L-histidine side chain. In an embodiment, R 6 is an L-phenylalanine side chain. In an embodiment, R 6 is an L-tyrosine side chain. 6 is the L-tryptophan side chain. In an embodiment, R 6 is the side chain of L-arginine. 6 It is the side chain of L-lysine.

[0308] In an embodiment, R 6 is an amino acid side chain. In an embodiment, R 6 is a D-glycine side chain. In an embodiment, R 6 is a D-alanine side chain. In an embodiment, R 6 is a D-valine side chain. In an embodiment, R 6 is a D-leucine side chain. In an embodiment, R 6 is a D-isoleucine side chain. 6 is a D-methionine side chain. In an embodiment, R 6 is a D-serine side chain. In an embodiment, R 6 is a D-threonine side chain. 6 is a D-cysteine ​​side chain. In an embodiment, R 6 is a D-aspartic acid side chain. In an embodiment, R 6 is a D-glutamic acid side chain. 6 is a D-asparagine side chain. In an embodiment, R 6 is a D-glutamine side chain. In an embodiment, R 6 is a D-histidine side chain. 6 is a D-phenylalanine side chain. In an embodiment, R 6 is a D-tyrosine side chain. 6 is a D-tryptophan side chain. 6 is a D-arginine side chain. 6 It is the side chain of D-lysine.

[0309] In an embodiment, R 6 is hydrogen, unsubstituted methyl, unsubstituted isopropyl,

[0310]

[0311] In an embodiment, when R bonded to the same nitrogen atom3 and R 6 The substituted ring formed when the substituents are joined (e.g., substituted heterocycloalkyl and / or substituted heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if R 3 and R 6 The substituted ring formed when the substituents are joined is substituted with a plurality of groups selected from substituents, substituents of limited size, and lower substituents; each substituent, substituent of limited size, and / or lower substituent may optionally be different. In an embodiment, when R 3 and R 6 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent. In an embodiment, when R 3 and R 6 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 3 and R 6 When the substituted ring formed when the substituents are joined is substituted, it is substituted with at least one lower substituent.

[0312] In an embodiment, R 3 and R 6 Can be optionally joined to form unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered), or unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered).

[0313] In an embodiment, R 3 and R 6 are joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl. In an embodiment, R 3 and R 6 to form a substituted or unsubstituted 4- to 8-membered heterocycloalkyl. 3 and R 6 to form an unsubstituted pyrrolidinyl group. In an embodiment, R 3 and R 6 Conjugation is performed to form an unsubstituted piperidinyl.

[0314] R 1A 、R 1B 、R 1C 、R 1D 、R 6A 、R 6B 、R 6C and R 6Dare independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered, 5- to 9-membered, or 5- to 6-membered); R 1A and R 1B Substituents can be optionally joined to form unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), or unsubstituted heteroaryl (e.g., 5 to 10 members, 5 to 9 members, or 5 to 6 members); R 6A and R 6B The substituents can be optionally joined to form an unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered) or an unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered).

[0315] R 4A 、R 4B 、R 4C 、R 4D 、R 5A 、R 5B 、R 5C and R 5D are independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2), unsubstituted heteroalkyl (e.g., 2 to 8 members, 2 to 6 members, 4 to 6 members, 2 to 3 members, or 4 to 5 members), unsubstituted cycloalkyl (e.g., C3-C8, C3-C6, C4-C6, or C5-C6), unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), unsubstituted aryl (e.g., C6-C 10 or phenyl), or unsubstituted heteroaryl (e.g., 5- to 10-membered, 5- to 9-membered, or 5- to 6-membered); R 4A and R 4BSubstituents can be optionally joined to form unsubstituted heterocycloalkyl (e.g., 3 to 8 members, 3 to 6 members, 4 to 6 members, 4 to 5 members, or 5 to 6 members), or unsubstituted heteroaryl (e.g., 5 to 10 members, 5 to 9 members, or 5 to 6 members); R 5A and R 5B The substituents can be optionally joined to form an unsubstituted heterocycloalkyl (e.g., 3-8, 3-6, 4-6, 4-5, or 5-6 membered) or an unsubstituted heteroaryl (e.g., 5-10, 5-9, or 5-6 membered).

[0316] In an embodiment, substituted R 7 (e.g., substituted alkyl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if the substituted R 7 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 7 When R is substituted, it is substituted with at least one substituent. 7 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 7 When substituted, it is substituted with at least one lower substituent.

[0317] In an embodiment, R 7 is hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2). 7 is hydrogen, halogen, -OH, -N3 or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2). 7 is hydrogen. In an embodiment, R 7 In an embodiment, R 7 In an embodiment, R 7 In the embodiment, R 7 is -Br. In an embodiment, R 7 In an embodiment, R 7 In the embodiment, R 7 In the embodiment, R 7 is a substituted or unsubstituted C1-C4 alkyl group. 7 is an unsubstituted C1-C4 alkyl. 7 is an unsubstituted methyl group. In an embodiment, R7 is an unsubstituted ethyl group. In an embodiment, R 7 is unsubstituted propyl. In an embodiment, R 7 is unsubstituted n-propyl. In an embodiment, R 7 is unsubstituted isopropyl. In an embodiment, R 7 is an unsubstituted butyl group. In an embodiment, R 7 is unsubstituted n-butyl. In an embodiment, R 7 is an unsubstituted isobutyl group. In an embodiment, R 7 is an unsubstituted tert-butyl group.

[0318] In an embodiment, substituted R 8 (e.g., substituted alkyl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if the substituted R 8 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 8 When R is substituted, it is substituted with at least one substituent. 8 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 8 When substituted, it is substituted with at least one lower substituent.

[0319] In an embodiment, R 8 is hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2). 8 is hydrogen, halogen, -OH, -N3 or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2). 8 is hydrogen. In an embodiment, R 8 is halogen. In an embodiment, R 8 In an embodiment, R 8 In the embodiment, R 8 is -Br. In an embodiment, R 8 In an embodiment, R 8 In the embodiment, R 8 In the embodiment, R 8 is a substituted or unsubstituted C1-C4 alkyl group. 8 is an unsubstituted C1-C4 alkyl.8 is an unsubstituted methyl group. In an embodiment, R 8 is an unsubstituted ethyl group. In an embodiment, R 8 is unsubstituted propyl. In an embodiment, R 8 is unsubstituted n-propyl. In an embodiment, R 8 is unsubstituted isopropyl. In an embodiment, R 8 is an unsubstituted butyl group. In an embodiment, R 8 is unsubstituted n-butyl. In an embodiment, R 8 is an unsubstituted isobutyl group. In an embodiment, R 8 is an unsubstituted tert-butyl group.

[0320] In an embodiment, substituted R 9 (e.g., substituted alkyl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if the substituted R 9 is substituted with a plurality of groups selected from substituents, size-restricted substituents and lower substituents; each substituent, size-restricted substituent and / or lower substituent may optionally be different. In an embodiment, when R 9 When R is substituted, it is substituted with at least one substituent. 9 When substituted, it is substituted with at least one substituent of limited size. In an embodiment, when R 9 When substituted, it is substituted with at least one lower substituent.

[0321] In an embodiment, R 9 is hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4, or C1-C2). 9 is hydrogen, halogen, -OH, -N3 or unsubstituted alkyl (e.g., C1-C8, C1-C6, C1-C4 or C1-C2). 9 is hydrogen. In an embodiment, R 9 In an embodiment, R 9 In an embodiment, R 9 In the embodiment, R 9 is -Br. In an embodiment, R 9 In an embodiment, R 9 In the embodiment, R 9 In the embodiment, R 9 is a substituted or unsubstituted C1-C4 alkyl group. 9is an unsubstituted C1-C4 alkyl. 9 is an unsubstituted methyl group. In an embodiment, R 9 is an unsubstituted ethyl group. In an embodiment, R 9 is unsubstituted propyl. In an embodiment, R 9 is unsubstituted n-propyl. In an embodiment, R 9 is unsubstituted isopropyl. In an embodiment, R 9 is an unsubstituted butyl group. In an embodiment, R 9 is unsubstituted n-butyl. In an embodiment, R 9 is an unsubstituted isobutyl group. In an embodiment, R 9 is an unsubstituted tert-butyl group.

[0322] In an embodiment, the substituted ring A (e.g., substituted phenyl and / or substituted 5- to 6-membered heteroaryl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if the substituted ring A is substituted with multiple groups selected from substituents, substituents of limited size, and lower substituents; each substituent, substituent of limited size, and / or lower substituent may optionally be different. In an embodiment, when the ring A is substituted, it is substituted with at least one substituent. In an embodiment, when the ring A is substituted, it is substituted with at least one substituent of limited size. In an embodiment, when the ring A is substituted, it is substituted with at least one lower substituent.

[0323] In embodiments, Ring A is unsubstituted phenyl or unsubstituted 5- to 6-membered heteroaryl. In embodiments, Ring A is substituted phenyl. In embodiments, Ring A is unsubstituted phenyl. In embodiments, Ring A is substituted 5- to 6-membered heteroaryl. In embodiments, Ring A is unsubstituted 5- to 6-membered heteroaryl. In embodiments, Ring A is substituted thienyl. In embodiments, Ring A is unsubstituted thienyl. In embodiments, Ring A is substituted 2-thienyl. In embodiments, Ring A is unsubstituted 2-thienyl. In embodiments, Ring A is substituted 3-thienyl. In embodiments, Ring A is unsubstituted 3-thienyl. In embodiments, Ring A is substituted pyridyl. In embodiments, Ring A is unsubstituted pyridyl. In embodiments, Ring A is substituted 2-pyridyl. In embodiments, Ring A is unsubstituted 2-pyridyl. In embodiments, Ring A is substituted 3-pyridyl. In embodiments, Ring A is an unsubstituted 3-pyridyl group. In embodiments, Ring A is a substituted 4-pyridyl group. In embodiments, Ring A is an unsubstituted 4-pyridyl group. In embodiments, Ring A is a substituted pyrrolyl group. In embodiments, Ring A is an unsubstituted pyrrolyl group. In embodiments, Ring A is a substituted furanyl group. In embodiments, Ring A is an unsubstituted furanyl group. In embodiments, Ring A is a substituted pyrazolyl group. In embodiments, Ring A is an unsubstituted pyrazolyl group. In embodiments, Ring A is a substituted imidazolyl group. In embodiments, Ring A is an unsubstituted imidazolyl group. In embodiments, Ring A is a substituted oxazolyl group. In embodiments, Ring A is an unsubstituted oxazolyl group. In embodiments, Ring A is a substituted isoxazolyl group. In embodiments, Ring A is an unsubstituted isoxazolyl group. In embodiments, Ring A is a substituted thiazolyl group. In embodiments, Ring A is an unsubstituted thiazolyl group. In embodiments, Ring A is a substituted triazolyl group. In an embodiment, Ring A is unsubstituted triazolyl.

[0324] In an embodiment, Ring A is phenyl. In an embodiment, Ring A is a 5- to 6-membered heteroaryl. In an embodiment, Ring A is thienyl. In an embodiment, Ring A is 2-thienyl. In an embodiment, Ring A is 3-thienyl. In an embodiment, Ring A is pyridyl. In an embodiment, Ring A is 2-pyridyl. In an embodiment, Ring A is 3-pyridyl. In an embodiment, Ring A is 4-pyridyl. In an embodiment, Ring A is pyrrolyl. In an embodiment, Ring A is furanyl. In an embodiment, Ring A is pyrazolyl. In an embodiment, Ring A is imidazolyl. In an embodiment, Ring A is oxazolyl. In an embodiment, Ring A is isoxazolyl. In an embodiment, Ring A is thiazolyl. In an embodiment, Ring A is triazolyl.

[0325] In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is In an embodiment, Ring A is

[0326] In an embodiment, the substituted ring B (e.g., substituted phenyl, substituted naphthyl, substituted quinolyl, and / or substituted isoquinolyl) is substituted with at least one substituent, a substituent of limited size, or a lower substituent; wherein if the substituted ring B is substituted with multiple groups selected from substituents, substituents of limited size, and lower substituents; each substituent, substituent of limited size, and / or lower substituent may optionally be different. In an embodiment, when ring B is substituted, it is substituted with at least one substituent. In an embodiment, when ring B is substituted, it is substituted with at least one substituent of limited size. In an embodiment, when ring B is substituted, it is substituted with at least one lower substituent.

[0327] In embodiments, Ring B is unsubstituted phenyl, unsubstituted naphthyl, unsubstituted quinolyl, or unsubstituted isoquinolyl. In embodiments, Ring B is substituted phenyl. In embodiments, Ring B is unsubstituted phenyl. In embodiments, Ring B is substituted naphthyl. In embodiments, Ring B is unsubstituted naphthyl. In embodiments, Ring B is substituted 1-naphthyl. In embodiments, Ring B is unsubstituted 1-naphthyl. In embodiments, Ring B is substituted 2-naphthyl. In embodiments, Ring B is unsubstituted 2-naphthyl. In embodiments, Ring B is substituted quinolyl. In embodiments, Ring B is unsubstituted quinolyl. In embodiments, Ring B is substituted 2-quinolyl. In embodiments, Ring B is unsubstituted 2-quinolyl. In embodiments, Ring B is substituted 3-quinolyl. In embodiments, Ring B is unsubstituted 3-quinolyl. In embodiments, Ring B is substituted 4-quinolyl. In an embodiment, Ring B is an unsubstituted 4-quinolyl group. In an embodiment, Ring B is a substituted isoquinolyl group. In an embodiment, Ring B is an unsubstituted isoquinolyl group. In an embodiment, Ring B is a substituted 1-isoquinolyl group. In an embodiment, Ring B is an unsubstituted 1-isoquinolyl group. In an embodiment, Ring B is a substituted 3-isoquinolyl group. In an embodiment, Ring B is an unsubstituted 3-isoquinolyl group. In an embodiment, Ring B is a substituted 4-isoquinolyl group. In an embodiment, Ring B is an unsubstituted 4-isoquinolyl group.

[0328] In an embodiment, Ring B is phenyl. In an embodiment, Ring B is naphthyl. In an embodiment, Ring B is 1-naphthyl. In an embodiment, Ring B is 2-naphthyl. In an embodiment, Ring B is quinolyl. In an embodiment, Ring B is 2-quinolyl. In an embodiment, Ring B is 3-quinolyl. In an embodiment, Ring B is 4-quinolyl. In an embodiment, Ring B is isoquinolyl. In an embodiment, Ring B is 1-isoquinolyl. In an embodiment, Ring B is 3-isoquinolyl. In an embodiment, Ring B is 4-isoquinolyl.

[0329] In an embodiment, Ring B is In an embodiment, Ring B is In an embodiment, Ring B is In an embodiment, Ring B is In an embodiment, Ring B is In an embodiment, Ring B is In an embodiment, Ring B is In an embodiment, Ring B is

[0330] In an embodiment, m is 0. In an embodiment, m is 1. In an embodiment, m is 2. In an embodiment, m is 3. In an embodiment, m is 4. In an embodiment, m is 5.

[0331] In an embodiment, n is 0. In an embodiment, n is 1. In an embodiment, n is 2. In an embodiment, n is 3. In an embodiment, n is 4. In an embodiment, n is 5. In an embodiment, n is 6. In an embodiment, n is 7. In an embodiment, n is 8. In an embodiment, n is 9. In an embodiment, n is 10.

[0332] In an embodiment, the compound has the formula:

[0333] R 1 ,z1,R 2 、R 3 、R 4 , z4 and R 6 As described herein (including in the embodiments).

[0334] In an embodiment, the compound has the formula:

[0335] R 1 ,z1,R 2 、R 3 、R 4 , z4 and R 6 As described herein (including in the embodiments).

[0336] In an embodiment, the compound has the formula:

[0337] R 2 、R 3 、R 4 , z4 and R 6 As described herein (including in the embodiments).

[0338] In an embodiment, the compound has the formula:

[0339] R 2 、R 3 、R 4 , z4 and R 6 As described herein (including in the embodiments).

[0340] In an embodiment, the compound has the formula:

[0341] R 4 , z4 and R 6As described herein (including in the embodiments). In embodiments, the compound has the formula:

[0342] R 4 , z4 and R 6 As described herein (including in the embodiments). In embodiments, the compound has the formula:

[0343] R 4 , z4 and R 6 As described herein (including in the embodiments). In embodiments, the compound has the formula:

[0344] R 4 , z4 and R 6 As described herein (including in the embodiments). In embodiments, the compound has the formula:

[0345] R 6 As described herein (including in the embodiments).

[0346] In an embodiment, the compound has the formula:

[0347] R 6 As described herein (including in the embodiments).

[0348] In an embodiment, the compound has the formula:

[0349] R 6 As described herein (including in the embodiments).

[0350] In an embodiment, the compound has the formula:

[0351] R 6 As described herein (including in the embodiments).

[0352] In an embodiment, the compound has the formula:

[0353] R 2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0354] In an embodiment, the compound has the formula:

[0355] R2 、R 3 、R 4 、z4、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0356] In an embodiment, the compound has the formula:

[0357] R 4 、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0358] In an embodiment, the compound has the formula:

[0359] R 4 、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0360] In an embodiment, the compound has the formula:

[0361] R 4 、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0362] In an embodiment, the compound has the formula:

[0363] R 4 、R 5 , z5 and R 6 As described herein (including in the embodiments).

[0364] In an embodiment, the compound has the formula:

[0365] R 5 , z5 and R 6 As described herein (including in the embodiments).

[0366] In an embodiment, the compound has the formula:

[0367] R 5 , z5 and R 6 As described herein (including in the embodiments).

[0368] In an embodiment, the compound has the formula:

[0369] R 5 , z5 and R 6 As described herein (including in the embodiments).

[0370] In an embodiment, the compound has the formula:

[0371] R 5 , z5 and R 6 As described herein (including in the embodiments).

[0372] In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound is a compound of this paragraph, wherein R 2 In this embodiment, the compound is a compound of this paragraph, wherein R 3 In this embodiment, the compound is a compound of this paragraph, wherein R 2 and R 3 The positions are each methyl instead of hydrogen.

[0373] In an embodiment, the compound has the formula:

[0374] R 1 ,z1,R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0375] In an embodiment, the compound has the formula:

[0376] R 1 ,z1,R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0377] In an embodiment, the compound has the formula:

[0378] R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0379] In an embodiment, the compound has the formula:

[0380] R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0381] In an embodiment, the compound has the formula:

[0382] R 4 As described herein (including in the embodiments).

[0383] In an embodiment, the compound has the formula:

[0384] R 4 As described herein (including in the embodiments).

[0385] In an embodiment, the compound has the formula:

[0386] R 4 As described herein (including in the embodiments).

[0387] In an embodiment, the compound has the formula:

[0388] R 4 As described herein (including in the embodiments).

[0389] In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula:

[0390] In an embodiment, the compound has the formula:

[0391] R 1 ,z1,R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0392] In an embodiment, the compound has the formula:

[0393] R 1 ,z1,R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0394] In an embodiment, the compound has the formula:

[0395] R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0396] In an embodiment, the compound has the formula:

[0397] R 2 、R 4 and z4 are as described herein (including in the embodiments).

[0398] In an embodiment, the compound has the formula:

[0399] R 4 As described herein (including in the embodiments).

[0400] In an embodiment, the compound has the formula:

[0401] R 4 As described herein (including in the embodiments).

[0402] In an embodiment, the compound has the formula:

[0403] R 4 As described herein (including in the embodiments).

[0404] In an embodiment, the compound has the formula:

[0405] R 4 As described herein (including in the embodiments).

[0406] In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula: In an embodiment, the compound has the formula:

[0407] In one aspect, a compound or a pharmaceutically acceptable salt thereof is provided, which has the formula:

[0408] L 1 , Ring A, R 1 ,z1,R 2 、R 3 、R 6 and m are as described herein (including in the embodiments).

[0409] In an embodiment, the compound has the formula:

[0410] L 1 , Ring A, R 1 ,z1,R 2 、R 3 、R 4 、z4、R 6 and m are as described herein (including in the embodiments).

[0411] In an embodiment, the compound has the formula:

[0412] L 1 , Ring A, R 1 ,z1,R 2 、R 3 、R 4 , z4 and R 6 As described herein (including in the embodiments).

[0413] In an embodiment, when R 1 When substituted, R 1 By one or more R 1.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1.1 When the substituent is substituted, R 1.1 The substituent is composed of one or more R 1.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1.2 When the substituent is substituted, R 1.2 The substituent is composed of one or more R 1.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1 、R 1.1 、R 1.2 and R 1.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 1 、R 1.1 、R 1.2 and R 1.3 .

[0414] In the embodiment, when two adjacent R 1 When substituents are optionally joined to form a substituted moiety (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl), the moiety is replaced by one or more R 1.1 The first substituent represented by is substituted as described in the definition section above in the description of the "first substituent". In an embodiment, when R 1.1 When the substituent is substituted, R 1.1 The substituent is composed of one or more R 1.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1.2 When the substituent is substituted, R 1.2 The substituent is composed of one or more R 1.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1 、R 1.1 、R 1.2 and R 1.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 1 、R 1.1 、R 1.2 and R 1.3 .

[0415] In an embodiment, when R 1A When substituted, R 1A By one or more R 1A.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1A.1 When the substituent is substituted, R 1A.1 The substituent is composed of one or more R 1A.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1A.2 When the substituent is substituted, R 1A.2 The substituent is composed of one or more R 1A.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1A 、R1A.1 、R 1A.2 and R 1A.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 1A 、R 1A.1 、R 1A.2 and R 1A.3 .

[0416] In an embodiment, when R 1B When substituted, R 1B By one or more R 1B.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1B.1 When the substituent is substituted, R 1B.1 The substituent is composed of one or more R 1B.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1B.2 When the substituent is substituted, R 1B.2 The substituent is composed of one or more R 1B.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1B 、R 1B.1 、R 1B.2 and R 1B.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 1B 、R 1B.1 、R 1B.2 and R 1B.3 .

[0417] In an embodiment, when R bonded to the same nitrogen atom 1A and R 1BWhen substituents are optionally joined to form a substituted moiety (e.g., substituted heterocycloalkyl or substituted heteroaryl), the moiety is replaced by one or more R 1A.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1A.1 When the substituent is substituted, R 1A.1 The substituent is composed of one or more R 1A.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1A.2 When the substituent is substituted, R 1A.2 The substituent is composed of one or more R 1A.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1A.1 、R 1A.2 and R 1A.3 The values ​​corresponding to R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW.1 、R WW.2 and R WW.3 Corresponding to R 1A.1 、R 1A.2 and R 1A.3 .

[0418] In an embodiment, when R bonded to the same nitrogen atom 1A and R 1B When substituents are optionally joined to form a substituted moiety (e.g., substituted heterocycloalkyl or substituted heteroaryl), the moiety is replaced by one or more R 1B.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1B.1 When the substituent is substituted, R 1B.1 The substituent is composed of one or more R 1B.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1B.2 When the substituent is substituted, R 1B.2 The substituent is composed of one or more R 1B.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1B.1 、R 1B.2 and R 1B.3 The values ​​corresponding to R WW.1 、RWW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW.1 、R WW.2 and R WW.3 Corresponding to R 1B.1 、R 1B.2 and R 1B.3 .

[0419] In an embodiment, when R 1C When substituted, R 1C By one or more R 1C.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1C.1 When the substituent is substituted, R 1C.1 The substituent is composed of one or more R 1C.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1C.2 When the substituent is substituted, R 1C.2 The substituent is composed of one or more R 1C.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1C 、R 1C.1 、R 1C.2 and R 1C.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 1C 、R 1C.1 、R 1C.2 and R 1C.3 .

[0420] In an embodiment, when R 1D When substituted, R 1D By one or more R 1D.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1D.1 When the substituent is substituted, R 1D.1 The substituent is composed of one or more R 1D.2The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 1D.2 When the substituent is substituted, R 1D.2 The substituent is composed of one or more R 1D.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 1D 、R 1D.1 、R 1D.2 and R 1D.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 1D 、R 1D.1 、R 1D.2 and R 1D.3 .

[0421] In an embodiment, when R 2 When substituted, R 2 By one or more R 2.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 2.1 When the substituent is substituted, R 2.1 The substituent is composed of one or more R 2.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 2.2 When the substituent is substituted, R 2.2 The substituent is composed of one or more R 2.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 2 、R 2.1 、R 2.2 and R 2.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R2 、R 2.1 、R 2.2 and R 2.3 .

[0422] In an embodiment, when R 3 When substituted, R 3 By one or more R 3.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 3.1 When the substituent is substituted, R 3.1 The substituent is composed of one or more R 3.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 3.2 When the substituent is substituted, R 3.2 The substituent is composed of one or more R 3.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 3 、R 3.1 、R 3.2 and R 3.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 3 、R 3.1 、R 3.2 and R 3.3 .

[0423] In an embodiment, when R 4 When substituted, R 4 By one or more R 4.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4.1 When the substituent is substituted, R 4.1 The substituent is composed of one or more R 4.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4.2 When the substituent is substituted, R 4.2 The substituent is composed of one or more R 4.3The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4 、R 4.1 、R 4.2 and R 4.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 4 、R 4.1 、R 4.2 and R 4.3 .

[0424] In the embodiment, when two adjacent R 4 When substituents are optionally joined to form a substituted moiety (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl), the moiety is replaced by one or more R 4.1 The first substituent represented by is substituted as described in the definition section above in the description of the "first substituent". In an embodiment, when R 4.1 When the substituent is substituted, R 4.1 The substituent is composed of one or more R 4.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4.2 When the substituent is substituted, R 4.2 The substituent is composed of one or more R 4.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4 、R 4.1 、R 4.2 and R 4.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 4 、R 4.1 、R 4.2 and R 4.3 .

[0425] In an embodiment, when R 4A When substituted, R 4A By one or more R 4A.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4A.1 When the substituent is substituted, R 4A.1 The substituent is composed of one or more R 4A.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4A.2 When the substituent is substituted, R 4A.2 The substituent is composed of one or more R 4A.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4A 、R 4A.1 、R 4A.2 and R 4A.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 4A 、R 4A.1 、R 4A.2 and R 4A.3 .

[0426] In an embodiment, when R 4B When substituted, R 4B By one or more R 4B.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4B.1 When the substituent is substituted, R 4B.1 The substituent is composed of one or more R 4B.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4B.2 When the substituent is substituted, R 4B.2 The substituent is composed of one or more R 4B.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4B 、R 4B.1 、R 4B.2 and R4B.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 4B 、R 4B.1 、R 4B.2 and R 4B.3 .

[0427] In an embodiment, when R bonded to the same nitrogen atom 4A and R 4B When substituents are optionally joined to form a substituted moiety (e.g., substituted heterocycloalkyl or substituted heteroaryl), the moiety is replaced by one or more R 4A.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4A.1 When the substituent is substituted, R 4A.1 The substituent is composed of one or more R 4A.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4A.2 When the substituent is substituted, R 4A.2 The substituent is composed of one or more R 4A.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4A.1 、R 4A.2 and R 4A.3 The values ​​corresponding to R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW.1 、R WW.2 and R WW.3 Corresponding to R 4A.1 、R 4A.2 and R 4A.3 .

[0428] In an embodiment, when R bonded to the same nitrogen atom 4A and R 4B When substituents are optionally joined to form a substituted moiety (e.g., substituted heterocycloalkyl or substituted heteroaryl), the moiety is replaced by one or more R 4B.1The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4B.1 When the substituent is substituted, R 4B.1 The substituent is composed of one or more R 4B.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4B.2 When the substituent is substituted, R 4B.2 The substituent is composed of one or more R 4B.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4B.1 、R 4B.2 and R 4B.3 The values ​​corresponding to R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW.1 、R WW.2 and R WW.3 Corresponding to R 4B.1 、R 4B.2 and R 4B.3 .

[0429] In an embodiment, when R 4C When substituted, R 4C By one or more R 4C.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4C.1 When the substituent is substituted, R 4C.1 The substituent is composed of one or more R 4C.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4C.2 When the substituent is substituted, R 4C.2 The substituent is composed of one or more R 4C.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4C 、R 4C.1 、R 4C.2 and R 4C.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1、R WW.2 and R WW.3 Corresponding to R 4C 、R 4C.1 、R 4C.2 and R 4C.3 .

[0430] In an embodiment, when R 4D When substituted, R 4D By one or more R 4D.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4D.1 When the substituent is substituted, R 4D.1 The substituent is composed of one or more R 4D.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 4D.2 When the substituent is substituted, R 4D.2 The substituent is composed of one or more R 4D.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 4D 、R 4D.1 、R 4D.2 and R 4D.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 4D 、R 4D.1 、R 4D.2 and R 4D.3 .

[0431] In an embodiment, when R 5 When substituted, R 5 By one or more R 5.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5.1 When the substituent is substituted, R 5.1 The substituent is composed of one or more R 5.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5.2 When the substituent is substituted, R 5.2The substituent is composed of one or more R 5.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 5 、R 5.1 、R 5.2 and R 5.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW .. 2 and R WW.3 Corresponding to R 5 、R 5.1 、R 5.2 and R 5.3 .

[0432] In an embodiment, when two adjacent R5 substituents are optionally joined to form a substituted moiety (e.g., substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, or substituted heteroaryl), the moiety is replaced by one or more R5 substituents. 5.1 The first substituent represented by is substituted as described in the definition section above in the description of the "first substituent". In an embodiment, when R 5.1 When the substituent is substituted, R 5.1 The substituent is composed of one or more R 5.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5.2 When the substituent is substituted, R 5.2 The substituent is composed of one or more R 5.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 5 、R 5.1 、R 5.2 and R 5.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 5 、R 5.1 、R 5.2 and R5.3 .

[0433] In an embodiment, when R 5A When substituted, R 5A By one or more R 5A.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5A.1 When the substituent is substituted, R 5A.1 The substituent is composed of one or more R 5A.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5A .. 2 When the substituent is substituted, R 5A.2 The substituent is composed of one or more R 5A.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 5A 、R 5A.1 、R 5A.2 and R 5A.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 5A 、R 5A.1 、R 5A.2 and R 5A.3 .

[0434] In an embodiment, when R 5B When substituted, R 5B By one or more R 5B.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5B.1 When the substituent is substituted, R 5B.1 The substituent is composed of one or more R 5B.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5B.2 When the substituent is substituted, R 5B.2 The substituent is composed of one or more R 5B.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R5B 、R 5B.1 、R 5B.2 and R 5B.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 5B 、R 5B.1 、R 5B.2 and R 5B.3 .

[0435] In an embodiment, when R bonded to the same nitrogen atom 5A and R 5B When substituents are optionally joined to form a substituted moiety (e.g., substituted heterocycloalkyl or substituted heteroaryl), the moiety is replaced by one or more R 5A.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5A.1 When the substituent is substituted, R 5A.1 The substituent is composed of one or more R 5A.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5A.2 When the substituent is substituted, R 5A.2 The substituent is composed of one or more R 5A.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 5A.1 、R 5A.2 and R 5A.3 The values ​​corresponding to R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW.1 、R WW.2 and R WW.3 Corresponding to R 5A.1 、R 5A.2 and R 5A.3 .

[0436] In an embodiment, when R bonded to the same nitrogen atom 5A and R 5BWhen substituents are optionally joined to form a substituted moiety (e.g., substituted heterocycloalkyl or substituted heteroaryl), the moiety is replaced by one or more R 5B.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5B.1 When the substituent is substituted, R 5B.1 The substituent is composed of one or more R 5B.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5B.2 When the substituent is substituted, R 5B.2 The substituent is composed of one or more R 5B.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 5B.1 、R 5B.2 and R 5B.3 The values ​​corresponding to R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW.1 、R WW.2 and R WW.3 Corresponding to R 5B.1 、R 5B.2 and R 5B.3 .

[0437] In an embodiment, when R 5C When substituted, R 5C By one or more R 5C.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5C.1 When the substituent is substituted, R 5C.1 The substituent is composed of one or more R 5C.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5C.2 When the substituent is substituted, R 5C.2 The substituent is composed of one or more R 5C.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 5C 、R 5C.1 、R 5C.2 and R 5C.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and RWW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 5C 、R 5C.1 、R 5C.2 and R 5C.3 .

[0438] In an embodiment, when R 5D When substituted, R 5D By one or more R 5D.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5D.1 When the substituent is substituted, R 5D.1 The substituent is composed of one or more R 5D.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 5D.2 When the substituent is substituted, R 5D.2 The substituent is composed of one or more R 5D.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 5D 、R 5D.1 、R 5D.2 and R 5D.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 5D 、R 5D.1 、R 5D.2 and R 5D.3 .

[0439] In an embodiment, when R 6 When substituted, R 6 By one or more R 6.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 6.1 When the substituent is substituted, R 6.1 The substituent is composed of one or more R 6.2The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 6.2 When the substituent is substituted, R 6.2 The substituent is composed of one or more R 6.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 6 、R 6.1 、R 6.2 and R 6.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R 6 、R 6.1 、R 6.2 and R 6.3 .

[0440] In an embodiment, when R 6A When substituted, R 6A By one or more R 6A.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 6A.1 When the substituent is substituted, R 6A.1 The substituent is composed of one or more R 6A.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 6A.2 When the substituent is substituted, R 6A.2 The substituent is composed of one or more R 6A.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 6A 、R 6A.1 、R 6A.2 and R 6A.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition section in the description of the "first substituent" above, wherein R WW 、R WW.1 、R WW.2 and R WW.3 Corresponding to R6A 、R 6A.1 、R 6A.2 and R 6A.3 .

[0441] In an embodiment, when R 6B When substituted, R 6B By one or more R 6B.1 The first substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 6B.1 When the substituent is substituted, R 6B.1 The substituent is composed of one or more R 6B.2 The second substituent represented by is substituted as explained in the definition section above in the description of the "first substituent". In an embodiment, when R 6B.2 When the substituent is substituted, R 6B.2 The substituent is composed of one or more R 6B.3 The third substituent represented by is substituted as explained in the definition section of the description of the "first substituent" above. In the above embodiment, R 6B 、R 6B.1 、R 6B.2 and R 6B.3 The values ​​corresponding to R WW 、R WW.1 、R WW.2 and R WW.3 The value of is as explained in the definition secti...

Claims

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: in L 1 -O-, -NR 7 -, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 7 C(O)-、-C(O)NR 7 、-NR 7 C(O)NR 8 、-NR 7 S(O)2O-、-OS(O)2NR 7 、-NR 7 S(O)2-、-S(O)2NR 7 , -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OR 7 )-、-OP(O)(OR 7 )O-、-OP(O)(OR 7 )-、-P(O)(OR 7 )O-, or -CR 8 R 9 -; R 7 , R 8 and R 9 are independently hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl; Ring A is a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- to 6-membered heteroaryl group; Ring B is substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted quinolyl, or substituted or unsubstituted isoquinolyl; R 1 are independently halogen, -CX 1 3. -CHX 1 2. -CH2X 1 、-OCX 1 3. -OCHX 1 2. -OCH2X 1 、-CN、-SO n1 R 1D 、-SO v1 NR 1A R 1B 、-NR 1C NR 1A R 1B 、-ONR 1A R 1B、-NHC(O)NR 1C NR 1A R 1B 、-NR 1C C(O)NR 1A R 1B 、-N(O) m1 、-NR 1A R 1B 、-C(O)R 1C 、-C(O)OR 1C 、-OC(O)R 1C 、-OC(O)OR 1C 、-C(O)NR 1A R 1B 、-OR 1D 、-SR 1D 、-NR 1A S02R 1D 、-NR 1A C(O)R 1C 、-NR 1A C(O)OR 1C 、-OC(O)NR 1A R 1B 、-NR 1A OR 1C 、-P(O)R 1A R 1B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 1 The substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R 2 For hydrogen, halogen, -CX 2 3. -CHX 2 2. -CH2X 2 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3 For hydrogen, halogen, -CX 3 3. -CHX 3 2. -CH2X 3, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 6 For hydrogen, halogen, -CX 6 3. -CHX 6 2. -CH2X 6 、-OCX 6 3. -OCHX 6 2. -OCH2X 6 、-CN、-SO n6 R6 D 、-SO v6 NR 6A R 6B 、-NR 6C NR 6A R 6B 、-ONR 6A R 6B 、-NHC(O)NR 6C NR 6A R 6B 、-NR 6C C(O)NR 6A R 6B 、-N(O)m6、-NR 6A R 6B 、-C(O)R 6C 、-C(O)OR 6C 、-OC(O)R 6C 、-OC(O)OR 6C 、-C(O)NR 6A R 6B 、-OR 6D 、-SR 6D 、-NR 6A S02R 6D 、-NR 6A C(O)R 6C 、-NR 6A C(O)OR 6C 、-OC(O)NR 6A R 6B 、-NR 6A OR 6C 、-P(O)R 6A R 6B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3 and R 6 can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R 1A , R 1B , R 1C , R 1D , R 6A , R 6B , R 6C and R 6D R is independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 1A and R 1B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 6A and R 6B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; z1 is an integer from 0 to 4; m1, m6, v1 and v6 are independently 1 or 2; n1 and n6 are independently integers from 0 to 4; X, X 1 , X 2 , X 3 and X 6 are independently -Cl, -Br, -I, or -F; m is an integer from 0 to 5; and n is an integer from 0 to 10; The condition is that when L 1 When R is -O-, m is 0, n is 0, and Ring B is substituted or unsubstituted naphthyl, substituted or unsubstituted quinolyl, or substituted or unsubstituted isoquinolyl, then R 6 Not hydrogen.

2. The compound according to claim 1, which has the formula: in Ring A is phenyl or a 5- to 6-membered heteroaryl group; Ring B is phenyl, naphthyl, quinolyl, or isoquinolyl; R 4are independently halogen, -CX 4 3. -CHX 4 2. -CH2X 4 、-OCX 4 3. -OCHX 4 2. -OCH2X 4 、-CN、-SO n4 R 4D 、-SO v4 NR 4A R 4B 、-NR 4C NR 4A R 4B 、-ONR 4A R 4B 、-NHC(O)NR 4C NR 4A R 4B 、-NR 4C C(O)NR 4A R 4B 、-N(O) m4 、-NR 4A R 4B 、-C(O)R 4C 、-C(O)OR 4C 、-OC(O)R 4C 、-OC(O)OR 4C 、-C(O)NR 4A R 4B 、-OR 4D 、-SR 4D 、-NR 4A S02R 4D 、-NR 4A C(O)R 4C 、-NR 4A C(O)OR 4C 、-OC(O)NR 4A R 4B 、-NR 4A OR 4C 、-P(O)R 4A R 4B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R4 substituents can optionally join to form a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 5 are independently halogen, -CX 53. -CHX 5 2. -CH2X 5 、-OCX 5 3. -OCHX 5 2. -OCH2X 5 、-CN、-SO n5 R 5D 、-SO v5 NR 5A R 5B 、-NR 5C NR 5A R 5B 、-ONR 5A R 5B 、-NHC(O)NR 5C NR 5A R 5B 、-NR 5C C(O)NR 5A R 5B 、-N(O) m5 、-NR 5A R 5B 、-C(O)R 5C 、-C(O)OR 5C 、-OC(O)R 5C 、-OC(O)OR 5C 、-C(O)NR 5A R 5B 、-OR 5D 、-SR 5D 、-NR 5A S02R 5D 、-NR 5A C(O)R 5C 、-NR 5A C(O)OR 5C 、-OC(O)NR 5A R 5B 、-NR 5A OR 5C 、-P(O)R 5A R 5B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 5 The substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R4 A 、R4 B 、R4 C 、R4D , R 5A , R 5B 、R5 C and R 5D R is independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 4A and R 4B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 5A and R 5B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; z4 is an integer from 0 to 5; z5 is an integer from 0 to 7; m4, m5, v4 and v5 are independently 1 or 2; n4 and n5 are independently integers from 0 to 4; and X 4 and X 5 are independently -Cl, -Br, -I, or -F.

3. The compound according to claim 2, which has the formula:

4. The compound according to claim 3, which has the following formula:

5. The compound according to claim 3, which has the formula:

6. The compound according to claim 3, which has the formula:

7. The compound according to claim 3, which has the formula:

8. The compound according to claim 3, which has the formula:

9. The compound according to claim 1, wherein L 1is -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -NHS(O)2O-, -OS(O)2NH-, -NHS(O)2-, -S(O)2NH-, -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -OP(O)(OH)-, -P(O)(OH)O-, -CHR 9 , or -CR 8 R 9 -;and R 8 and R 9 is independently halogen or unsubstituted methyl.

10. The compound according to claim 1, wherein L 1 For -O-.

11. The compound according to claim 1, wherein L 1 For -S-.

12. The compound according to claim 1, wherein L 1 It is -S(O)2-.

13. The compound according to claim 1, wherein R 1 are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

14. The compound according to claim 1, wherein R 1 independently halogen, -CF3, -OH, -NH2, -SH, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2-4 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl.

15. The compound according to claim 1, wherein R 1independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, -NH2, -SH, unsubstituted C1-C4 alkyl, or unsubstituted 2-4 membered heteroalkyl.

16. The compound according to claim 1, wherein R 1 are independently halogen, -OH, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, unsubstituted methyl, or unsubstituted methoxy.

17. The compound according to claim 1, wherein z1 is 1. The compound according to claim 1 , wherein z1 is 0.

19. The compound according to claim 1, wherein R 2 Hydrogen, -CX 2 3. -CHX 2 2. -CH2X 2 , -CN, -C(O)H, -C(O)OH, -C(O)NH2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2-6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl.

20. The compound according to claim 1, wherein R 2 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

21. The compound according to claim 1, wherein R 2 For hydrogen.

22. The compound according to claim 1, wherein R 3 Hydrogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -C(O)H, -C(O)OH, -C(O)NH2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted 2-6 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl.

23. The compound according to claim 1, wherein R 3 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

24. The compound according to claim 1, wherein R 3 For hydrogen.

25. The compound according to claim 1, wherein R 6 is hydrogen, halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

26. The compound according to claim 1, wherein R 6 is a substituted or unsubstituted C1-C6 alkyl group, or a substituted or unsubstituted 2- to 6-membered heteroalkyl group.

27. The compound according to claim 1, wherein R 6 is hydrogen, unsubstituted methyl, unsubstituted isopropyl, 28. The compound according to claim 1, wherein R 3 and R 6 The groups are joined to form a substituted or unsubstituted heterocycloalkyl group, or a substituted or unsubstituted heteroaryl group.

29. The compound according to claim 1, wherein R 3 and R 6 The groups are joined to form a substituted or unsubstituted 4- to 8-membered heterocycloalkyl group.

30. The compound according to claim 1, wherein R 3 and R 6 Conjugation to form an unsubstituted pyrrolidinyl group.

31. The compound according to claim 1, wherein R 3 and R 6 Conjugation to form an unsubstituted piperidinyl.

32. The compound according to claim 2, wherein R 4 are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

33. The compound according to claim 2, wherein R 4 independently halogen, -CF3, -OH, -NH2, -SH, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2-4 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl.

34. The compound of claim 2, wherein R4 is independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, -NH2, -SH, unsubstituted C1-C4 alkyl, or unsubstituted 2 to 4 membered heteroalkyl.

35. The compound of claim 2, wherein R4 is independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, or unsubstituted methoxy.

36. The compound according to claim 2, wherein R4 is independently -OR 4D .

37. The compound according to claim 36, wherein R4 D is hydrogen, or substituted or unsubstituted alkyl.

38. The compound according to claim 36, wherein R 4D is hydrogen or unsubstituted alkyl.

39. The compound according to claim 36, wherein R4 D is hydrogen or unsubstituted C1-C5 alkyl.

40. The compound according to claim 36, wherein R 4D is hydrogen or unsubstituted methyl.

41. The compound according to claim 36, wherein R4 D is an unsubstituted methyl group.

42. The compound of claim 2, wherein z4 is 1.

43. The compound according to claim 2, wherein z4 is 0.

44. The compound according to claim 2, wherein R 5are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

45. The compound according to claim 2, wherein R 5 independently halogen, -CF3, -OH, -NH2, -SH, substituted or unsubstituted C1-C4 alkyl, substituted or unsubstituted 2-4 membered heteroalkyl, substituted or unsubstituted C3-C6 cycloalkyl, substituted or unsubstituted 3-6 membered heterocycloalkyl, substituted or unsubstituted phenyl, or substituted or unsubstituted 5-6 membered heteroaryl.

46. ​​The compound according to claim 2, wherein R 5 independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, -NH2, -SH, unsubstituted C1-C4 alkyl, unsubstituted 2-4 membered heteroalkyl, or unsubstituted phenyl.

47. The compound according to claim 2, wherein R 5 independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, unsubstituted methoxy, or unsubstituted phenyl.

48. The compound of claim 2, wherein z5 is 1.

49. The compound of claim 2, wherein z5 is 0.

50. The compound of claim 1, wherein Ring A is substituted or unsubstituted phenyl.

51. The compound of claim 1, wherein Ring A is a substituted or unsubstituted 5- to 6-membered heteroaryl.

52. The compound of claim 1, wherein Ring A is substituted or unsubstituted thienyl.

53. The compound of claim 1, wherein Ring A is substituted or unsubstituted 2-thienyl.

54. The compound according to claim 1, wherein Ring A is substituted or unsubstituted 3-thienyl.

55. The compound of claim 1, wherein Ring A is substituted or unsubstituted pyridinyl.

56. The compound of claim 1, wherein Ring A is substituted or unsubstituted 2-pyridinyl.

57. The compound of claim 1, wherein Ring A is substituted or unsubstituted 3-pyridinyl.

58. The compound of claim 1, wherein Ring A is substituted or unsubstituted 4-pyridinyl.

59. The compound of claim 1, wherein Ring B is substituted or unsubstituted phenyl.

60. The compound of claim 1, wherein Ring B is substituted or unsubstituted naphthyl.

61. The compound of claim 1, wherein Ring B is substituted or unsubstituted 1-naphthyl.

62. The compound of claim 1, wherein Ring B is substituted or unsubstituted 2-naphthyl.

63. The compound of claim 1, wherein Ring B is substituted or unsubstituted quinolyl.

64. The compound of claim 1, wherein Ring B is substituted or unsubstituted 2-quinolyl.

65. The compound of claim 1, wherein Ring B is substituted or unsubstituted 3-quinolyl.

66. The compound of claim 1, wherein Ring B is substituted or unsubstituted 4-quinolyl.

67. The compound of claim 1, wherein Ring B is substituted or unsubstituted isoquinolinyl.

68. The compound of claim 1, wherein Ring B is substituted or unsubstituted 1-isoquinolyl.

69. The compound of claim 1, wherein Ring B is substituted or unsubstituted 3-isoquinolyl.

70. The compound of claim 1, wherein Ring B is substituted or unsubstituted 4-isoquinolyl.

71. The compound of claim 2, which has the formula:

72. The compound of claim 2, which has the formula:

73. The compound of claim 2, which has the formula:

74. The compound of claim 2, which has the formula:

75. The compound of claim 1, which has the formula:

76. The compound of claim 1, which has the formula:

77. The compound of claim 2, which has the formula:

78. The compound of claim 2, which has the formula:

79. The compound of claim 2, which has the formula:

80. The compound of claim 1, which has the formula:

81. The compound of claim 2, which has the formula:

82. The compound of claim 2, which has the formula:

83. The compound of claim 2, which has the formula:

84. The compound of claim 2, which has the formula:

85. The compound of claim 1, which has the formula:

86. The compound of claim 1, which has the formula:

87. The compound of claim 1, which has the formula:

88. A pharmaceutical composition comprising a compound according to one of claims 1 to 87 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

89. The pharmaceutical composition of claim 88, further comprising an anticancer agent.

90. The pharmaceutical composition of claim 89, wherein the anticancer agent is a platinum-based compound, a topoisomerase inhibitor, or a Chk1 inhibitor.

91. The pharmaceutical composition of claim 89, wherein the anticancer agent is cisplatin.

92. The pharmaceutical composition of claim 89, wherein the anticancer agent is etoposide, SN-38, camptothecin, or gemcitabine.

93. The pharmaceutical composition of claim 89, wherein the anticancer agent is CHIR-124, debromohymenialdisine, SB 218078, LY2603618, SCH900776, TCS 2312, PF 477736, UCN-01, or AZD7762.

94. A method of treating a disease associated with PCNA activity in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a compound according to one of claims 1 to 87, or a pharmaceutically acceptable salt thereof.

95. A method of treating cancer in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a compound according to one of claims 1 to 87, or a pharmaceutically acceptable salt thereof.

96. The method of claim 95, further comprising administering radiation.

97. The method of claim 95, wherein the cancer is a sarcoma, adenocarcinoma, leukemia, or lymphoma.

98. The method of claim 95, wherein the cancer is lung cancer, colon cancer, central nervous system cancer, brain cancer, neuroblastoma, skin cancer, head and neck cancer, melanoma, ovarian cancer, kidney cancer, prostate cancer, breast cancer, mesothelioma, liver cancer, stomach cancer, esophageal cancer, bladder cancer, cervical cancer, osteosarcoma, pancreatic cancer, adrenocortical carcinoma, adrenal adenocarcinoma, colorectal cancer, testicular cancer, myeloma, B-acute lymphocytic lymphoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic leukemia, acute leukemia, adenocarcinoma, or a blood cancer.

99. A method of inhibiting PCNA activity, comprising contacting PCNA with an effective amount of a compound according to one of claims 1 to 87, or a pharmaceutically acceptable salt thereof.

100. according to the method for claim 99, wherein said compound is combined with His44, Val45, Leu47, Pro234, Tyr250, Leu251, Ala252, Met40, Leu47, Leu126, Leu128, Val233, Pro234, Ala252, Pro253 or Asp 232 of PCNA.

101. according to the method for claim 99, wherein said compound is non-covalently bound to His44, Val45, Leu47, Pro234, Tyr250, Leu251, Ala252, Met40, Leu47, Leu126, Leu128, Val233, Pro234, Ala252, Pro253 or Asp 232 of PCNA.

102. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the formula: in L 1 -O-, -NR 7 -, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 7 C(O)-、-C(O)NR 7 -、-NR 7 C(O)NR 8 、-NR 7 S(O)2O-、-OS(O)2NR 7 -、-NR 7 S(O)2-、-S(O)2NR 7 , -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OR 7 )-、-OP(O)(OR 7 )O-、-OP(O)(OR 7 )-、-P(O)(OR 7 )O-, or -CR 8 R 9 -; R 7 , R 8 and R 9 are independently hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl; Ring A is a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- to 6-membered heteroaryl group; R 1 are independently halogen, -CX 1 3. -CHX1 2. -CH2X 1 、-OCX 1 3. -OCHX 1 2. -OCH2X 1 、-CN、-SO n1 R 1D 、-SO v1 NR 1A R 1B 、-NR 1C NR 1A R 1B 、-ONR 1A R 1B 、-NHC(O)NR 1C NR 1A R 1B 、-NR 1C C(O)NR 1A R 1B 、-N(O) m1 、-NR 1A R 1B 、-C(O)R 1C 、-C(O)OR 1C 、-OC(O)R 1C 、-OC(O)OR 1C 、-C(O)NR 1A R 1B 、-OR 1D 、-SR 1D 、-NR 1A S02R 1D 、-NR 1A C(O)R 1C 、-NR 1A C(O)OR 1C 、-OC(O)NR 1A R 1B 、-NR 1A OR 1C 、-P(O)R 1A R 1B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 1 The substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R 2 For hydrogen, halogen, -CX 2 3. -CHX 22. -CH2X 2 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3 For hydrogen, halogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 6 For hydrogen, halogen, -CX 6 3. -CHX 6 2. -CH2X 6 、-OCX 6 3. -OCHX 6 2. -OCH2X 6 、-CN、-SO n6 R6 D 、-SO v6 NR 6A R 6B 、-NR 6C NR 6A R 6B 、-ONR 6A R 6B 、-NHC(O)NR 6C NR 6A R 6B 、-NR 6C C(O)NR 6A R 6B 、-N(O) m6 、-NR 6A R 6B 、-C(O)R 6C 、-C(O)OR 6C 、-OC(O)R 6C 、-OC(O)OR 6C 、-C(O)NR 6A R 6B 、-OR 6D 、-SR 6D 、-NR 6A S02R 6D 、-NR 6A C(O)R 6C 、-NR6A C(O)OR 6C 、-OC(O)NR 6A R 6B 、-NR 6A OR 6C 、-P(O)R 6A R 6B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3 and R 6 can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R 1A , R 1B , R 1C , R 1D , R 6A , R 6B , R 6C and R 6D R is independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 1A and R 1B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 6A and R 6B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; z1 is an integer from 0 to 4; m1, m6, v1 and v6 are independently 1 or 2; n1 and n6 are independently integers from 0 to 4; X, X 1 , X 2 , X 3 and X 6 are independently -Cl, -Br, -I, or -F; and m is an integer of 0-5.

103. The compound of claim 102, which has the formula: in R 4 are independently halogen, -CX 4 3. -CHX 4 2. -CH2X 4 、-OCX 4 3. -OCHX 4 2. -OCH2X 4 、-CN、-SO n4 R 4D 、-SO v4 NR 4A R 4B 、-NR 4C NR 4A R 4B 、-ONR 4A R 4B 、-NHC(O)NR 4C NR 4A R 4B 、-NR 4C C(O)NR 4A R 4B 、-N(O) m4 、-NR 4A R 4B 、-C(O)R 4C 、-C(O)OR 4C 、-OC(O)R 4C 、-OC(O)OR 4C 、-C(O)NR 4A R 4B 、-OR 4D 、-SR 4D 、-NR 4A S02R 4D 、-NR 4A C(O)R 4C 、-NR 4A C(O)OR 4C 、-OC(O)NR 4A R 4B 、-NR 4A OR 4C 、-P(O)R 4A R 4B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 4 The substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R4A , R 4B , R 4C , and R 4D R is independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 4A and R 4B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; z4 is an integer from 0 to 5; m4 and v4 are independently 1 or 2; n4 is an integer from 0 to 4; and X 4 are independently -Cl, -Br, -I, or -F.

104. The compound of claim 103, which has the formula:

105. The compound according to claim 102, wherein L 1 is -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -NHS(O)2O-, -OS(O)2NH-, -NHS(O)2-, -S(O)2NH-, -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -OP(O)(OH)-, -P(O)(OH)O-, -CHR 9 , or -CR 8 R 9 -;and R 8 and R 9 is independently halogen or unsubstituted methyl.

106. The compound according to claim 102, wherein L 1 For -O-.

107. The compound according to claim 102, wherein L 1 For -S-.

108. The compound according to claim 102, wherein L 1 It is -S(O)2-.

109. The compound according to claim 102, wherein R 1 are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

110. The compound according to claim 102, wherein R 1 are independently halogen, -OH, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, unsubstituted methyl, or unsubstituted methoxy.

111. The compound of claim 102, wherein z1 is 1.

112. The compound of claim 102, wherein z1 is 0.

113. The compound according to claim 102, wherein R 2 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

114. The compound according to claim 102, wherein R 3 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

115. The compound according to claim 102, wherein R 6 is hydrogen, halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

116. The compound according to claim 102, wherein R 6 is a substituted or unsubstituted C1-C6 alkyl group, or a substituted or unsubstituted 2- to 6-membered heteroalkyl group.

117. The compound according to claim 102, wherein R 6 is hydrogen, unsubstituted methyl, unsubstituted isopropyl, 118. The compound of claim 103, wherein R4 is independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C8 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

119. The compound of claim 103, wherein R4 is independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, or unsubstituted methoxy.

120. The compound according to claim 103, wherein R4 is independently -OR 4D .

121. The compound according to claim 120, wherein R 4D is hydrogen, or substituted or unsubstituted alkyl.

122. The compound according to claim 120, wherein R 4D is hydrogen or unsubstituted C1-C5 alkyl.

123. The compound according to claim 120, wherein R 4D is an unsubstituted methyl group.

124. The compound of claim 103, wherein z4 is 1.

125. The compound of claim 103, wherein z4 is 0.

126. The compound according to claim 103, wherein R 5 are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

127. The compound according to claim 103, wherein R 5independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, unsubstituted methoxy, or unsubstituted phenyl.

128. The compound of claim 103, wherein z5 is 1.

129. The compound of claim 103, wherein z5 is 0.

130. The compound of claim 102, wherein Ring A is substituted or unsubstituted phenyl.

131. The compound of claim 102, wherein Ring A is a substituted or unsubstituted 5- to 6-membered heteroaryl.

132. The compound of claim 102, wherein Ring A is substituted or unsubstituted thienyl.

133. The compound of claim 102, wherein Ring A is substituted or unsubstituted pyridinyl.

134. A method for preparing compound (I) or a pharmaceutically acceptable salt thereof, the method comprising mixing compound (VII) and compound (X) together in a reaction vessel; wherein Compound (I) has the following formula: Compound (VII) has the following formula: Compound (X) has the following formula: L 1 -O-, -NR 7 -, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NR 7 C(O)-、-C(O)NR 7 -、-NR 7 C(O)NR 8 -、-NR 7 S(O)2O-、-OS(O)2NR 7 -、-NR 7 S(O)2-、-S(O)2NR 7 -, -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OR 7 )-、-OP(O)(OR 7 )O-、-OP(O)(OR 7 )-、-P(O)(OR 7 )O-, or -CR 8 R 9 -; R7 , R 8 and R 9 are independently hydrogen, halogen, -OH, -N3, or substituted or unsubstituted alkyl; Ring A is a substituted or unsubstituted phenyl group, or a substituted or unsubstituted 5- to 6-membered heteroaryl group; Ring B is substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted quinolyl, or substituted or unsubstituted isoquinolyl; R 1 are independently halogen, -CX 1 3. -CHX 1 2. -CH2X 1 、-OCX 1 3. -OCHX 1 2. -OCH2X 1 、-CN、-SO n1 R 1D 、-SO v1 NR 1A R 1B 、-NR 1C NR 1A R 1B 、-ONR 1A R 1B 、-NHC(O)NR 1C NR 1A R 1B 、-NR 1C C(O)NR 1A R 1B 、-N(O) m1 、-NR 1A R 1B 、-C(O)R 1C 、-C(O)OR 1C 、-OC(O)R 1C 、-OC(O)OR 1C 、-C(O)NR 1A R 1B 、-OR 1D 、-SR 1D 、-NR 1A S02R 1D 、-NR 1A C(O)R 1C 、-NR 1A C(O)OR 1C 、-OC(O)NR 1A R 1B 、-NR 1A OR 1C 、-P(O)R 1A R1B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 1 The substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R 2 For hydrogen, halogen, -CX 2 3. -CHX 2 2. -CH2X 2 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3 For hydrogen, halogen, -CX 3 3. -CHX 3 2. -CH2X 3 , -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 6 For hydrogen, halogen, -CX 6 3. -CHX 6 2. -CH2X 6 、-OCX 6 3. -OCHX 6 2. -OCH2X 6 、-CN、-SO n6 R 6D 、-SO v6 NR 6A R 6B 、-NR 6C NR 6A R 6B 、-ONR 6A R 6B 、-NHC(O)NR 6C NR 6A R 6B 、-NR 6C C(O)NR 6A R 6B 、-N(O) m6 、-NR 6A R6B 、-C(O)R 6C 、-C(O)OR 6C 、-OC(O)R 6C 、-OC(O)OR 6C 、-C(O)NR 6A R 6B 、-OR 6D 、-SR 6D 、-NR 6A S02R 6D 、-NR 6A C(O)R 6C 、-NR 6A C(O)OR 6C 、-OC(O)NR 6A R 6B 、-NR 6A OR 6C 、-P(O)R 6A R 6B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 3 and R 6 can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R 1A , R 1B , R 1C , R 1D , R 6A , R 6B , R 6C and R 6D R is independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 1A and R 1B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 6A and R 6B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; z1 is an integer from 0 to 4; m1, m6, v1 and v6 are independently 1 or 2; n1 and n6 are independently integers from 0 to 4; X, X 1 , X 2 , X 3 and X 6 are independently -Cl, -Br, -I, or -F; m is an integer from 0 to 5; n is an integer from 0 to 10; and LG is a leaving group.

135. The method of claim 134, wherein LG is a halogen.

136. The method of claim 134, wherein LG is -C1.

137. The method of claim 134, further comprising a base.

138. The method of claim 137, wherein the base is N,N-diisopropylethylamine.

139. The method of claim 134, wherein LG is -OH.

140. The method of claim 134, further comprising a peptide coupling agent.

141. The method of claim 140, wherein the peptide coupling agent is dicyclohexylcarbodiimide.

142. The method of claim 140, wherein the peptide coupling agent is HBTU.

143. The method of claim 140, wherein the peptide coupling agent is HOBt.

144. The method of claim 140, wherein the peptide coupling agent is PyBOP.

145. The method of claim 134, wherein Compound (I) is a compound of formula (II): Compound (VII) is a compound of formula (VIII): Compound (X) is a compound of formula (XI): R 4 are independently halogen, -CX 4 3. -CHX 4 2. -CH2X 4 、-OCX 4 3. -OCHX 4 2. -OCH2X 4、-CN、-SO n4 R 4D 、-SO v4 NR 4A R 4B 、-NR 4C NR 4A R 4B 、-ONR 4A R 4B 、-NHC(O)NR 4C NR 4A R 4B 、-NR 4C C(O)NR 4A R 4B 、-N(O) m4 、-NR 4A R 4B 、-C(O)R 4C 、-C(O)OR 4C 、-OC(O)R 4C 、-OC(O)OR 4C 、-C(O)NR 4A R 4B 、-OR 4D 、-SR 4D 、-NR 4A S02R 4D 、-NR 4A C(O)R 4C 、-NR 4A C(O)OR 4C 、-OC(O)NR 4A R 4B 、-NR 4A OR 4C 、-P(O)R 4A R 4B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 4 The substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R 5 are independently halogen, -CX 5 3. -CHX 5 2. -CH2X 5 、-OCX 5 3. -OCHX 5 2. -OCH2X 5 、-CN、-SOn5 R 5D 、-SO v5 NR 5A R 5B 、-NR 5C NR 5A R 5B 、-ONR 5A R 5B 、-NHC(O)NR 5C NR 5A R 5B 、-NR 5C C(O)NR 5A R 5B 、-N(O) m5 、-NR 5A R 5B 、-C(O)R 5C 、-C(O)OR 5C 、-OC(O)R 5C 、-OC(O)OR 5C 、-C(O)NR 5A R 5B 、-OR 5D 、-SR 5D 、-NR 5A S02R 5D 、-NR 5A C(O)R 5C 、-NR 5A C(O)OR 5C 、-OC(O)NR 5A R 5B 、-NR 5A OR 5C 、-P(O)R 5A R 5B , -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; two adjacent R 5 The substituents can be optionally joined to form a substituted or unsubstituted cycloalkyl, a substituted or unsubstituted heterocycloalkyl, a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; R4 A 、R4 B 、R4 C 、R4 D , R 5A , R 5B 、R5 v and R 5DR is independently hydrogen, halogen, -CX3, -CHX2, -CH2X, -CN, -COOH, -CONH2, -N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 4A and R 4B The substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; R bonded to the same nitrogen atom 5A and R 5B Substituents can be optionally joined to form a substituted or unsubstituted heterocycloalkyl, or a substituted or unsubstituted heteroaryl; z4 is an integer from 0 to 5; z5 is an integer from 0 to 7; m4, m5, v4 and v5 are independently 1 or 2; n4 and n5 are independently integers from 0 to 4; and X 4 and X 5 are independently -Cl, -Br, -I, or -F.

146. The method of claim 134, wherein L 1 is -O-, -NH-, -NCH3-, -S-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -C(O)NH-, -NHC(O)NH-, -NHS(O)2O-, -OS(O)2NH-, -NHS(O)2-, -S(O)2NH-, -S(O)-, -S(O)2-, -OS(O)2O-, -S(O)2O-, -OS(O)2-, -P(O)(OH)-, -OP(O)(OH)O-, -Op(O)(OH)-, -p(O)(OH)O-, -CHR 9 -, or -CR 8 R 9 -;and R 8 and R 9 is independently halogen or unsubstituted methyl.

147. The method of claim 134, wherein L 1 For -O-.

148. The method of claim 134, wherein L 1 For -S-.

149. The method of claim 134, wherein L 1 It is -S(O)2-.

150. The method of claim 134, wherein R 1 are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

151. The method of claim 134, wherein R 1 are independently halogen, -OH, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, unsubstituted methyl, or unsubstituted methoxy.

152. The method of claim 134, wherein z1 is 1.

153. The method of claim 134, wherein z1 is 0.

154. The method of claim 134, wherein R 2 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

155. The method of claim 134, wherein R 3 is hydrogen, unsubstituted methyl, unsubstituted ethyl, or unsubstituted isopropyl.

156. The method of claim 134, wherein R 6 is hydrogen, halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

157. The method of claim 134, wherein R 6 is a substituted or unsubstituted C1-C6 alkyl group, or a substituted or unsubstituted 2- to 6-membered heteroalkyl group.

158. The method of claim 134, wherein R 6 is hydrogen, unsubstituted methyl, unsubstituted isopropyl, 159. The method of claim 145, wherein R 4 are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

160. The method of claim 145, wherein R 4 are independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, or unsubstituted methoxy.

161. The method of claim 145, wherein R 4 Independently -OR 4D .

162. The method of claim 161, wherein R 4D is hydrogen, or substituted or unsubstituted alkyl.

163. The method of claim 161, wherein R 4D is hydrogen or unsubstituted C1-C5 alkyl.

164. The method of claim 161, wherein R 4D is an unsubstituted methyl group.

165. The method of claim 145, wherein z4 is 1.

166. The method of claim 145, wherein z4 is 0.

167. The method of claim 145, wherein R 5 are independently halogen, -CF3, -CHF2, -CH2F, -CN, -OH, -NH2, -COOH, -CONH2, -NO2, -SH, -OCF3, -OCHF2, -OCH2F, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2-8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3-8 membered heterocycloalkyl, substituted or unsubstituted C6-C 10 aryl, or a substituted or unsubstituted 5- to 10-membered heteroaryl.

168. The method of claim 145, wherein R 5independently halogen, -CF3, -CHF2, -CH2F, -OCF3, -OCHF2, -OCH2F, -OH, unsubstituted methyl, unsubstituted methoxy, or unsubstituted phenyl.

169. The method of claim 145, wherein z5 is 1.

170. The method of claim 145, wherein z5 is 0.

171. The method of claim 134, wherein Ring A is substituted or unsubstituted phenyl.

172. The method of claim 134, wherein Ring A is a substituted or unsubstituted 5-6 membered heteroaryl.

173. The method of claim 134, wherein Ring A is substituted or unsubstituted thienyl.

174. The method of claim 134, wherein Ring A is substituted or unsubstituted pyridinyl.

175. The method of claim 134, wherein Ring B is substituted or unsubstituted phenyl.

176. The method of claim 134, wherein Ring B is substituted or unsubstituted naphthyl.

177. The method of claim 134, wherein Ring B is substituted or unsubstituted quinolinyl.

178. The method of claim 134, wherein Ring B is substituted or unsubstituted isoquinolinyl.